

10/ 539,220

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format  
NEWS 3 MAR 16 CASREACT coverage extended  
NEWS 4 MAR 20 MARPAT now updated daily  
NEWS 5 MAR 22 LWPI reloaded  
NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements  
NEWS 7 APR 02 JICST-EPLUS removed from database clusters and STN  
NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field  
NEWS 9 APR 30 CHEMCATS enhanced with 1.2 million new records  
NEWS 10 APR 30 CA/CAPplus enhanced with 1870-1889 U.S. patent records  
NEWS 11 APR 30 INPADOC replaced by INPADOCDB on STN  
NEWS 12 MAY 01 New CAS web site launched  
NEWS 13 MAY 08 CA/CAPplus Indian patent publication number format defined  
NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields  
NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data  
NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reload  
NEWS 17 MAY 21 CA/CAPplus enhanced with additional kind codes for German patents  
NEWS 18 MAY 22 CA/CAPplus enhanced with IPC reclassification in Japanese patents  
NEWS 19 JUN 18 CA/CAPplus to be enhanced with pre-1967 CAS Registry Numbers  
NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:25:54 ON 22 JUN 2007

10/ 539,220

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:26:27 ON 22 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JUN 2007 HIGHEST RN 938223-21-3

DICTIONARY FILE UPDATES: 21 JUN 2007 HIGHEST RN 938223-21-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10539220.str

10/ 539,220



chain nodes :  
11 12 13 16 17 18 19 20  
ring nodes :  
1 2 3 4 5 6 7 8 9 10  
chain bonds :  
5-17 7-11 11-16 12-13 17-18 18-19 19-20  
ring bonds :  
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10  
exact/norm bonds :  
5-17 7-11 11-16 12-13 17-18 19-20  
exact bonds :  
18-19  
normalized bonds :  
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10  
isolated ring systems :  
containing 1 :

G1:O,S,N,SO2,[\*1]

G2:N,P,Cy

Hydrogen count :  
9:= exact 1  
Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:CLASS 12:CLASS 13:CLASS 16:Atom 17:CLASS 18:CLASS 19:CLASS 20:CLASS  
Generic attributes :  
16:  
Number of Carbon Atoms : less than 7  
Type of Ring System : Monocyclic  
  
Element Count :  
Node 16: Limited  
C,C2-4  
N,N1-3


10/ 539,220

L1 STRUCTURE UPLOADED

=> d L1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 12:26:53 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1816 TO ITERATE

100.0% PROCESSED 1816 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 33764 TO 38876

PROJECTED ANSWERS: 1131 TO 2229

L2 50 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 12:26:58 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 36537 TO ITERATE

100.0% PROCESSED 36537 ITERATIONS

1704 ANSWERS

SEARCH TIME: 00.00.01

L3 1704 SEA SSS FUL L1

=> file zcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'ZCAPLUS' ENTERED AT 12:27:06 ON 22 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)



Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 22 Jun 2007 VOL 147 ISS 1  
FILE LAST UPDATED: 21 Jun 2007 (20070621/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 24 L3

=> d his

(FILE 'HOME' ENTERED AT 12:25:54 ON 22 JUN 2007)

FILE 'REGISTRY' ENTERED AT 12:26:27 ON 22 JUN 2007

L1 STRUCTURE UPLOADED

L2 50 S L1

L3 1704 S L1 FUL

FILE 'ZCAPLUS' ENTERED AT 12:27:06 ON 22 JUN 2007

L4 24 S L3

=> d l4 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 24 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:527454 ZCAPLUS

DOCUMENT NUMBER: 146:501073

TITLE: Preparation of quinazolinylaminothiazoles as protein kinase inhibitors for treatment of cancer.

INVENTOR(S): Ehlert, Jan; Herz, Thomas; Krauss, Rolf; Kubbutat, Michael; Lang, Martin; Pegoraro, Stefano; Schaechtele, Christoph; Totzke, Frank; Zirrgiebel, Ute

PATENT ASSIGNEE(S): 4SC AG, Germany

SOURCE: Eur. Pat. Appl., 31pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 1785420	A1	20070516	EP 2005-24847	20051114
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				


WO 2007054357      A1      20070518      WO 2006-EP10870      20061113  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,  
KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,  
MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,  
RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,  
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

EP 2005-24847

A 20051114

GI



AB Title compds. [I; R1 = CR6R7(CR8R9)<sub>n</sub>AR5; R2 = H, halo, cyano, alkyl, alkoxy, haloalkoxy, alkylamino; R3 = (substituted) quinazolinyl, quinolyl, pyrimidyl, triazinyl, pyridyl, etc.; X = S, O, NR4, SO, SO2; n = 1-3; A = CO, CS, SO, SO2, CO2, CONR12, etc.; R5 = H, alkyl, cycloalkyl aryl, heteroaryl, etc.; R6 = H, halo cyano, OH, amino, alkyl, alkoxy, haloalkoxy, cycloalkyl, etc.; R7 = H, halo, cyano, OH, amino, alkyl, alkoxy cycloalkyl, haloalkoxy, etc.; R8 = H, halo, cyano, OH, amino, alkyl, alkoxy, alkylamino, cycloalkyl, haloalkyl, etc.; R6R8 = atoms to form a 3-8 membered (substituted) (hetero)cyclyl; R12 = H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl], were prepared Title compds. e.g. (II) (preparation outlined) inhibited  $\geq 1$  protein kinase with IC<sub>50</sub> <500 nM.

IT 936449-18-2P 936449-19-3P 936449-22-8P  
936449-23-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of quinazolinylaminothiazoles as protein kinase inhibitors for treatment of cancer)

RN 936449-18-2 ZCAPLUS

CN Benzamide, 3-fluoro-N-[2-[2-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-

10/ 539,220


quinazolinyl]amino]-5-thiazolyl]ethyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 936449-19-3 ZCAPLUS


CN Benzamide, N-[2-[2-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]-5-thiazolyl]ethyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 936449-22-8 ZCAPLUS


CN 5-Thiazolepropanamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 936449-23-9 ZCAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[2-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]-4-thiazolyl]ethyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:321162 ZCAPLUS

DOCUMENT NUMBER: 146:521755

TITLE: Discovery, Synthesis, and in Vivo Activity of a New Class of Pyrazolylamino Quinazolines as Selective Inhibitors of Aurora B Kinase

AUTHOR(S): Mortlock, Andrew A.; Foote, Kevin M.; Heron, Nicola M.; Jung, Frederic H.; Pasquet, Georges; Lohmann,

Jean-Jacques M.; Warin, Nicolas; Renaud, Fabrice; De Savi, Chris; Roberts, Nicola J.; Johnson, Trevor; Dousson, Cyril B.; Hill, George B.; Perkins, David; Hatter, Glenn; Wilkinson, Robert W.; Wedge, Stephen R.; Heaton, Simon P.; Odedra, Rajesh; Keen, Nicholas J.; Crafter, Claire; Brown, Elaine; Thompson, Katherine; Brightwell, Stephen; Khatri, Liz; Brady, Madeleine C.; Kearney, Sarah; McKillop, David; Rhead, Steve; Parry, Tony; Green, Stephen

CORPORATE SOURCE: AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, SK10 4TG, UK

SOURCE: Journal of Medicinal Chemistry (2007), 50(9), 2213-2224


CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

GI





AB A series of pyrazolylamino-substituted quinazolines was synthesized and biol. evaluated as inhibitors of Aurora kinases, which have been the subject of considerable interest as targets for the development of new anticancer agents. Some of the products demonstrated greater than 1000-fold selectivity for Aurora B over Aurora A kinase activity in recombinant enzyme assays. These compds. have been designed for parenteral administration and achieve high levels of solubility by virtue of their ability to be delivered as readily activated phosphate derivs. The prodrugs are comprehensively converted to the des-phosphate form in vivo, and the active species have advantageous pharmacokinetic properties and safety pharmacol. profiles. The compds. display striking in vivo activity, and I (AZD1152) has been selected for clin. evaluation and is currently in phase 1 clin. trials.

IT 557770-38-4P 557770-93-1P 722544-51-6P  
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (lipophilicity; synthesis and in vivo activity of pyrazolylamino-substituted quinazolines as selective inhibitors of Aurora B kinase and antitumor agents)

RN 557770-38-4 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)propylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 557770-93-1 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 722544-51-6 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-4-

quinazolinyl]amino]-N-(3-fluorophenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




IT 557770-42-0P  
 RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
 (lipophilicity; synthesis and in vivo activity of pyrazolylamino-substituted quinazolines as selective inhibitors of Aurora B kinase and antitumor agents)  
 RN 557770-42-0 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




IT 557769-46-7P 557770-39-5P 557770-53-3P  
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (lipophilicity; synthesis and in vivo activity of pyrazolylamino-substituted quinazolines as selective inhibitors of Aurora B kinase and antitumor agents)  
 RN 557769-46-7 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (CA INDEX NAME)

PAGE 1-A






PAGE 2-A




RN 557770-39-5 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)(2-methylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)



PAGE 1-A





PAGE 2-A



RN 557770-53-3 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)




IT	722542-97-4P 722543-04-6P 722543-31-9P 722543-45-5P RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (solubility; synthesis and in vivo activity of pyrazolylamino-substituted quinazolines as selective inhibitors of Aurora B kinase and antitumor agents)
RN	722542-97-4 ZCAPLUS
CN	1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[6-methoxy-7-[3-[[2- (phosphonooxy)ethyl]propylamino]propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 722543-04-6 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[6-methoxy-7-[3-[(2R)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 722543-31-9 ZCAPLUS


10/ 539,220

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 722543-45-5 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2R)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl


IT 557769-50-3P 557769-52-5P 557769-63-8P  
 557769-66-1P 557769-77-4P 557770-20-4P  
 557770-36-2P 557770-47-5P 557770-48-6P  
 557770-49-7P 557770-62-4P 557770-64-6P  
 557770-65-7P 557770-68-0P 557770-69-1P  
 557770-70-4P 557770-73-7P 557770-74-8P  
 557770-77-1P 557770-85-1P 557770-87-3P  
 557770-94-2P 722544-55-0P 722544-57-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
 (Biological study); PREP (Preparation)  
 (synthesis and in vivo activity of pyrazolylamino-substituted  
 quinazolines as selective inhibitors of Aurora B kinase and antitumor  
 agents)  
 RN 557769-50-3 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2-  
 hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX  
 NAME)



RN 557769-52-5 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)


PAGE 1-A





RN 557769-63-8 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 557769-66-1 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 557769-77-4 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)propylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA

INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 557770-20-4 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-  
 (CA INDEX NAME)




10/ 539,220



RN 557770-36-2 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 557770-47-5 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)

10/ 539,220



RN 557770-48-6 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 557770-49-7 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)

10/ 539,220



RN 557770-62-4 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-methoxyphenyl)- (CA INDEX NAME)



RN 557770-64-6 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-phenyl- (CA INDEX NAME)

10/ 539,220



RN 557770-65-7 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(4-fluorophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

F


RN 557770-68-0 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

10/ 539,220



RN 557770-69-1 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-hydroxyphenyl)-  
(CA INDEX NAME)



RN 557770-70-4 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-nitrophenyl)-  
(CA INDEX NAME)

10/ 539,220



RN 557770-73-7 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(3-chlorophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 557770-74-8 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(2-fluorophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)

10/ 539,220



RN 557770-77-1 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-  
(CA INDEX NAME)



RN 557770-85-1 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(3-cyanophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)

10/ 539,220




RN 557770-87-3 ZCAPLUS  
CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)

PAGE 1-A






PAGE 2-A




RN 557770-94-2 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)propylamino]propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 722544-55-0 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)propylamino]propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 722544-57-2 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



IT 557770-63-5P 722543-50-2P 722543-78-4P

722544-03-8P 936731-81-6P 936731-82-7P


936731-84-9P 936731-86-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and in vivo activity of pyrazolylamino-substituted quinazolines as selective inhibitors of Aurora B kinase and antitumor agents)


RN 557770-63-5 ZCAPLUS

CN 1H-Pyrazole-3-acetic acid, 5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 722543-50-2 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)-, dihydrochloride (9CI) (CA INDEX NAME)




PAGE 2-A




● 2 HCl

RN 722543-78-4 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[6-methoxy-7-[3-[[2-(phosphonooxy)ethyl]propylamino]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● 2 HCl

10/ 539,220

RN 722544-03-8 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[6-methoxy-7-[3-[(2R)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.





● 2 HCl

RN 936731-81-6 ZCAPLUS

CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A






RN 936731-82-7 ZCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.





RN 936731-84-9 ZCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 936731-86-1 ZCAPLUS  
CN INDEX NAME NOT YET ASSIGNED



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1176345 ZCAPLUS

DOCUMENT NUMBER: 145:489566

TITLE: Preparation of quinoline and quinazoline amino acid derivatives as inhibitors of kinase enzymatic activity  
INVENTOR(S): Davidson, Alan Hornsby; Davies, Stephen John; Moffat, David Festus Charles

PATENT ASSIGNEE(S): Chroma Therapeutics Ltd., UK

SOURCE: PCT Int. Appl., 205pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006117552	A1	20061109	WO 2006-GB1609	20060504
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:


GB 2005-9227

A 20050505

OTHER SOURCE(S):

MARPAT 145:489566

GI



AB The invention relates to quinoline and quinazoline linker-attached amino acid derivs. which are inhibitors of kinase enzymic activity. Thus, quinoline derivative I was prepared by a multistep sequence, including etherification of 4-chloro-6-methoxy-7-quinolinol with (S)-4-bromo-2-(tert-butoxycarbonylamino)butyric acid cyclopentyl ester, followed by reaction with N-(4-mercaptophenyl)benzamide. Compound I showed IC<sub>50</sub> < 2,000 nM in the aurora-A inhibition assay and IC<sub>50</sub> < 1,000 nM for inhibition of cancer cell lines U937, HCT 116 and HUT.

IT 914488-15-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of quinoline and quinazoline amino acid derivs. as inhibitors of kinase enzymic activity)

RN 914488-15-6 ZCAPLUS


CN L-Homoserine, O-[4-[[2-(benzoylamino)-5-pyrimidinyl]amino]-6-methoxy-7-quinazolinyl]-, cyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






IT 914490-20-3P 914490-21-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of quinoline and quinazoline amino acid derivs. as inhibitors  
 of kinase enzymic activity)  
 RN 914490-20-3 ZCAPLUS  
 CN Benzamide, N-[5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-  
 pyrimidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 914490-21-4 ZCAPLUS  
 CN L-Homoserine, O-[4-[[2-(benzoylamino)-5-pyrimidinyl]amino]-6-methoxy-7-  
 quinazolinyl]-N-[(1,1-dimethylethoxy)carbonyl]-, cyclopentyl ester (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1085923 ZCAPLUS

DOCUMENT NUMBER: 146:434348

TITLE: Validating Aurora B as an anti-cancer drug target

AUTHOR(S): Girdler, Fiona; Gascoigne, Karen E.; Evers, Patrick A.; Hartmuth, Sonya; Crafter, Claire; Foote, Kevin M.; Keen, Nicholas J.; Taylor, Stephen S.

CORPORATE SOURCE: Faculty of Life Sciences, University of Manchester, Manchester, M13 9PT, UK

SOURCE: Journal of Cell Science (2006), 119(17), 3664-3675  
CODEN: JNCSAI; ISSN: 0021-9533

PUBLISHER: Company of Biologists Ltd.

DOCUMENT TYPE: Journal


LANGUAGE: English

AB The Aurora kinases, a family of mitotic regulators, have received much attention as potential targets for novel anti-cancer therapeutics. Several Aurora kinase inhibitors have been described including ZM447439, which prevents chromosome alignment, spindle checkpoint function and cytokinesis. Subsequently, ZM447439-treated cells exit mitosis without dividing and lose viability. Because ZM447439 inhibits both Aurora A and B, we set out to determine which phenotypes are due to inhibition of which kinase. Using mol. genetic approaches, we show that inhibition of Aurora B kinase activity phenocopies ZM447439. Furthermore, a novel ZM compound, which is 100 times more selective for Aurora B over Aurora A in vitro, induces identical phenotypes. Importantly, inhibition of Aurora B kinase activity induces a penetrant anti-proliferative phenotype, indicating that Aurora B is an attractive anti-cancer drug target. Using mol. genetic and chemical-genetic approaches, we also probe the role of Aurora A kinase activity. We show that simultaneous repression of Aurora A plus induction of a catalytic mutant induces a monopolar phenotype. Consistently, another novel ZM-related inhibitor, which is 20 times as potent against Aurora A compared with ZM447439, induces a monopolar phenotype. Expression of a drug-resistant Aurora A mutant reverts this phenotype, demonstrating that Aurora A kinase activity is required for spindle bipolarity in human cells. Because small mol.-mediated inhibition of Aurora A and Aurora B yields distinct phenotypes, our observations indicate that the Auroras may present two avenues for anti-cancer drug discovery.


10/ 539,220

IT 557770-87-3, ZM 2  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(ZM 2; validating Aurora B as an anti-cancer drug target)  
RN 557770-87-3 ZCAPLUS  
CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[ethyl(2-  
hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)



PAGE 1-A



PAGE 2-A



IT 557770-43-1, ZM 3  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(ZM 3; validating Aurora B as an anti-cancer drug target)  
RN 557770-43-1 ZCAPLUS  
CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)-  
2-propynylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX  
NAME)



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:695015 ZCAPLUS

DOCUMENT NUMBER: 145:327648

TITLE: Accurate Prediction of the Relative Potencies of Members of a Series of Kinase Inhibitors Using Molecular Docking and MM-GBSA Scoring

AUTHOR(S): Lyne, Paul D.; Lamb, Michelle L.; Saeh, Jamal C.  
CORPORATE SOURCE: Cancer Discovery, AstraZeneca R & D Boston, Waltham, MA, 02451, USA

SOURCE: Journal of Medicinal Chemistry (2006), 49(16), 4805-4808

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The ability of mol. docking, using the program Glide and an MM-GBSA postdocking scoring protocol, to correctly rank a number of congeneric kinase inhibitors was assessed. The approach was successful for the cases considered and suggests that this may be useful for the design of

10/ 539,220


inhibitors in the lead optimization phase of drug discovery.

IT 331787-26-9 331787-58-7 331788-25-1  
331792-49-5 331792-64-4 331792-74-6  
331793-17-0 331793-83-0 331794-30-0  
331794-50-4 909551-89-9

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(accurate prediction of relative potencies of kinase inhibitors using mol. docking and MM-GBSA scoring)

RN 331787-26-9 ZCAPLUS


CN Benzamide, N-[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 331787-58-7 ZCAPLUS

CN Benzamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 331788-25-1 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-2-hydroxy-3-(1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/ 539,220



RN 331792-49-5 ZCAPLUS


CN 4-Pyridinecarboxamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331792-64-4 ZCAPLUS


CN Benzamide, 3-bromo-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331792-74-6 ZCAPLUS


CN Benzamide, 3-chloro-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331793-17-0 ZCAPLUS


CN Benzamide, 3-chloro-4-fluoro-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331793-83-0 ZCAPLUS

CN Benzamide, 4-ethyl-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 331794-30-0 ZCAPLUS

CN Pentanamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




10/ 539,220



RN 331794-50-4 ZCAPLUS  
 CN Benzamide, 4-[(dipropylamino)sulfonyl]-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 909551-89-9 ZCAPLUS  
 CN Benzamide, 3-chloro-N-[5-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-

quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:366862 ZCAPLUS

DOCUMENT NUMBER: 144:412531

TITLE: Preparation of quinazoline derivatives for use in treatment of cell proliferative disorders or disease associated with angiogenesis and/or vascular permeability

INVENTOR(S): Ple, Patrick; Jung, Frederic Henri

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 212 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006040526	A1	20060420	WO 2005-GB3881	20051007
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: EP 2004-292418 A 20041012

OTHER SOURCE(S): MARPAT 144:412531

GI



I

AB Quinazoline derivs. I, wherein p is 0-3; R1 is halogen, CF<sub>3</sub>, Cn, OH, SH, NH<sub>2</sub>, alkyl, alkenyl, alkynyl, alkoxy, alkenyl-oxy, alkynyl-oxy, alkylthio, alkyl-sulfinyl, alkyl-sulfonyl, alkylamino, Q1X2; X2 is O, S, SO, SO<sub>2</sub>, substituted amine, CO, amide, amino-carbonyl; Q1 is aryl, arylalkyl, cycloalkyl, cyclo-alkenyl, cyclo-alkenyl-alkyl, heteroaryl, heterocycle, heterocycl-alkyl; q = 0-2; R2 is halogen CF<sub>3</sub>, CN, OH, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylamino; R3 is H, alkyl, alkenyl, alkynyl; R3 and R4 together with the carbon atom to which they are attached form a cycloalkyl group; R5 is H, alkyl, alkenyl, alkynyl; ring is 6-membered mono-cyclic, 10-membered bicyclic aryl ring, heterocycle; X1 is O, S, SO, SO<sub>2</sub>, substituted nitrogen, Co, amide, amino-carbonyl, sulfonyl-amine, amino-sulfonyl, ; R6 and R7 are independently halogen, CF<sub>3</sub>, CN, OH, SH, amino, carboxy, carbamoyl, sulfamoyl, ureido, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkyl-sulfinyl, alkyl-sulfonyl, alkylamino, alkoxy-carbonyl, alkanoyl, alkanoyl-oxy, alkyl-carbamoyl; r is 0-3, were prepared for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability. Thus, N-(2,3-methylenedioxy-phenyl)-2-[4-[6-[2-(4-hydroxy-piperidin-1-yl)ethoxy]-7-methoxy-quinazolin-4-yl-oxy]pyrazol-1-yl]acetamide was prepared for use in treatment of cell proliferative disorders or disease associated with angiogenesis and/or vascular permeability. The compds. of the present invention were tested as inhibitors of PDGFR $\alpha$ , PDGFR $\beta$  and KDR tyrosine kinase enzymes, as inhibitors in vitro of the phosphorylation of PDGFR expressed on MG63 osteosarcoma cells, as inhibitors in vitro of the proliferation of MG63 osteosarcoma cells, as inhibitors in vitro of the proliferation of human umbilical vein endothelial cells (HUVECs), and as inhibitors in vivo of the growth in nude mice of xenografts of human tumor tissue such as CaLu-6 and Colo205.


IT 884343-86-6P 884343-87-7P 884343-88-8P  
884343-89-9P 884343-90-2P 884343-91-3P  
884343-92-4P 884343-93-5P 884343-94-6P  
884343-95-7P 884343-96-8P 884343-97-9P  
884344-01-8P 884344-03-0P 884344-06-3P  
884344-10-9P 884344-13-2P 884344-46-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazoline derivs. for use in treatment of cell proliferative disorders or disease assocd with angiogenesis and or vascular permeability)


RN 884343-86-6 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-1,3-benzodioxol-4-yl-4-[[6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 884343-87-7 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, 4-[[7-[2-(4-acetyl-1-piperazinyl)ethoxy]-6-methoxy-4-quinazolinyl]oxy]-N-(5-fluoro-1,3-benzodioxol-4-yl)- (9CI) (CA INDEX NAME)




RN 884343-88-8 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(5-fluoro-1,3-benzodioxol-4-yl)-4-[[6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)



RN 884343-89-9 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(5-fluoro-1,3-benzodioxol-4-yl)-4-[[7-[2-(4-hydroxy-1-piperidinyl)ethoxy]-6-methoxy-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 884343-90-2 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-1,3-benzodioxol-5-yl-4-[[6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)

10/ 539,220




RN 884343-91-3 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[2-(4-acetyl-1-piperazinyl)ethoxy]-6-methoxy-4-quinazolinyl]oxy]-N-1,3-benzodioxol-5-yl- (9CI) (CA INDEX NAME)




RN 884343-92-4 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-1,3-benzodioxol-5-yl-4-[[6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)

10/ 539,220




RN 884343-93-5 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-1,3-benzodioxol-5-yl-4-[[7-[2-(4-hydroxy-1-piperidinyl)ethoxy]-6-methoxy-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 884343-94-6 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,2-dimethyl-1,3-benzodioxol-5-yl)-4-[[6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)



RN 884343-95-7 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[[6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 884343-96-8 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[[6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)




10/ 539,220



RN 884343-97-9 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[[7-[2-(4-hydroxy-1-piperidinyl)ethoxy]-6-methoxy-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)



RN 884344-01-8 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-1,3-benzodioxol-5-yl-4-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 884344-03-0 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, 4-[[7-[2-(4-acetyl-1-piperazinyl)ethoxy]-6-methoxy-4-quinazolinyl]oxy]-N-(2,3-dihydro-1,4-benzodioxin-6-yl)- (9CI)  
(CA INDEX NAME)



RN 884344-06-3 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-dihydro-1-methyl-1H-indol-5-yl)-4-[[6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 884344-10-9 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-dihydro-1-methyl-1H-indol-6-yl)-4-[[6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)



RN 884344-13-2 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-1,3-benzodioxol-4-yl-4-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 884344-46-1 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-dihydro-1H-indol-6-yl)-4-[[6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)



IT 884344-14-3P 884344-15-4P 884344-17-6P  
884344-18-7P 884344-20-1P 884344-21-2P  
884344-22-3P 884344-23-4P 884344-24-5P  
884344-30-3P 884344-31-4P 884344-32-5P  
884344-47-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of quinazoline derivs. for use in treatment of cell proliferative disorders or disease assocd with angiogenesis and or vascular permeability)

RN 884344-14-3 ZCAPLUS


10/ 539,220

CN 1H-Pyrazole-1-acetic acid, 4-[[6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)



RN 884344-15-4 ZCAPLUS


CN 1H-Pyrazole-1-acetic acid, 4-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 884344-17-6 ZCAPLUS


CN 1H-Pyrazole-1-acetic acid, 4-[[6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/ 539,220




RN 884344-18-7 ZCAPLUS

CN 1H-Pyrazole-1-acetic acid, 4-[[7-[2-(4-acetyl-1-piperazinyl)ethoxy]-6-methoxy-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)



RN 884344-20-1 ZCAPLUS


CN 1H-Pyrazole-1-acetic acid, 4-[[7-[2-(4-acetyl-1-piperazinyl)ethoxy]-6-methoxy-4-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 884344-21-2 ZCAPLUS


10/ 539,220

CN 1H-Pyrazole-1-acetic acid, 4-[[6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 884344-22-3 ZCAPLUS

CN 1H-Pyrazole-1-acetic acid, 4-[[6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]-4-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 884344-23-4 ZCAPLUS


CN 1H-Pyrazole-1-acetic acid, 4-[[7-[2-(4-hydroxy-1-piperidinyl)ethoxy]-6-methoxy-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)



10/ 539,220


RN 884344-24-5 ZCAPLUS

CN 1H-Pyrazole-1-acetic acid, 4-[[7-[2-(4-hydroxy-1-piperidinyl)ethoxy]-6-methoxy-4-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 884344-30-3 ZCAPLUS


CN 1H-Pyrazole-1-acetic acid, 4-[[7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-6-methoxy-4-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 884344-31-4 ZCAPLUS


CN 1H-Pyrazole-1-acetic acid, 4-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)






RN 884344-32-5 ZCAPLUS

CN 1H-Pyrazole-1-acetic acid, 4-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 884344-47-2 ZCAPLUS

CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-6-[[[4-[[6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]oxy]-1H-pyrazol-1-yl]acetyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:87918 ZCAPLUS

DOCUMENT NUMBER: 144:324127

TITLE: SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors

AUTHOR(S): Heron, Nicola M.; Anderson, Malcolm; Blowers, David P.; Breed, Jason; Eden, Jonathan M.; Green, Stephen; Hill, George B.; Johnson, Trevor; Jung, Frederic H.; McMiken, Helen H. J.; Mortlock, Andrew A.; Pannifer, Andrew D.; Pauptit, Richard A.; Pink, Jennifer; Roberts, Nicola J.; Rowsell, Sian

CORPORATE SOURCE: AstraZeneca, Mereside, Cheshire, Macclesfield, SK10 4TG, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(5), 1320-1323  
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A novel series of 5-aminopyrimidinyl quinazolines has been developed from anilino-quinazoline 1, which was identified in a high throughput screen for Aurora A. Introduction of the pyrimidine ring and optimization of the substituents both on this ring and at the C7 position of the quinazoline led to the discovery of compds. that are highly specific Aurora kinase inhibitors. Co-crystallization of one of these inhibitors with a fragment of Aurora A shows the importance of the benzamido group in achieving selectivity.

IT 331787-26-9 331787-58-7 331792-49-5  
331792-64-4 331792-74-6 331793-17-0  
331793-83-0 331794-30-0 331794-50-4  
880469-45-4 880469-46-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(SAR and inhibitor complex structure determination of a novel class of potent

10/ 539,220

and specific Aurora kinase inhibitors)

RN 331787-26-9 ZCAPLUS


CN Benzamide, N-[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 331787-58-7 ZCAPLUS


CN Benzamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331792-49-5 ZCAPLUS


CN 4-Pyridinecarboxamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331792-64-4 ZCAPLUS


CN Benzamide, 3-bromo-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 331792-74-6 ZCAPLUS


CN Benzamide, 3-chloro-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331793-17-0 ZCAPLUS


CN Benzamide, 3-chloro-4-fluoro-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331793-83-0 ZCAPLUS


CN Benzamide, 4-ethyl-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220




RN 331794-30-0 ZCAPLUS

CN Pentanamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 331794-50-4 ZCAPLUS

CN Benzamide, 4-[(dipropylamino)sulfonyl]-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 880469-45-4 ZCAPLUS

CN Benzamide, 3-chloro-N-[2-[[6-methoxy-7-[3-(1-piperidiny)propoxy]-4-quinazolinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 880469-46-5 ZCAPLUS

CN Benzamide, N-[2-[[7-[(2S)-2-hydroxy-3-(1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:20543 ZCAPLUS

DOCUMENT NUMBER: 144:292702

TITLE: Discovery of Novel and Potent Thiazoloquinazolines as Selective Aurora A and B Kinase Inhibitors

AUTHOR(S): Jung, Frederic H.; Pasquet, Georges; Van der Brempt, Christine Lambert; Lohmann, Jean-Jacques M.; Warin, Nicolas; Renaud, Fabrice; Germain, Herve; De Savi, Chris; Roberts, Nicola; Johnson, Trevor; Dousson, Cyril; Hill, George B.; Mortlock, Andrew A.; Heron, Nicola; Wilkinson, Robert W.; Wedge, Stephen R.; Heaton, Simon P.; Odedra, Rajesh; Keen, Nicholas J.; Green, Stephen; Brown, Elaine; Thompson, Katherine; Brightwell, Stephen

CORPORATE SOURCE: Centre de Recherches, AstraZeneca, Reims, 51689, Fr.  
SOURCE: Journal of Medicinal Chemistry (2006), 49(3), 955-970  
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:292702

AB The synthesis of a novel series of quinazolines substituted at C4 by five-membered ring aminoheterocycles is reported. Their in vitro structure-activity relationships vs. Aurora A and B serine-threonine kinases is discussed. Our results demonstrate that quinazolines with a substituted aminothiazole at C4 possess potent Aurora A and B inhibitory activity and excellent selectivity against a panel of various serine-threonine and tyrosine kinases, as exemplified by N-(3-fluorophenyl)-2-[2-[[7-[3-[4-(hydroxymethyl)piperidin-1-yl]propoxy]-6-methoxy-quinazolinyl]amino]-1,3-thiazol-5-yl]acetamide (I). It was found also that the position and nature of the substituent on the thiazole play key roles in cellular potency. Compds. with an acetanilide substituent at



C5' have the greatest cellular activity. The importance of the C5' position for substitution has been rationalized by ab initio MO calcns. Results show that the planar conformation with the sulfur of the thiazole next to the quinazoline N-3 is strongly favored over the other possible planar conformation. I is a potent suppressor of the expression of phospho-histone H3 in tumor cells in vitro as well as in vivo, where I, administered as its phosphate prodrug suppresses the expression of phospho-histone H3 in s.c. implanted tumors in nude mice.


IT 385785-53-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(amidation of (quinazolinylamino)imidazolecarboxylate in preparation of (aminoalkoxy) [(heterocyclic)amino]quinazolines as inhibitors of aurora A and B kinase)

RN 385785-53-5 ZCAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 878376-10-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(amidation of oxazoleacetic acid derivative in preparation of (aminoalkoxy) [(heterocyclic)amino]quinazolines as inhibitors of aurora A and B kinase)

RN 878376-10-4 ZCAPLUS

CN 5-Oxazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/ 539,220


IT 878375-97-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(amidation of thiazoleacetate ester derivative in preparation of  
(aminoalkoxy)[(heterocyclic)amino]quinazolines as inhibitors of aurora  
A and B kinase)  
RN 878375-97-4 ZCAPLUS  
CN 5-Thiazoleacetic acid, 2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-  
pyrrolidiny]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 385784-81-6P 385785-60-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(amidation of thiazoleacetic acid derivative with fluoroaniline in  
preparation  
of (aminoalkoxy)[(heterocyclic)amino]quinazolines as inhibitors of  
aurora A and B kinase)  
RN 385784-81-6 ZCAPLUS  
CN 5-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-  
quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385785-60-4 ZCAPLUS  
CN 4-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-  
quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 385780-24-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(amidation of thiazolecarboxylic acid derivative with fluoroaniline in preparation of (aminoalkoxy)[(heterocyclic)amino]quinazolines as inhibitors of aurora A and B kinase)

RN 385780-24-5 ZCAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 723278-14-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(hydrolysis of [(quinazolinylloxy)propyl]piperidinylmethyl phosphate ester in preparation of (aminoalkoxy)[(heterocyclic)amino]quinazolines as inhibitors of aurora A and B kinase)

RN 723278-14-6 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) [1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-piperidinyl]methyl ester (9CI) (CA INDEX NAME)

10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 331788-25-1


RL: PAC (Pharmacological activity); BIOL (Biological study)

(preparation of (aminoalkoxy)[(heterocyclic)amino]quinazolines as inhibitors of aurora A and B kinase)

RN 331788-25-1 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-2-hydroxy-3-(1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 385782-89-8P, N-(3-Fluorophenyl)-2-[2-[[7-[3-[4-(hydroxymethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (aminoalkoxy)[(heterocyclic)amino]quinazolines as inhibitors of aurora A and B kinase)

RN 385782-89-8 ZCAPLUS

10/ 539,220

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 385779-87-3P 385781-84-0P 385782-93-4P  
385782-97-8P 385784-01-0P 385784-57-6P  
385784-59-8P 723278-11-3P 723278-79-3P  
723279-41-2P 723281-54-7P 723282-96-0P  
878375-89-4P 878375-90-7P 878375-91-8P  
878375-92-9P 878375-95-2P 878375-98-5P  
878375-99-6P 878376-00-2P 878376-04-6P  
878376-05-7P 878376-08-0P 878376-09-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
(Biological study); PREP (Preparation)  
(preparation of (aminoalkoxy)[(heterocyclic)amino]quinazolines as inhibitors  
of aurora A and B kinase)

RN 385779-87-3 ZCAPLUS

CN 5-Thiazolecarboxamide, N-(4-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-84-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-93-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-97-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-ethyl-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-01-0 ZCAPLUS

CN 1H-Imidazole-4-carboxamide, N-(4-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-57-6 ZCAPLUS

CN 4-Quinazolinamine, 6-methoxy-N-(5-methyl-2-thiazolyl)-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-59-8 ZCAPLUS

CN 4-Quinazolinamine, N-(5-butyl-2-thiazolyl)-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-11-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[4-  
[(phosphonoxy)methyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-79-3 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-41-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 723281-54-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-

10/ 539,220

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-96-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[2-[4-(2-hydroxyethyl)-1-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878375-89-4 ZCAPLUS

CN 5-Oxazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878375-90-7 ZCAPLUS

CN 4-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878375-91-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878375-92-9 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878375-95-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[[7-[3-[(2-hydroxyethyl)-2-propynylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878375-98-5 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-methoxyphenyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878375-99-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-[3-(dimethylamino)phenyl]-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878376-00-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-[2-(aminocarbonyl)phenyl]-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878376-04-6 ZCAPLUS

CN 4-Piperidinemethanol, 1-[3-[[4-[[5-(3-fluorophenoxy)-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878376-05-7 ZCAPLUS

CN 4-Piperidinemethanol, 1-[3-[[4-[[5-[[3-(3-fluorophenyl)methyl]thio]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878376-08-0 ZCAPLUS

CN Benzamide, 3-fluoro-N-[[2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-5-thiazolyl]methyl]- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878376-09-1 ZCAPLUS

CN Benzenesulfonamide, 3-fluoro-N-[[2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-5-thiazolyl]methyl]-  
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 878375-88-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)


(saponification of oxazoleacetate derivative in preparation of  
(aminoalkoxy)[(heterocyclic)amino]quinazolines as inhibitors of aurora

10/ 539,220

A and B kinase)

RN 878375-88-3 ZCAPLUS

CN 5-Oxazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 385780-20-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(saponification of thiazoleacetate derivative in preparation of (aminoalkoxy)[(heterocyclic)amino]quinazolines as inhibitors of aurora A and B kinase)

RN 385780-20-1 ZCAPLUS

CN 4-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 385784-82-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(saponification of thiazoleacetate ester derivative in preparation of (aminoalkoxy)[(heterocyclic)amino]quinazolines as inhibitors of aurora A and B kinase)

RN 385784-82-7 ZCAPLUS

CN 5-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 385780-23-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(saponification of thiazolecarboxylate derivative in preparation of (aminoalkoxy) [(heterocyclic)amino]quinazolines as inhibitors of aurora A and B kinase)

RN 385780-23-4 ZCAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1178222 ZCAPLUS

DOCUMENT NUMBER: 144:88236


TITLE: New heterocyclic analogues of 4-(2-chloro-5-methoxyanilino)quinazolines as potent and selective c-Src kinase inhibitors

AUTHOR(S): Barlaam, Bernard; Fennell, Mike; Germain, Herve; Green, Tim; Hennequin, Laurent; Morgentin, Remy; Olivier, Annie; Ple, Patrick; Vautier, Michel; Costello, Gerard

CORPORATE SOURCE: AstraZeneca, Centre de Recherches, Z.I.S.E. La Pompelle B.P.1050, Reims, 51689, Fr.

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(24), 5446-5449

PUBLISHER: CODEN: BMCLE8; ISSN: 0960-894X  
 Elsevier B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 144:88236  
 GI




AB A series of 5,7-disubstituted quinazolines, bearing 4-heteroaryl substituents such as 2-pyridinylamine or 2-pyrazinylamine, has been synthesized and evaluated as c-Src kinase inhibitors. Highly potent inhibition, high selectivity and phys. properties suitable for oral dosing were achieved within this series: I [X = CH, N] were identified as sub-0.1  $\mu$ M inhibitors in a c-Src-driven cell proliferation assay and displayed adequate rat pharmacokinetics after oral administration.

IT 808141-63-1P 808736-04-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation of new heterocyclic analogs of 4-(2-chloro-5-methoxyanilino)quinazolines as potent and selective c-Src kinase inhibitors)

RN 808141-63-1 ZCAPLUS


CN Piperazine, 1-acetyl-4-[2-[[4-[(3-chloro-6-methoxypyrazinyl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-04-1 ZCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-[(5-chloro-2-methoxy-4-pyrimidinyl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:714214 ZCAPLUS

DOCUMENT NUMBER: 143:326323

TITLE: Valuable synthetic building blocks: Useful  
2-substituted 5-aminopyrimidines from a stable  
precursor

AUTHOR(S): Dousson, Cyril B.; Heron, Nicola M.; Hill, George B.

CORPORATE SOURCE: AstraZeneca Healthcare, Macclesfield, SK10 4TG, UK

SOURCE: Synthesis (2005), (11), 1817-1821

CODEN: SYNTBF; ISSN: 0039-7881

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:326323


AB An efficient large-scale synthesis of 5-aminopyrimidine derivs. is described. The dihexafluorophosphate salt of a vinamidinium cation important in 5-aminopyrimidine synthesis has been prepared as a stable, easily purified intermediate. It was used to prepare several 2-functionalized aminopyrimidines, valuable as synthetic building blocks.

IT 331800-66-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of aminopyrimidines from stable vinamidinium fluorophosphate on large scale)

RN 331800-66-9 ZCAPLUS

CN Carbamic acid, [[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1154697 ZCAPLUS

DOCUMENT NUMBER: 142:93862

TITLE: Preparation of (triazolylamino)quinazoline derivatives as aurora kinase inhibitors

INVENTOR(S): Mortlock, Andrew Austen; Heron, Nicola Murdoch; Jung, Frederic Henri

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113324	A1	20041229	WO 2004-GB2564	20040614
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249477	A1	20041229	AU 2004-249477	20040614
CA 2529250	A1	20041229	CA 2004-2529250	20040614
EP 1644361	A1	20060412	EP 2004-736769	20040614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004011503	A	20060725	BR 2004-11503	20040614
CN 1835945	A	20060920	CN 2004-80023140	20040614
JP 2006527748	T	20061207	JP 2006-516425	20040614
NO 2005005891	A	20060207	NO 2005-5891	20051212
US 2006178382	A1	20060810	US 2005-560659	20051213

PRIORITY APPLN. INFO.:

EP 2003-291463

A 20030617


WO 2004-GB2564

W 20040614


OTHER SOURCE(S):

MARPAT 142:93862

GI



I



II

AB Title compds. represented by the formula I [wherein X = O or (alkyl)amino; R1, R3, R4 = independently H, halo or X1R11; R2 = H, halo, nitro, cyano, X2R12; X1-X2 = independently a direct bond, O, NH, (alkyl)amino, etc.; R11, R12 = independently H, (cyclo)alkyl, (cyclo)alkenyl, heterocyclyl, etc.; R5 = (un)substituted (hetero)aryl; and salts, esters or prodrugs thereof] were prepared as aurora kinase inhibitors. For example, II was given in a multi-step synthesis starting from the reaction of 2-(4-amino-1H-1,2,3-triazol-1-yl)-N-(3-fluorophenyl)acetamide with 4-chloro-7-(3-chloropropoxy)-6-methoxyquinazoline. II showed 50% inhibition of enzyme activity at concentration of 0.1  $\mu$ M in vitro aurora-A kinase inhibition test, and the compds. of invention are generally active at 1 nM to 100  $\mu$ M in vitro cell proliferation assay and 1 nM to 10  $\mu$ M in vitro cell cycle anal. assay. Thus, I and their pharmaceutical compns. are useful as aurora kinase inhibitors for the treatment of proliferative diseases, such as cancer (no data).


IT 816430-19-0P 816430-20-3P 816430-21-4P  
 816430-22-5P 816430-23-6P 816430-24-7P  
 816430-25-8P 816430-26-9P 816430-27-0P  
 816430-28-1P 816430-29-2P 816430-30-5P  
 816430-31-6P 816430-32-7P 816430-33-8P  
 816430-34-9P 816430-35-0P 816430-36-1P  
 816430-37-2P 816430-38-3P 816430-39-4P  
 816430-40-7P 816430-41-8P 816430-42-9P  
 816430-43-0P 816430-44-1P 816430-45-2P  
 816430-46-3P 816430-47-4P 816430-48-5P  
 816430-49-6P 816430-50-9P 816430-51-0P  
 816430-52-1P 816430-53-2P 816430-54-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of (triazolylamino)quinazoline derivs. as aurora kinase

inhibitors for the treatment of cancers)  
 RN 816430-19-0 ZCAPLUS  
 CN 1H-1,2,3-Triazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)propylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 816430-20-3 ZCAPLUS  
 CN 1H-1,2,3-Triazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/ 539,220




RN 816430-21-4 ZCAPLUS  
 CN 1H-1,2,3-Triazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2S)-hydroxyethyl]propylamino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 816430-22-5 ZCAPLUS  
 CN 1H-1,2,3-Triazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2S)-2-

10/ 539,220


(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 816430-23-6 ZCAPLUS


CN 1H-1,2,3-Triazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 816430-24-7 ZCAPLUS


CN 1H-1,2,3-Triazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220





RN 816430-25-8 ZCAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 816430-26-9 ZCAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 816430-27-0 ZCAPLUS  
 CN 1H-1,2,3-Triazole-1-acetamide, 4-[[7-[3-(cyclopropylamino)propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)


10/ 539,220




RN 816430-28-1 ZCAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, 4-[[7-[3-[[2-(dimethylamino)ethyl]methylamino]propoxy]-4-quinazoliny]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)


PAGE 1-A





RN 816430-29-2 ZCAPLUS


CN 1H-1,2,3-Triazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 816430-30-5 ZCAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 816430-31-6 ZCAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-(4-hydroxy-1-


10/ 539,220


piperidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 816430-32-7 ZCAPLUS  
CN 1H-1,2,3-Triazole-1-acetamide, 4-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 816430-33-8 ZCAPLUS  
 CN 1H-1,2,3-Triazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 816430-34-9 ZCAPLUS  
 CN 1H-1,2,3-Triazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-(1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)






RN 816430-35-0 ZCAPLUS  
 CN 1H-1,2,3-Triazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[4-(2-hydroxyethyl)-1-piperidiny]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




RN 816430-36-1 ZCAPLUS  
 CN 1H-1,2,3-Triazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[4-(2-hydroxymethyl)-1-piperidiny]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




RN 816430-37-2 ZCAPLUS  
 CN 1H-1,2,3-Triazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)(1-methylethyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 816430-38-3 ZCAPLUS  
 CN 1H-1,2,3-Triazole-1-acetamide, 4-[[7-[3-[cyclopropyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 816430-39-4 ZCAPLUS  
 CN 1H-1,2,3-Triazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

10/ 539,220




RN 816430-40-7 ZCAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 816430-41-8 ZCAPLUS


CN 1H-1,2,3-Triazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 816430-42-9 ZCAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A







RN 816430-43-0 ZCAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, 4-[[7-[3-(cyclopropylamino)propoxy]-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 816430-44-1 ZCAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[[2-(dimethylamino)ethyl]methylamino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 816430-45-2 ZCAPLUS  
 CN 1H-1,2,3-Triazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



RN 816430-46-3 ZCAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 816430-47-4 ZCAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-(4-hydroxy-1-piperidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)





10/ 539,220



RN 816430-48-5 ZCAPLUS  
CN 1H-1,2,3-Triazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazoliny]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 816430-49-6 ZCAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 816430-50-9 ZCAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-(1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 816430-51-0 ZCAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[4-(2-hydroxyethyl)-1-piperidiny]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 816430-52-1 ZCAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[4-(hydroxymethyl)-1-piperidiny]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 816430-53-2 ZCAPLUS  
 CN 1H-1,2,3-Triazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)(1-methylethyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 816430-54-3 ZCAPLUS  
 CN 1H-1,2,3-Triazole-1-acetamide, 4-[[7-[3-[cyclopropyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1080893 ZCAPLUS



DOCUMENT NUMBER: 142:56356

TITLE: Preparation of pyrazinyl quinazoline derivatives as c-Src tyrosine kinase inhibitors for use in the treatment of tumors

INVENTOR(S): Barlaam, Bernard  
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SOURCE: PCT Int. Appl., 77 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004108711	A1	20041216	WO 2004-GB2366	20040603
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: EP 2003-291342 A 20030605  
 OTHER SOURCE(S): MARPAT 142:56356  
 GI



AB The invention concerns quinazoline derivs. I [Z = O, S, SO, SO<sub>2</sub>, NR<sub>2</sub> or CR<sub>2</sub>R<sub>3</sub> (wherein R<sub>2</sub>, R<sub>3</sub> = H, alkyl); m = 1-3; R<sub>1</sub> = halo, CF<sub>3</sub>, CN, etc.; R<sub>4</sub> = alkoxy; and R<sub>5</sub> = H, halo, alkyl or alkoxy; R<sub>6</sub> = H, halo] or a pharmaceutically-acceptable salt thereof; processes for their preparation; pharmaceutical compns. containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or


treatment of solid tumor disease. E.g., a multi-step synthesis of the quinazoline II, starting from 5,7-difluoro-3,4-dihydroquinazolin-4-one, was given. The compds. I were tested for their activity against c-Src tyrosine kinase. They demonstrated IC<sub>50</sub> values in the range, for example, 0.001-10  $\mu$ M in in vitro enzyme assay.

IT 808141-67-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of pyrazinyl quinazolines as c-Src tyrosine kinase inhibitors for treating tumors)

RN 808141-67-5 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-7-[(2,4-dimethoxyphenyl)methoxy]-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 808141-63-1P 808141-64-2P 808141-66-4P

808141-72-2P 808141-73-3P 808141-74-4P

808141-75-5P 808141-76-6P 808141-77-7P

808141-78-8P 808141-79-9P 808141-80-2P

808141-81-3P 808141-82-4P 808141-85-7P

808141-86-8P 808141-87-9P 808141-88-0P

808141-89-1P 808141-90-4P 808141-91-5P

808141-92-6P 808141-93-7P 808141-94-8P

808141-95-9P 808141-96-0P 808141-97-1P

808141-98-2P 808141-99-3P 808142-00-9P

808142-01-0P 808142-02-1P 808142-04-3P

808142-34-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazinyl quinazolines as c-Src tyrosine kinase inhibitors for treating tumors)

RN 808141-63-1 ZCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-[(3-chloro-6-methoxypyrazinyl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-64-2 ZCAPLUS


CN Piperazine, 1-acetyl-4-[2-[[4-[(3,5-dichloro-6-methoxypyrazinyl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-66-4 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-6-methoxy-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-72-2 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-5-(1-methylethoxy)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-73-3 ZCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-5-(1-methylethoxy)-7-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-74-4 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-5-(1-methylethoxy)-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-75-5 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-5-(1-methylethoxy)-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-76-6 ZCAPLUS


CN 4-Piperidinol, 1-[2-[[4-[(3-chloro-6-methoxypyrazinyl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-77-7 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-5-(1-methylethoxy)-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-78-8 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-5-(1-methylethoxy)-7-[3-(1-piperidiny)propoxy]- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-82-4 ZCAPLUS


CN 4-Piperidinol, 1-[3-[[4-[(3-chloro-6-methoxypyrazinyl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-85-7 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-86-8 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-87-9 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-6-methoxy-7-[2-  
[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel-  
(9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-88-0 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-6-methoxy-7-[3-  
[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]propoxy]-, rel-  
(9CI) (CA INDEX NAME)


Relative stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-89-1 ZCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-6-methoxy-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-90-4 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-91-5 ZCAPLUS

10/ 539,220


CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-6-methoxy-7-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-92-6 ZCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-93-7 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-94-8 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-95-9 ZCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-6-methoxy-7-[2-[4-(2-propenyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-96-0 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-6-methoxy-7-[3-[4-(2-propenyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-97-1 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxypyrazinyl)-6-methoxy-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-98-2 ZCAPLUS


CN Piperazine, 1-acetyl-4-[2-[[4-[(3-chloro-6-methoxypyrazinyl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808141-99-3 ZCAPLUS

CN Piperazine, 1-acetyl-4-[3-[[4-[(3-chloro-6-methoxypyrazinyl)amino]-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808142-00-9 ZCAPLUS

CN Piperazine, 1-[2-[[4-[(3-chloro-6-methoxypyrazinyl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]-4-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808142-01-0 ZCAPLUS


CN Piperazine, 1-[3-[[4-[(3-chloro-6-methoxypyrazinyl)amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808142-02-1 ZCAPLUS


CN Piperazine, 1-[2-[[4-[(3-chloro-6-methoxypyrazinyl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]-4-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808142-04-3 ZCAPLUS


CN Piperazine, 1-[3-[[4-[(3-chloro-6-methoxypyrazinyl)amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808142-34-9 ZCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-[(3-chloro-6-methoxypyrazinyl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1080892 ZCAPLUS

DOCUMENT NUMBER: 142:56342

TITLE: Preparation of 4-pyrimidinyl quinazoline derivatives as c-Src tyrosine kinase inhibitors for use in the treatment of tumors

INVENTOR(S): Barlaam, Bernard

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004108710	A1	20041216	WO 2004-GB2356	20040603
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				

	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
	SN, TD, TG
PRIORITY APPLN. INFO.:	EP 2003-291344 A 20030605
OTHER SOURCE(S):	MARPAT 142:56342
GI	




AB The invention concerns quinazoline derivs. I [Z = O, S, SO, SO<sub>2</sub>, NR<sub>2</sub> or CR<sub>2</sub>R<sub>3</sub> (wherein R<sub>2</sub>, R<sub>3</sub> = H, alkyl); m = 1-3; R<sub>1</sub> = halo, CF<sub>3</sub>, CN, etc.; R<sub>4</sub> = alkoxy; and R<sub>5</sub> = H, halo, alkyl or alkoxy; R<sub>6</sub> = H, halo] or a pharmaceutically-acceptable salt thereof; processes for their preparation; pharmaceutical compns. containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumor disease. E.g., a multi-step synthesis of the quinazoline II, starting from 5,7-difluoro-3,4-dihydroquinazolin-4-one, which showed IC<sub>50</sub> of 0.015  $\mu$ M in in vitro human c-Src kinase assay, was given.

IT 808736-05-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of 4-pyrimidinyl quinazolines as c-Src tyrosine kinase inhibitors for treating tumors)

RN 808736-05-2 ZCAPLUS

CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-7-[(2,4-dimethoxyphenyl)methoxy]-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 808736-03-0P 808736-04-1P 808736-10-9P  
 808736-11-0P 808736-12-1P 808736-13-2P  
 808736-14-3P 808736-15-4P 808736-16-5P  
 808736-17-6P 808736-18-7P 808736-19-8P  
 808736-20-1P 808736-21-2P 808736-22-3P  
 808736-23-4P 808736-24-5P 808736-25-6P  
 808736-26-7P 808736-27-8P 808736-28-9P  
 808736-29-0P 808736-30-3P 808736-31-4P  
 808736-32-5P 808736-33-6P 808736-34-7P  
 808736-35-8P 808736-36-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of 4-pyrimidinyl quinazolines as c-Src tyrosine kinase  
 inhibitors for treating tumors)

RN 808736-03-0 ZCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-[(5-chloro-2-methoxy-4-pyrimidinyl)amino]-5-  
 [(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]- (9CI) (CA  
 INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-04-1 ZCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-[(5-chloro-2-methoxy-4-pyrimidinyl)amino]-5-  
 (1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-10-9 ZCAPLUS


CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-5-(1-methylethoxy)-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-11-0 ZCAPLUS

CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-5-(1-methylethoxy)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-12-1 ZCAPLUS

CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-5-(1-methylethoxy)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-13-2 ZCAPLUS


CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-5-(1-methylethoxy)-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-14-3 ZCAPLUS

CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-5-(1-methylethoxy)-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-15-4 ZCAPLUS

CN Piperazine, 1-acetyl-4-[3-[[4-[(5-chloro-2-methoxy-4-pyrimidinyl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-16-5 ZCAPLUS


CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-5-(1-methylethoxy)-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-17-6 ZCAPLUS

CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-18-7 ZCAPLUS

CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-19-8 ZCAPLUS

CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-20-1 ZCAPLUS

CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-6-methoxy-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 808736-21-2 ZCAPLUS

CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-6-methoxy-7-[3-

10/ 539,220

[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]propoxy]-, rel-  
(9CI) (CA INDEX NAME)


Relative stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-22-3 ZCAPLUS

CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-6-methoxy-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-23-4 ZCAPLUS

CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-6-methoxy-7-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-24-5 ZCAPLUS


CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-25-6 ZCAPLUS

CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-26-7 ZCAPLUS

CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-27-8 ZCAPLUS


CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-6-methoxy-7-[2-[4-(2-propenyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-28-9 ZCAPLUS

CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-6-methoxy-7-[3-[4-(2-propenyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-29-0 ZCAPLUS

CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-6-methoxy-7-[2-[4-(2-propenyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-30-3 ZCAPLUS


CN 4-Quinazolinamine, N-(5-chloro-2-methoxy-4-pyrimidinyl)-6-methoxy-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-31-4 ZCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-[(5-chloro-2-methoxy-4-pyrimidinyl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-32-5 ZCAPLUS

CN Piperazine, 1-acetyl-4-[3-[[4-[(5-chloro-2-methoxy-4-pyrimidinyl)amino]-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-33-6 ZCAPLUS


CN Piperazine, 1-[2-[[4-[(5-chloro-2-methoxy-4-pyrimidinyl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]-4-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-34-7 ZCAPLUS


CN Piperazine, 1-[3-[[4-[(5-chloro-2-methoxy-4-pyrimidinyl)amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-35-8 ZCAPLUS


CN Piperazine, 1-[2-[[4-[(5-chloro-2-methoxy-4-pyrimidinyl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]-4-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 808736-36-9 ZCAPLUS

CN Piperazine, 1-[3-[[4-[(5-chloro-2-methoxy-4-pyrimidinyl)amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1080889 ZCAPLUS

DOCUMENT NUMBER: 142:56341

TITLE: Preparation of pyridazinyl quinazoline derivatives as c-Src tyrosine kinase inhibitors for use in the treatment of tumors

INVENTOR(S): Barlaam, Bernard

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004108707	A1	20041216	WO 2004-GB2365	20040603
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG



PRIORITY APPLN. INFO.:

EP 2003-291345

A 20030605

OTHER SOURCE(S): MARPAT 142:56341

GI



AB The invention concerns quinazoline derivs. I [Z = O, S, SO, SO<sub>2</sub>, NR<sub>2</sub> or CR<sub>2</sub>R<sub>3</sub> (wherein R<sub>2</sub>, R<sub>3</sub> = H, alkyl); m = 1-3; R<sub>1</sub> = halo, CF<sub>3</sub>, CN, etc.; R<sub>4</sub>, R<sub>5</sub> = halo, alkoxy; R<sub>6</sub> = H, halo, alkyl, alkoxy] or a pharmaceutically-acceptable salt thereof; processes for their preparation; pharmaceutical compns. containing them and their use in the manufacture of a medicament for use as

an anti-invasive agent in the containment and/or treatment of solid tumor disease. E.g., a multi-step synthesis of the quinazoline II, starting from 5,7-difluoro-3,4-dihydroquinazolin-4-one, was given. The compds. I were tested for their activity against c-Src tyrosine kinase. In general, the exemplified compds. I demonstrated IC<sub>50</sub> values in the range, for example, 0.001-0.5  $\mu$ M in in vitro enzyme assay.

IT 808145-07-5P 808145-08-6P 808145-15-5P  
 808145-16-6P 808145-17-7P 808145-18-8P  
 808145-19-9P 808145-20-2P 808145-21-3P  
 808145-22-4P 808145-23-5P 808145-24-6P  
 808145-25-7P 808145-26-8P 808145-27-9P  
 808145-28-0P 808145-29-1P 808145-30-4P  
 808145-31-5P 808145-32-6P 808145-33-7P  
 808145-34-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)



(preparation of pyridazinyl quinazolines as c-Src tyrosine kinase inhibitors for treating tumors)


RN 808145-07-5 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-4-pyridazinyl)-5-(1-methylethoxy)-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 808145-08-6 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-3-methoxy-4-pyridazinyl)-5-(1-methylethoxy)-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 808145-15-5 ZCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-4-pyridazinyl)-6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 808145-16-6 ZCAPLUS

10/ 539,220


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-4-pyridazinyl)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 808145-17-7 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-4-pyridazinyl)-6-methoxy-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 808145-18-8 ZCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-4-pyridazinyl)-6-methoxy-7-[3-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]propoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 808145-19-9 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-4-pyridazinyl)-6-methoxy-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 808145-20-2 ZCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-4-pyridazinyl)-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 808145-21-3 ZCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-4-pyridazinyl)-6-methoxy-7-[2-(1-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)

piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 808145-22-4 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-4-pyridazinyl)-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 808145-23-5 ZCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-4-pyridazinyl)-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 808145-24-6 ZCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-4-pyridazinyl)-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)

10/ 539,220




RN 808145-25-7 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-4-pyridazinyl)-6-methoxy-7-[2-[4-(2-propenyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 808145-26-8 ZCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-4-pyridazinyl)-6-methoxy-7-[3-[4-(2-propenyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)



RN 808145-27-9 ZCAPLUS


CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-4-pyridazinyl)-6-methoxy-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)

10/ 539,220




RN 808145-28-0 ZCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-6-methoxy-4-pyridazinyl)-6-methoxy-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)




RN 808145-29-1 ZCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-[(3-chloro-6-methoxy-4-pyridazinyl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 808145-30-4 ZCAPLUS

CN Piperazine, 1-acetyl-4-[3-[[4-[(3-chloro-6-methoxy-4-pyridazinyl)amino]-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 808145-31-5 ZCAPLUS

CN Piperazine, 1-[2-[[4-[(3-chloro-6-methoxy-4-pyridazinyl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]-4-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 808145-32-6 ZCAPLUS

CN Piperazine, 1-[3-[[4-[(3-chloro-6-methoxy-4-pyridazinyl)amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 808145-33-7 ZCAPLUS

CN Piperazine, 1-[2-[[4-[(3-chloro-6-methoxy-4-pyridazinyl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]-4-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 808145-34-8 ZCAPLUS

CN Piperazine, 1-[3-[[4-[(3-chloro-6-methoxy-4-pyridazinyl)amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1059177 ZCAPLUS

DOCUMENT NUMBER: 142:38269

TITLE: Preparation of (3-((quinazolin-4-yl)amino)-1H-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer

INVENTOR(S): Mortlock, Andrew Austen; Heron, Nicola Murdoch; Jung, Frederic Henri; Pasquet, Georges Rene

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004105764	A1	20041209	WO 2004-GB2281	20040527
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				




LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG  
 EP 1635837 A1 20060322 EP 2004-735028 20040527  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK  
 JP 2006526599 T 20061124 JP 2006-508376 20040527  
 US 2006135541 A1 20060622 US 2005-559328 20051201  
 PRIORITY APPLN. INFO.: EP 2003-291314 A 20030602  
 WO 2004-GB2281 W 20040527  
 OTHER SOURCE(S): MARPAT 142:38269  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Quinazoline derivs. I [X = O, NR6; R1-R4 = independently H, halo, X1R7; R5  
 = optionally substituted aryl, heteroaryl; R6 = H, C1-4 alkyl; X1 = bond,  
 O, NH, N(C1-6 alkyl); R7 = H, optionally substituted heterocyclyl, C1-6  
 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkenyl] for  
 use in the treatment of proliferative diseases such as cancer and in the  
 preparation of medicaments for use in the treatment of proliferative diseases,  
 and to processes for their preparation, as well as pharmaceutical compns.  
 containing, them as active ingredient. Thus, coupling of chloroquinazoline II  
 (preparation given) with aminopyrazole III (preparation given), followed by  
 substitution with D-prolinol gave title compound IV.  
 IT 804550-45-6P 804550-47-8P 804550-49-0P  
 804550-51-4P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of (quinazolinylamino)pyrazolylacetamide derivs. as aurora  
 kinase inhibitors and anticancer agents)  
 RN 804550-45-6 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-3-[[7-[3-[(2R)-2-  
 (hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 804550-47-8 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-3-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 804550-49-0 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-3-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 804550-51-4 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-3-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 804550-46-7P 804550-48-9P 804550-50-3P

804550-52-5P 804550-53-6P 804550-54-7P



804550-55-8P 804550-56-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (quinazolinylamino)pyrazolylacetamide derivs. as aurora kinase inhibitors and anticancer agents)

RN 804550-46-7 ZCAPLUS



CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-3-[[7-[3-[(2R)-2-(hydroxyethyl)propylamino]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 804550-48-9 ZCAPLUS



CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-3-[[7-[3-[(2-hydroxyethyl)propylamino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 804550-50-3 ZCAPLUS



CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-3-[[7-[3-[(2-hydroxyethyl)propylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 804550-52-5 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-3-[[7-[3-[(2-hydroxyethyl)propylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 804550-53-6 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-3-[[7-[3-[(2R)-2-  
[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 804550-54-7 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-3-[[7-[3-[(2R)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 804550-55-8 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-3-[[6-methoxy-7-[3-[(2R)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.






ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 804550-56-9 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-3-[[6-methoxy-7-[3-[(2R)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:927198 ZCAPLUS

DOCUMENT NUMBER: 141:395569

TITLE: Quinazoline derivatives as aurora kinase inhibitors, process for their preparations, pharmaceutical compositions and uses in the treatment of proliferative diseases

INVENTOR(S): Heron, Nicola Murdoch; Pasquet, Georges Rene; Mortlock, Andrew Austen; Jung, Frederic Henri

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited


SOURCE: PCT Int. Appl., 300 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094410	A1	20041104	WO 2004-GB1614	20040414
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004232527	A1	20041104	AU 2004-232527	20040414
CA 2522079	A1	20041104	CA 2004-2522079	20040414
EP 1613619	A1	20060111	EP 2004-727325	20040414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009427	A	20060418	BR 2004-9427	20040414
CN 1809557	A	20060726	CN 2004-80016546	20040414
JP 2006523660	T	20061019	JP 2006-506123	20040414
US 2006270692	A1	20061130	US 2005-552425	20051007
NO 2005004842	A	20051108	NO 2005-4842	20051019
PRIORITY APPLN. INFO.:			EP 2003-290951	A 20030416
			WO 2004-GB1614	W 20040414
OTHER SOURCE(S):		MARPAT 141:395569		
GI				



AB Quinazoline derivs. of formula I [wherein X = O, NH or N(alkyl); R1-R4 = H, halo or alkoxy; R2 = nitro, cyano, OPO3H2; R3 = phosphonooxyalkoxy; R5 = (un)substituted (hetero)aryl; R19 = H, alkyl, acyl, amide, ester, etc.; and salts, esters or prodrugs thereof] were prepared as aurora kinase

inhibitors. Thus, II was synthesized in 95% yield by condensation of the corresponding 4-chloroquinazoline derivative (preparation given) with 4-aminopyrazole derivative (preparation given). Compds. I generally showed 50% inhibition activity at the concns. of 1-1000 nM against both aurora-A and aurora-B kinases, and were active in the in vitro cell proliferation assay and in the in vitro cell cycle anal. assay at the concns. of 1 nM to 100  $\mu$ M and 1 nM to 10  $\mu$ M, resp. Also disclosed are processes for the prepns. of I, pharmaceutical compns. comprising I and uses of I for the treatment of proliferative diseases such as cancer.

IT 786683-66-7P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[(3-hydroxypropyl)(propyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-55-7P, N-(3-Fluorophenyl)-2-[4-[[7-[3-[(2-hydroxyethyl)(2-methoxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(inhibitor, reactant; preparation of quinazoline derivs. as aurora kinase inhibitors)


RN 786683-66-7 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(3-hydroxypropyl)propylamino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786684-55-7 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)(2-methoxyethyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




IT 786682-27-7P 786682-41-5P 786682-48-2P,  
 2-[4-[[7-[3-[Ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide  
 786682-79-9P, N-(3-Fluorophenyl)-2-[4-[[7-[3-[(2-hydroxyethyl)(2-methoxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-80-2P, 2-[4-[[7-[3-[Cyclobutyl(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786682-92-6P  
 786682-93-7P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[(2-

hydroxyethyl)(propyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-02-1P 786683-06-5P,  
N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide  
786683-24-7P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[(2-hydroxyethyl)(2-methoxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-25-8P,  
2-[4-[[7-[3-[Cyclobutyl(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide  
786683-32-7P 786683-46-3P, N-(2,3-Difluorophenyl)-2-[4-[[6-methoxy-7-[2-[(tetrahydro-2H-pyran-4-yl)amino]ethoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-48-5P,  
N-(2,3-Difluorophenyl)-2-[4-[[7-[2-[(2-hydroxyethyl)(tetrahydro-2H-pyran-4-yl)amino]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide  
786683-49-6P 786683-52-1P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[(2-hydroxyethyl)(propyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-54-3P 786683-55-4P  
786683-57-6P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-58-7P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-60-1P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[(3-hydroxy-1,1-dimethylpropyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-65-6P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[(3-hydroxypropyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-67-8P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[ethyl(3-hydroxypropyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-70-3P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-(propylamino)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-71-4P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-(piperazin-1-yl)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-72-5P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[(2-hydroxyacetyl)(propyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-73-6P 786683-90-7P,  
2-[4-[[7-(3-Aminopropoxy)quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-95-2P, 2-[4-[[7-[2-(Cyclopropylamino)ethoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-96-3P, 2-[4-[[7-[2-(Cyclobutylamino)ethoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-98-5P, 2-[4-[[7-[2-(Cyclopentylamino)ethoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-99-6P, N-(2,3-Difluorophenyl)-2-[4-[[7-[2-[(2-hydroxyethyl)(tetrahydro-2H-pyran-4-yl)amino]ethoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-15-9P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[(2-hydroxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-27-3P, N-(3-Fluorophenyl)-2-[4-[[7-[3-[(2-hydroxyethyl)(propyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-28-4P, 2-[4-[[7-[3-[Ethyl(2-hydroxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786684-29-5P 786684-31-9P,  
N-(3-Fluorophenyl)-2-[4-[[7-[3-[(3-hydroxy-1,1-dimethylpropyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-33-1P, N-(3-Fluorophenyl)-2-[4-[[7-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-40-0P 786684-75-1P  
786684-78-4P 786684-79-5P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propoxy]-5-isopropoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-80-8P,  
N-(2,3-Difluorophenyl)-2-[4-[[5-isopropoxy-7-[3-(piperazin-1-

yl)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide  
 786684-82-0P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[(2-hydroxyethyl)amino]propoxy]-5-isopropoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-84-2P 786685-10-7P,  
 4-[[1-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-6-yl benzoate  
 786685-16-3P, N-(2,3-Difluorophenyl)-2-[4-[[6-hydroxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786685-20-9P, Ethyl (R)-1-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-4-[[7-[3-[2-(hydroxymethyl)pyrrolidin-1-yl]propoxy]quinazolin-4-yl]amino]-1H-pyrazole-3-carboxylate  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (inhibitor; preparation of quinazoline derivs. as aurora kinase inhibitors)  
 RN 786682-27-7 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786682-41-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/ 539,220




RN 786682-48-2 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




10/ 539,220

RN 786682-79-9 ZCAPLUS  
CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)(2-methoxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 786682-80-2 ZCAPLUS  
CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[cyclobutyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




10/ 539,220



RN 786682-92-6 ZCAPLUS



CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786682-93-7 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2S)-2-(hydroxyethyl)propylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786683-02-1 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/ 539,220




RN 786683-06-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




10/ 539,220


RN 786683-24-7 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)(2-methoxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 786683-25-8 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[cyclobutyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)


10/ 539,220



RN 786683-32-7 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786683-46-3 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[6-methoxy-7-[2-[(tetrahydro-2H-pyran-4-yl)amino]ethoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



RN 786683-48-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[(2-hydroxyethyl)(tetrahydro-2H-pyran-4-yl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 786683-49-6 ZCAPLUS



CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786683-52-1 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)propylamino]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




RN 786683-54-3 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/ 539,220



RN 786683-55-4 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 786683-57-6 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN	786683-58-7	ZCAPLUS	
CN	1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)		


10/ 539,220




RN 786683-60-1 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[[3-[(3-hydroxy-1,1-dimethylpropyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A







RN 786683-65-6 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-(3-hydroxypropyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786683-67-8 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[ethyl(3-hydroxypropyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786683-70-3 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-(propylamino)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220





RN 786683-71-4 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-(1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786683-72-5 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(hydroxyacetyl)propylamino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786683-73-6 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[4-(hydroxyacetyl)-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 786683-90-7 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, 4-[[7-(3-aminopropoxy)-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 786683-95-2 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, 4-[[7-[2-(cyclopropylamino)ethoxy]-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




10/ 539,220




RN 786683-96-3 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, 4-[[7-[2-(cyclobutylamino)ethoxy]-4-quinazoliny]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 786683-98-5 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, 4-[[7-[2-(cyclopentylamino)ethoxy]-4-quinazoliny]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 786683-99-6 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[(2-hydroxyethyl)(tetrahydro-2H-pyran-4-yl)amino]ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A









RN 786684-15-9 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 786684-27-3 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)propylamino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786684-28-4 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 786684-29-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/ 539,220




RN 786684-31-9 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(3-hydroxy-1,1-dimethylpropyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



10/ 539,220

RN 786684-33-1 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 786684-40-0 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[(2S)-2-pyrrolidinylmethoxy]-4-quinazolinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 786684-38-6

CMF C24 H24 F N7 O2

Absolute stereochemistry.




10/ 539,220

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 786684-75-1 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[6-fluoro-7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786684-78-4 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-5-(1-methylethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






10/ 539,220


RN 786684-79-5 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-5-(1-methylethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 786684-80-8 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[5-(1-methylethoxy)-7-[3-(1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



10/ 539,220

RN 786684-82-0 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)amino]propoxy]-5-(1-methylethoxy)-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



RN 786684-84-2 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-5-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786685-10-7 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, 4-[[6-(benzoyloxy)-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)

10/ 539,220



RN 786685-16-3 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[6-hydroxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 786685-20-9 ZCAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-4-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 786682-28-8P, N-(3-Fluorophenyl)-2-[4-[[7-[3-[(2-hydroxyethyl)(isobutyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-30-2P, N-(3-Fluorophenyl)-2-[4-[[7-[3-[(2-hydroxyethyl)(propyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-32-4P, N-(3-Fluorophenyl)-2-[4-[[6-methoxy-7-[3-(piperidin-1-yl)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-33-5P, N-(3-Fluorophenyl)-2-[4-[[6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-34-6P, 2-[4-[[7-[3-(Diethylamino)propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786682-35-7P, N-(3-Fluorophenyl)-2-[4-[[6-methoxy-7-[3-(piperazin-1-yl)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-36-8P, N-(3-Fluorophenyl)-2-[4-[[7-[3-[(2-hydroxyethyl)(methyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-37-9P, 2-[4-[[7-[3-(Cyclopropylamino)propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786682-38-0P, 2-[4-[[7-[3-[[2-(Dimethylamino)ethyl](methyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786682-39-1P, N-(3-Fluorophenyl)-2-[4-[[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-43-7P, N-(3-Fluorophenyl)-2-[4-[[7-[3-(4-hydroxypiperidin-1-yl)propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-45-9P, 2-[4-[[7-[3-[Bis(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786682-47-1P, 2-[4-[[7-[3-[Ethyl(methyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786682-50-6P, 2-[4-[[7-[3-[[2-(Dimethylamino)ethyl](ethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786682-52-8P, N-(3-Fluorophenyl)-2-[4-[[7-[3-[2-(2-hydroxyethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-55-1P, N-(3-Fluorophenyl)-2-[4-[[7-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-58-4P, 2-[4-[[7-[3-[(Cyclopropylmethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786682-60-8P, N-(3-Fluorophenyl)-2-[4-[[7-[3-[4-(2-hydroxyethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-62-0P, N-(3-Fluorophenyl)-2-[4-[[6-methoxy-7-[3-[methyl(2-propyn-1-yl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-64-2P, 2-[4-[[7-[3-[Allyl(methyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-

yl]-N-(3-fluorophenyl)acetamide 786682-67-5P,  
N-(3-Fluorophenyl)-2-[4-[[7-[3-[isobutyl(methyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide  
786682-69-7P, N-(3-Fluorophenyl)-2-[4-[[7-[3-(3-hydroxypiperidin-1-yl)propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide  
786682-71-1P, N-(3-Fluorophenyl)-2-[4-[[7-[3-[4-(hydroxymethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-72-2P, N-(3-Fluorophenyl)-2-[4-[[6-methoxy-7-[3-[methyl(propyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-73-3P, 2-[4-[[7-[3-[[Cyclopropylmethyl](propyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786682-74-4P, 2-[4-[[7-[3-[[2-(Diethylamino)ethyl](methyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786682-75-5P, 2-[4-[[7-[3-[[2-(Diethylamino)ethyl](ethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786682-76-6P, N-(3-Fluorophenyl)-2-[4-[[6-methoxy-7-[3-(4-methyl-1,4-diazepan-1-yl)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-77-7P, N-(3-Fluorophenyl)-2-[4-[[7-[3-[[2-(2-hydroxyethyl)(isopropyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-78-8P, 2-[4-[[7-[3-[[Cyclopropyl(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786682-81-3P, 2-[4-[[7-[3-[[Cyclopropylmethyl](2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786682-82-4P, 2-[4-[[7-[3-[[Cyclobutylmethyl](2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786682-83-5P, N-(3-Fluorophenyl)-2-[4-[[7-[3-[[2-(2-hydroxyethyl)(2-propyn-1-yl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-84-6P, 2-[4-[[7-[3-[[Allyl](2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786682-85-7P, 2-[4-[[7-[3-[[2,2-Dimethylpropyl](2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786682-86-8P, N-(3-Fluorophenyl)-2-[4-[[7-[3-[[2-(2-hydroxyethyl)(3,3,3-trifluoropropyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-87-9P, 2-[4-[[7-[3-[[Azetidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786682-91-5P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[[2-(2-hydroxyethyl)(isobutyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-94-8P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[[dimethylamino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-95-9P, N-(2,3-Difluorophenyl)-2-[4-[[6-methoxy-7-[3-(piperidin-1-yl)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-96-0P, N-(2,3-Difluorophenyl)-2-[4-[[6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-97-1P, N-(2,3-Difluorophenyl)-2-[4-[[6-methoxy-7-[3-(piperazin-1-yl)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-98-2P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[[2-(2-hydroxyethyl)(methyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786682-99-3P, 2-[4-[[7-[3-[[Cyclopropylamino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-00-9P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[[2-(dimethylamino)ethyl](methyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-01-0P, N-(2,3-Difluorophenyl)-2-[4-[[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-03-2P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-(4-

hydroxypiperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-04-3P, 2-[4-[[7-[3-[Bis(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-05-4P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[ethyl(methyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-07-6P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[[2-(dimethylamino)ethyl](ethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-08-7P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[2-(2-hydroxyethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-09-8P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-10-1P, 2-[4-[[7-[3-[(Cyclopropylmethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-11-2P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[4-(2-hydroxyethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-13-4P, N-(2,3-Difluorophenyl)-2-[4-[[6-methoxy-7-[3-[methyl(2-propyn-1-yl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-14-5P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[isobutyl(methyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-15-6P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-(3-hydroxypiperidin-1-yl)propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-16-7P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[4-(hydroxymethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-17-8P, N-(2,3-Difluorophenyl)-2-[4-[[6-methoxy-7-[3-[methyl(propyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-18-9P, 2-[4-[[7-[3-[(Cyclopropylmethyl)(propyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-19-0P, 2-[4-[[7-[3-[[2-(Diethylamino)ethyl](methyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-20-3P, 2-[4-[[7-[3-[[2-(Diethylamino)ethyl](ethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-21-4P, N-(2,3-Difluorophenyl)-2-[4-[[6-methoxy-7-[3-(4-methyl-1,4-diazepan-1-yl)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-22-5P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[(2-hydroxyethyl)(isopropyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-23-6P, 2-[4-[[7-[3-[Cyclopropyl(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-26-9P, 2-[4-[[7-[3-[(Cyclopropylmethyl)(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-27-0P, 2-[4-[[7-[3-[(Cyclobutylmethyl)(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-28-1P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[(2-hydroxyethyl)(2-propyn-1-yl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-29-2P, 2-[4-[[7-[3-[(Allyl)(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-30-5P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[(2,2-dimethylpropyl)(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-31-6P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[(2-hydroxyethyl)(3,3,3-trifluoropropyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-35-0P, N-(2,3-Difluorophenyl)-2-[4-[[7-[2-[4-[2-(2-hydroxyethoxy)ethyl]piperazin-

1-yl]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-36-1P, N-(2,3-Difluorophenyl)-2-[4-[[7-[2-[2-(hydroxymethyl)piperidin-1-yl]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-37-2P, N-(2,3-Difluorophenyl)-2-[4-[[7-[2-[(2-hydroxy-1,1-dimethylethyl)amino]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-38-3P, N-(2,3-Difluorophenyl)-2-[4-[[7-[2-[4-(2-hydroxyethyl)piperazin-1-yl]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-39-4P, N-(2,3-Difluorophenyl)-2-[4-[[7-[2-[(trans-4-hydroxycyclohexyl)amino]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-40-7P, N-(2,3-Difluorophenyl)-2-[4-[[7-[2-[3-(hydroxymethyl)piperidin-1-yl]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-41-8P, N-(2,3-Difluorophenyl)-2-[4-[[7-[2-[[1-(hydroxymethyl)cyclopentyl]amino]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-42-9P, N-(2,3-Difluorophenyl)-2-[4-[[7-[2-[4-(3-hydroxypropyl)piperazin-1-yl]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-43-0P, 2-[4-[[7-[2-[Cyclohexyl(2-hydroxyethyl)amino]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-44-1P, N-(2,3-Difluorophenyl)-2-[4-[[7-[2-[(2-hydroxyethyl)(propyl)amino]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-45-2P, N-(2,3-Difluorophenyl)-2-[4-[[7-[2-[(3-hydroxy-2,2-dimethylpropyl)amino]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-47-4P, 2-[4-[[7-[2-[Cyclobutyl(2-hydroxyethyl)amino]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-50-9P, 786683-51-0P, 786683-53-2P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[(2-hydroxyethyl)(isobutyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-56-5P, 2-[4-[[7-[3-[Cyclopentyl(2-hydroxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-59-8P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[4-(hydroxymethyl)piperidin-1-yl]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-61-2P, 2-[4-[[7-[3-[(2-Cyanoethyl)(2-hydroxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-63-4P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-(morpholin-4-yl)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-64-5P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[(3-hydroxy-2,2-dimethylpropyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-68-9P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[4-(2-hydroxyethyl)-3-oxopiperazin-1-yl]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-74-7P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[(trans-2-(hydroxymethyl)cyclohexyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-76-9P, 786683-77-0P, 786683-78-1P, 786683-79-2P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-80-5P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[(2,3-dihydroxypropyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-81-6P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[[2-(2-hydroxyethoxy)ethyl]amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-82-7P, 2-[4-[[7-[3-(4-Acetylpiperazin-1-yl)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-83-8P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[[[tetrahydrofuran-2-yl)methyl]amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-84-9P, 2-[4-[[7-[3-(Allylamino)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-85-0P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[[1-(hydroxymethyl)-2-

methylpropyl]amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-86-1P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[[5-methylisoxazol-3-yl)methyl]amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-87-2P 786683-88-3P 786683-92-9P 786683-93-0P, N-(2,3-Difluorophenyl)-2-[4-[[7-[2-[(3-hydroxy-2,2-dimethylpropyl)amino]ethoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786683-94-1P, 2-[4-[[7-[2-[Cyclohexyl(2-hydroxyethyl)amino]ethoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786683-97-4P, N-(2,3-Difluorophenyl)-2-[4-[[7-[2-[(tetrahydro-2H-pyran-4-yl)amino]ethoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-01-3P, 2-[4-[[7-[2-[Cyclopentyl(2-hydroxyethyl)amino]ethoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786684-02-4P 786684-03-5P, 2-[4-[[7-[2-[Cyclopropyl(2-hydroxyethyl)amino]ethoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786684-04-6P, 2-[4-[[7-[2-[Cyclobutyl(2-hydroxyethyl)amino]ethoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786684-05-7P, 2-[4-[[7-[2-[Cyclopentyl(3-hydroxypropyl)amino]ethoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786684-06-8P, 2-[4-[[7-[2-[Cyclopentyl(2-hydroxyacetyl)amino]ethoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786684-07-9P 786684-09-1P 786684-10-4P 786684-11-5P, N-(2,3-Difluorophenyl)-2-[4-[[7-[2-[4-(hydroxymethyl)piperidin-1-yl]ethoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-12-6P, N-(2,3-Difluorophenyl)-2-[4-[[7-[2-[4-(2-hydroxyethyl)piperidin-1-yl]ethoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-13-7P, N-(2,3-Difluorophenyl)-2-[4-[[7-[2-[(2-hydroxyethyl)amino]ethoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-14-8P, N-(2,3-Difluorophenyl)-2-[4-[[7-[2-[[trans-2-(hydroxymethyl)cyclohexyl]amino]ethoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-16-0P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-18-2P, N-(2,3-Difluorophenyl)-2-[4-[[7-[3-[(2-hydroxyethyl)(tetrahydro-2H-pyran-4-yl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-19-3P 786684-20-6P 786684-22-8P 786684-23-9P 786684-24-0P 786684-25-1P 786684-26-2P 786684-30-8P, N-(3-Fluorophenyl)-2-[4-[[7-[3-[4-(hydroxymethyl)piperidin-1-yl]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-32-0P, N-(3-Fluorophenyl)-2-[4-[[7-[3-[2-(2-hydroxyethyl)piperidin-1-yl]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-34-2P, N-(3-Fluorophenyl)-2-[4-[[7-[3-[(2-hydroxyethyl)(tetrahydrofuran-3-yl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-37-5P, N-(3-Fluorophenyl)-2-[4-[[7-[3-(morpholin-4-yl)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-38-6P 786684-42-2P 786684-44-4P 786684-45-5P 786684-46-6P, N-(3-Fluorophenyl)-2-[4-[[7-[3-[(pyrrolidin-3-yl)methoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-49-9P, N-(3-Fluorophenyl)-2-[4-[[7-[1-(2-hydroxyethyl)pyrrolidin-3-yl]methoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-53-5P 786684-61-5P 786684-66-0P, 2-[4-[[7-[3-[Ethyl(2-hydroxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2-fluorophenyl)acetamide 786684-67-1P 786684-69-3P, 2-[4-[[7-[3-[Ethyl(2-hydroxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-phenylacetamide 786684-70-6P 786684-72-8P, 2-[4-[[7-[3-[Ethyl(2-hydroxyethyl)amino]propoxy]-6-fluoroquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide





786684-73-9P, 2-[4-[[7-[3-[(Cyclopropylmethyl)(2-hydroxyethyl)amino]propoxy]-6-fluoroquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786684-74-0P, N-(2,3-Difluorophenyl)-2-[4-[[6-fluoro-7-[3-[(2-hydroxyethyl)(propyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786684-76-2P, 2-[4-[[7-[3-[(Cyclopentyl)(2-hydroxyethyl)amino]propoxy]-6-fluoroquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786684-77-3P, 2-[4-[[7-[3-[Bis(2-hydroxyethyl)amino]propoxy]-5-isopropoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide 786684-81-9P 786684-83-1P 786685-12-9P 786685-17-4P, 1-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-4-[[7-[3-[(2-hydroxyethyl)(2-methoxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazole-3-carboxamide 786685-18-5P, (S)-1-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-4-[[7-[3-[2-(hydroxymethyl)pyrrolidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazole-3-carboxamide 786685-19-6P 786685-21-0P, (R)-1-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-4-[[7-[3-[2-(hydroxymethyl)pyrrolidin-1-yl]propoxy]quinazolin-4-yl]amino]-1H-pyrazole-3-carboxylic acid 786685-22-1P, 2-[[3-[[4-[[1-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl](propyl)amino]ethyl dihydrogen phosphate 786685-24-3P 786685-26-5P 786685-28-7P, 2-[Ethyl[3-[[4-[[1-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]ethyl dihydrogen phosphate 786685-30-1P 786685-32-3P, 2-[[3-[[4-[[1-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl](2-methoxyethyl)amino]ethyl dihydrogen phosphate 786685-34-5P 786685-36-7P 786685-38-9P 786685-40-3P, 2-[[3-[[4-[[1-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl](ethyl)amino]ethyl dihydrogen phosphate 786685-42-5P, 2-[[3-[[4-[[1-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]quinazolin-7-yl]oxy]propyl](propyl)amino]ethyl dihydrogen phosphate 786685-44-7P, 2-[Cyclobutyl[3-[[4-[[1-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]ethyl dihydrogen phosphate 786685-46-9P, 2-[Cyclobutyl[3-[[4-[[1-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]ethyl dihydrogen phosphate 786685-48-1P, 2-[[3-[[4-[[1-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl](2-methoxyethyl)amino]ethyl dihydrogen phosphate 786685-50-5P, 2-[[3-[[4-[[1-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]quinazolin-7-yl]oxy]propyl](propyl)amino]ethyl dihydrogen phosphate 786685-51-6P 786685-52-7P, 2-[4-[3-[[4-[[1-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]quinazolin-7-yl]oxy]propyl]piperazin-1-yl]ethyl dihydrogen phosphate 786685-53-8P, 2-[Ethyl[3-[[4-[[1-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]quinazolin-7-yl]oxy]propyl]amino]ethyl dihydrogen phosphate 786685-54-9P, 2-[[3-[[4-[[1-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]quinazolin-7-yl]oxy]propyl](ethyl)amino]ethyl dihydrogen phosphate 786685-55-0P, 3-[[3-[[4-[[1-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]quinazolin-7-yl]oxy]propyl]amino]-3-methylbutyl dihydrogen phosphate 786685-56-1P, 3-[[3-[[4-[[1-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]quinazolin-7-yl]oxy]propyl]amino]-3-methylbutyl dihydrogen phosphate 786685-57-2P 786685-58-3P, 2-[4-[3-[[4-[[1-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]quinazolin-7-

yl]oxy]propyl]piperazin-1-yl]ethyl dihydrogen phosphate  
 786685-59-4P, 3-[[3-[[4-[[1-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]quinazolin-7-yl]oxy]propyl]amino]propyl dihydrogen phosphate 786685-60-7P, 2-[[3-[[4-[[1-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]quinazolin-7-yl]oxy]propyl]amino]ethyl dihydrogen phosphate 786685-61-8P, 2-[[3-[[4-[[1-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]quinazolin-7-yl]oxy]propyl] (2-methoxyethyl)amino]ethyl dihydrogen phosphate 786685-62-9P, 3-[[3-[[4-[[1-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]quinazolin-7-yl]oxy]propyl] (ethyl)amino]propyl dihydrogen phosphate 786685-63-0P, 3-[[3-[[4-[[1-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]quinazolin-7-yl]oxy]propyl] (propyl)amino]propyl dihydrogen phosphate 786685-64-1P, 2-[[3-[[4-[[1-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]quinazolin-7-yl]oxy]propyl] (propyl)amino]-2-oxoethyl dihydrogen phosphate 786685-65-2P, 2-[4-[3-[[4-[[1-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]quinazolin-7-yl]oxy]propyl]piperazin-1-yl]-2-oxoethyl dihydrogen phosphate 786685-66-3P  
 786685-67-4P 786685-68-5P 786685-69-6P, 2-[4-[3-[[4-[[1-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-5-isopropoxyquinazolin-7-yl]oxy]propyl]piperazin-1-yl]ethyl dihydrogen phosphate 786685-70-9P, 2-[[3-[[4-[[1-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-5-isopropoxyquinazolin-7-yl]oxy]propyl]amino]ethyl dihydrogen phosphate 786685-71-0P 786685-73-2P 786685-74-3P, 2-[[2-[[4-[[1-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-6-methoxyquinazolin-7-yl]oxy]ethyl] (tetrahydro-2H-pyran-4-yl)amino]ethyl dihydrogen phosphate 786685-79-8P, 2-[[2-[[4-[[1-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]quinazolin-7-yl]oxy]ethyl] (tetrahydro-2H-pyran-4-yl)amino]ethyl dihydrogen phosphate 786685-80-1P, N-(2,3-Difluorophenyl)-2-[4-[[7-[2-[(3-hydroxy-2,2-diethylpropyl)amino]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide 786699-28-3P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)



(inhibitor; preparation of quinazoline derivs. as aurora kinase inhibitors)

RN 786682-28-8 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2-hydroxyethyl) (2-methylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786682-30-2 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)propylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)




RN 786682-32-4 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 786682-33-5 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 786682-34-6 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-(diethylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

10/ 539,220





RN 786682-35-7 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[6-methoxy-7-[3-(1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786682-36-8 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786682-37-9 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-(cyclopropylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 786682-38-0 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[[2-(dimethylamino)ethyl]methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A









RN 786682-39-1 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786682-43-7 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786682-45-9 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[bis(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786682-47-1 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-(ethylmethylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786682-50-6 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[[2-(dimethylamino)ethyl]ethylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 786682-52-8 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[2-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786682-55-1 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 786682-58-4 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[(cyclopropylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 786682-60-8 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220




RN 786682-62-0 ZCAPLUS  
CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[6-methoxy-7-[3-(methyl-2-propynylamino)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786682-64-2 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[6-methoxy-7-[3-(methyl-2-propenylamino)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 786682-67-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[6-methoxy-7-[3-[methyl(2-methylpropyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)






RN 786682-69-7 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-(3-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220





RN 786682-71-1 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[4-(hydroxymethyl)-1-piperidiny]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786682-72-2 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[6-methoxy-7-[3-(methylpropylamino)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786682-73-3 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[(cyclopropylmethyl)propylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 786682-74-4 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[[2-(diethylamino)ethyl]methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



PAGE 1-A





PAGE 2-A





RN 786682-75-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[[3-[[2-(diethylamino)ethyl]ethylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)-(9CI) (CA INDEX NAME)



RN 786682-76-6 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786682-77-7 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)(1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




RN 786682-78-8 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[cyclopropyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)






RN 786682-81-3 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, 4-[[7-[[3-[(cyclopropylmethyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN	786682-82-4	ZCAPLUS
CN	1H-Pyrazole-1-acetamide, 4-[[7-[3-[(cyclobutylmethyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)	




RN 786682-83-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)-2-propynylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786682-84-6 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)-2-propenylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



PAGE 1-A





PAGE 2-A




RN 786682-85-7 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[(2,2-dimethylpropyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 786682-86-8 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)(3,3,3-trifluoropropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)





RN 786682-87-9 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-(1-azetidinyloxy)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 786682-91-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)(2-methylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 786682-94-8 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-(dimethylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 786682-95-9 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220




RN 786682-96-0 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786682-97-1 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[6-methoxy-7-[3-(1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 786682-98-2 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)


PAGE 1-A







RN 786682-99-3 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-(cyclopropylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 786683-00-9 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[[2-(dimethylamino)ethyl]methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 786683-01-0 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220





RN 786683-03-2 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)





RN 786683-04-3 ZCAPLUS



CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[bis(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 786683-05-4 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-(ethylmethylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 786683-07-6 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[[2-(dimethylamino)ethyl]ethylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-  
 (9CI) (CA INDEX NAME)




RN 786683-08-7 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[2-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




10/ 539,220



RN 786683-09-8 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 786683-10-1 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[(cyclopropylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)

10/ 539,220





RN 786683-11-2 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)





RN 786683-13-4 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[6-methoxy-7-[3-(methyl-2-propynylamino)propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




RN 786683-14-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[6-methoxy-7-[3-[methyl(2-methylpropyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786683-15-6 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-(3-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220





RN 786683-16-7 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[4-(hydroxymethyl)-1-piperidiny]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786683-17-8 ZCAPLUS



CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[6-methoxy-7-[3-(methylpropylamino)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 786683-18-9 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[(cyclopropylmethyl)propylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 786683-19-0 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[[2-(diethylamino)ethyl]methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 786683-20-3 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[[3-[[2-(diethylamino)ethyl]ethylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)-(9CI) (CA INDEX NAME)





PAGE 1-A





PAGE 2-A




RN 786683-21-4 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propoxy]-6-methoxy-4-quinazolinyl]amino]-  
 (9CI) (CA INDEX NAME)



RN 786683-22-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)(1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




RN 786683-23-6 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[cyclopropyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 786683-26-9 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, 4-[[7-[[3-[(cyclopropylmethyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 786683-27-0 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[(cyclobutylmethyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 786683-28-1 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)-2-propynylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786683-29-2 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)-2-propenylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A





RN 786683-30-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2,2-dimethylpropyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786683-31-6 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)(3,3,3-trifluoropropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)






RN 786683-35-0 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]-  
 (9CI) (CA INDEX NAME)

10/ 539,220



RN 786683-36-1 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[2-(hydroxymethyl)-1-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786683-37-2 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[(2-hydroxy-1,1-dimethylethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 786683-38-3 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[4-(2-hydroxyethyl)-1-piperazinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)


10/ 539,220



RN 786683-39-4 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[(trans-4-hydroxycyclohexyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 786683-40-7 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[3-(hydroxymethyl)-1-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 786683-41-8 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[[1-(hydroxymethyl)cyclopentyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 786683-42-9 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[4-(3-hydroxypropyl)-1-piperazinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220




RN 786683-43-0 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[2-[cyclohexyl(2-hydroxyethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786683-44-1 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[(2-hydroxyethyl)propylamino]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 786683-45-2 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[(3-hydroxy-2,2-dimethylpropyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 786683-47-4 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[2-[cyclobutyl(2-hydroxyethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




10/ 539,220



RN 786683-50-9 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[(2R)-2-(2-hydroxyethyl)-1-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 786683-51-0 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[(2S)-2-(2-hydroxyethyl)-1-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.

10/ 539,220




RN 786683-53-2 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)(2-methylpropyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 786683-56-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[cyclopentyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786683-59-8 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220




RN 786683-61-2 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[[3-[(2-cyanoethyl)(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)-(9CI) (CA INDEX NAME)

PAGE 1-A






RN 786683-63-4 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786683-64-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(3-hydroxy-2,2-dimethylpropyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 786683-68-9 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[4-(2-hydroxyethyl)-3-oxo-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)


10/ 539,220



RN 786683-74-7 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(1R,2R)-2-(hydroxymethyl)cyclohexyl]amino]propoxy]-4-quinazolinyl]amino]-, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 786683-76-9 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-3-yl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




— F

RN 786683-77-0 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[[ (2R)-2-hydroxypropyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/ 539,220



RN 786683-78-1 ZCAPLUS



CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(1S)-2-hydroxy-1-methylethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 786683-79-2 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2S)-2-hydroxy-1,1-dimethylethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786683-80-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2,3-dihydroxypropyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786683-81-6 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[[2-(2-hydroxyethoxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 786683-82-7 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-(4-acetyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 786683-83-8 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[[[tetrahydro-2-furanyl)methyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220





RN 786683-84-9 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-(2-propenylamino)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786683-85-0 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[[1-(hydroxymethyl)-2-methylpropyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786683-86-1 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[[5-methyl-3-isoxazolyl)methyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 786683-87-2 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(tetrahydro-2H-pyran-4-yl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786683-88-3 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(3S)-3-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



RN 786683-92-9 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2S,4R)-4-hydroxy-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.





RN 786683-93-0 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[(3-hydroxy-2,2-dimethylpropyl)amino]ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)






RN 786683-94-1 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[2-[cyclohexyl(2-hydroxyethyl)amino]ethoxy]-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 786683-97-4 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[(tetrahydro-2H-pyran-4-yl)amino]ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 786684-01-3 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[2-(cyclopentyl(2-hydroxyethyl)amino)ethoxy]-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)-  
 (9CI) (CA INDEX NAME)

PAGE 1-A






RN 786684-02-4 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786684-03-5 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, 4-[[7-[2-[cyclopropyl(2-hydroxyethyl)amino]ethoxy]-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 786684-04-6 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[2-[cyclobutyl(2-hydroxyethyl)amino]ethoxy]-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)

10/ 539,220





RN 786684-05-7 ZCAPLUS  
CN 1H-Pyrazole-1-acetamide, 4-[[7-[2-(cyclopentyl(3-hydroxypropyl)amino)ethoxy]-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 786684-06-8 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[2-[cyclopentyl(hydroxyacetyl)amino]ethoxy]-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 786684-07-9 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[(3S)-3-(hydroxymethyl)-4-methyl-1-piperazinyl]ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



RN 786684-09-1 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786684-10-4 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[(2R)-2-(hydroxymethyl)-4-methyl-1-piperazinyl]ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/ 539,220




RN 786684-11-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[4-(hydroxymethyl)-1-piperidinyl]ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786684-12-6 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[4-(2-hydroxyethyl)-1-piperidinyl]ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 786684-13-7 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[(2-hydroxyethyl)amino]ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786684-14-8 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[[[(1R,2R)-2-(hydroxymethyl)cyclohexyl]amino]ethoxy]-4-quinazolinyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/ 539,220



RN 786684-16-0 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786684-18-2 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)(tetrahydro-2H-pyran-4-yl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 786684-19-3 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2R)-2-(2-hydroxyethyl)-1-piperidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/ 539,220

RN 786684-20-6 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2S)-2-(2-hydroxyethyl)-1-piperidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786684-22-8 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2R)-2-(hydroxymethyl)-4-methyl-1-piperazinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786684-23-9 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(3S)-3-(hydroxymethyl)-4-methyl-1-piperazinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



RN 786684-24-0 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2R)-2-(hydroxymethyl)-4-morpholinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786684-25-1 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(3S)-3-(hydroxymethyl)-4-morpholinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.


10/ 539,220



RN 786684-26-2 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-  
 [(hydroxyacetyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX  
 NAME)


PAGE 1-A





RN 786684-30-8 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 786684-32-0 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[2-(2-hydroxyethyl)-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)






RN 786684-34-2 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)(tetrahydro-3-furanyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 786684-37-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 786684-38-6 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[(2S)-2-pyrrolidinylmethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786684-42-2 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[[[(2S)-1-(2-hydroxyethyl)-2-pyrrolidinyl]methoxy]-4-quinazolinyl]amino]- (9CI) (CA

10/ 539,220

INDEX NAME)


Absolute stereochemistry.



RN 786684-44-4 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[[[(2S)-1-(2-hydroxyethyl)-2-pyrrolidinyl]methoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 786684-45-5 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[[[(2S)-1-(hydroxyacetyl)-2-pyrrolidinyl]methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




RN 786684-46-6 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-(3-pyrrolidinylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786684-49-9 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[[1-(2-hydroxyethyl)-3-pyrrolidinyl]methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



RN 786684-53-5 ZCAPLUS  
CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[[1-(hydroxyacetyl)-3-pyrrolidiny]methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A







RN 786684-61-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2-fluorophenyl)-4-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786684-66-0 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(2-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 786684-67-1 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786684-69-3 ZCAPLUS

10/ 539,220


CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 786684-70-6 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,6-difluorophenyl)-4-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.




RN 786684-72-8 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-fluoro-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)








RN 786684-73-9 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[(cyclopropylmethyl)(2-hydroxyethyl)amino]propoxy]-6-fluoro-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 786684-74-0 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[6-fluoro-7-[3-[(2-hydroxyethyl)propylamino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)





RN 786684-76-2 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[cyclopentyl(2-hydroxyethyl)amino]propoxy]-6-fluoro-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 786684-77-3 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[bis(2-hydroxyethyl)amino]propoxy]-5-(1-methylethoxy)-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 786684-81-9 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-5-(1-methylethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/ 539,220



RN 786684-83-1 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[4-(hydroxyacetyl)-1-piperazinyl]propoxy]-5-(1-methylethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 786685-12-9 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, 4-[[6-(benzoyloxy)-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)


10/ 539,220



RN 786685-17-4 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 3-(aminocarbonyl)-N-(3-fluorophenyl)-4-[[7-[3-[(2-hydroxyethyl)(2-methoxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 786685-18-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 3-(aminocarbonyl)-N-(3-fluorophenyl)-4-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786685-19-6 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 3-(acetyl amino)-N-(3-fluorophenyl)-4-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786685-21-0 ZCAPLUS  
 CN 1H-Pyrazole-3-carboxylic acid, 1-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-4-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220


Absolute stereochemistry.



RN 786685-22-1 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[6-methoxy-7-[3-[[2-(phosphonooxy)ethyl]propylamino]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


PAGE 1-A






RN 786685-24-3 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[6-methoxy-7-[3-[(2S)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786685-26-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[6-methoxy-7-[3-[(2S)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786685-28-7 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)-(9CI) (CA INDEX NAME)


10/ 539,220

NAME)

PAGE 1-A



PAGE 2-A




RN 786685-30-1 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[6-methoxy-7-[3-[(2R)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/ 539,220




RN 786685-32-3 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[6-methoxy-7-[3-[(2-methoxyethyl)[2-(phosphonoxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




10/ 539,220

RN 786685-34-5 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2S)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786685-36-7 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[(2R)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786685-38-9 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[6-methoxy-7-[3-[(2R)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/ 539,220




RN 786685-40-3 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




10/ 539,220


RN 786685-42-5 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[[2-(phosphonooxy)ethyl]propylamino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786685-44-7 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[cyclobutyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 786685-46-9 ZCAPLUS



CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[cyclobutyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)





RN 786685-48-1 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[6-methoxy-7-[3-[(2-methoxyethyl)[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)







RN 786685-50-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[[2-(phosphonoxy)ethyl]propylamino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786685-51-6 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[[2-(phosphonooxy)ethyl]propylamino]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 786685-52-7 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[4-[2-(phosphonooxy)ethyl]-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)




RN 786685-53-8 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[ethyl[2-(phosphonoxy)ethyl]amino]propoxy]-4-quinazoliny]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786685-54-9 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786685-55-0 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[[1,1-dimethyl-3-(phosphonooxy)propyl]amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN	786685-56-1	ZCAPLUS
CN	1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[[7-[3-[[1,1-dimethyl-3-(phosphonooxy)propyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)	

PAGE 1-A



PAGE 2-A




RN 786685-57-2 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2R)-2-  
[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




RN 786685-58-3 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[4-[2-(phosphonoxy)ethyl]-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)



RN 786685-59-4 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[[3-(phosphonoxy)propyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220



RN 786685-60-7 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786685-61-8 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-[3-[(2-methoxyethyl)[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786685-62-9 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[ethyl[3-(phosphonooxy)propyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786685-63-0 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[[3-(phosphonooxy)propyl]propylamino]propoxy]-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786685-64-1 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-  
 [(phosphonoxy)acetyl]propylamino]propoxy]-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 786685-65-2 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[4-  
 [(phosphonoxy)acetyl]-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)


10/ 539,220



RN 786685-66-3 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[6-fluoro-7-[3-[(2R)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786685-67-4 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[(1-methyl-4-piperidinyl)methoxy]-6-(phosphonooxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



RN 786685-68-5 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[5-(1-methylethoxy)-7-[3-[(2R)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786685-69-6 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[5-(1-methylethoxy)-7-[3-[4-[2-(phosphonooxy)ethyl]-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 786685-70-9 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[5-(1-methylethoxy)-7-[3-[[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 786685-71-0 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[5-methoxy-7-[3-[(2R)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



10/ 539,220


Absolute stereochemistry.



RN 786685-73-2 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[6-methoxy-7-[2-[(2S)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]ethoxy]-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 786685-74-3 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[6-methoxy-7-[2-[[2-(phosphonooxy)ethyl](tetrahydro-2H-pyran-4-yl)amino]ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)





RN 786685-79-8 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[[2-(phosphonoxy)ethyl](tetrahydro-2H-pyran-4-yl)amino]ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 786685-80-1 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[2-[[2-ethyl-2-(hydroxymethyl)butyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 786699-28-3 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-[3-oxo-4-[2-(phosphonooxy)ethyl]-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)




IT 786681-71-8P, 2-[4-[[7-(Benzyloxy)quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)acetamide  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of quinazoline derivs. as aurora kinase inhibitors)  
 RN 786681-71-8 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-(phenylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



IT 786682-18-6P 786682-25-5P 786683-91-8P,  
 N-(2,3-Difluorophenyl)-2-[4-[[7-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]acetamide  
 786684-35-3P, 2-[4-[[7-[3-[[2-[(tert-Butyldimethylsilyl)oxy]ethyl](tetrahydrofuran-3-yl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786684-39-7P, tert-Butyl  
 (2S)-2-[[[4-[[1-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]quinazolin-7-yl]oxy]methyl]pyrrolidine-1-carboxylate  
 786684-43-3P 786684-47-7P, tert-Butyl  
 3-[[[4-[[1-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]quinazolin-7-yl]oxy]methyl]pyrrolidine-1-carboxylate  
 786684-51-3P, 2-[4-[[7-[[1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]pyrrolidin-3-yl]methoxy]quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786684-57-9P 786684-60-4P,  
 2-[4-[[7-(Benzyloxy)quinazolin-4-yl]amino]-1H-pyrazol-1-yl]-N-(3-fluorophenyl)acetamide 786685-23-2P 786685-25-4P  
 786685-27-6P 786685-29-8P 786685-31-2P  
 786685-33-4P 786685-35-6P 786685-37-8P  
 786685-39-0P 786685-41-4P 786685-43-6P  
 786685-45-8P 786685-47-0P 786685-49-2P  
 786699-29-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of quinazoline derivs. as aurora kinase inhibitors)  
 RN 786682-18-6 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[6-fluoro-7-(phenylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 786682-25-5 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[6-fluoro-7-(phenylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 786683-91-8 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[7-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786684-35-3 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-[[7-[3-[[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl](tetrahydro-3-furanyl)amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 786684-39-7 ZCAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[[1-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/ 539,220



RN 786684-43-3 ZCAPLUS  
CN 1H-Pyrazole-1-acetamide, 4-[[7-[[[(2S)-1-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-2-pyrrolidinyl]methoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

PAGE 1-A



—F

RN 786684-47-7 ZCAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, 3-[[[4-[[1-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-7-quinazolinyl]oxy)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 786684-51-3 ZCAPLUS


10/ 539,220

CN 1H-Pyrazole-1-acetamide, 4-[[7-[[1-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-pyrrolidinyl]methoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)-  
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 786684-57-9 ZCAPLUS


CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-(phenylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

10/ 539,220





RN 786684-60-4 ZCAPLUS

CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-(phenylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 786685-23-2 ZCAPLUS


CN Phosphoric acid, 2-[[3-[[4-[[1-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]propylamino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 786685-25-4 ZCAPLUS

CN Phosphoric acid, [(2S)-1-[3-[[4-[[1-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/ 539,220

RN 786685-27-6 ZCAPLUS


CN Phosphoric acid, bis(1,1-dimethylethyl) [(2S)-1-[3-[[4-[[1-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786685-29-8 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[ethyl[3-[[4-[[1-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl ester (9CI) (CA INDEX NAME)




PAGE 1-A



RN 786685-31-2 ZCAPLUS



CN Phosphoric acid, bis(1,1-dimethylethyl) [(2R)-1-[3-[[4-[[1-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786685-33-4 ZCAPLUS

CN Phosphoric acid, 2-[[3-[[4-[[1-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl](2-methoxyethyl)amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 786685-35-6 ZCAPLUS

CN Phosphoric acid, [(2S)-1-[3-[[4-[[1-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/ 539,220



RN 786685-37-8 ZCAPLUS

CN Phosphoric acid, [(2R)-1-[3-[[4-[[1-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786685-39-0 ZCAPLUS

CN Phosphoric acid, [(2R)-1-[3-[[4-[[1-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/ 539,220




RN 786685-41-4 ZCAPLUS  
 CN Phosphoric acid, 2-[[3-[[4-[[1-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]ethylamino]ethyl 1 bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786685-43-6 ZCAPLUS

CN Phosphoric acid, 2-[[3-[[4-[[1-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-7-quinazolinyl]oxy]propyl]propylamino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 786685-45-8 ZCAPLUS

CN Phosphoric acid, 2-[cyclobutyl[3-[[4-[[1-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 786685-47-0 ZCAPLUS


CN Phosphoric acid, 2-[cyclobutyl[3-[[4-[[1-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 786685-49-2 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[[3-[[4-[[1-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl](2-methoxyethyl)amino]ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 786699-29-4 ZCAPLUS  
 CN Phosphoric acid, 2-[4-[3-[[4-[[1-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-4-yl]amino]-7-quinazolinyl]oxy]propyl]-2-oxo-1-piperazinyl]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



IT 786685-72-1P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (reactant, inhibitor; preparation of quinazoline derivs. as aurora kinase inhibitors)  
 RN 786685-72-1 ZCAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-(2,3-difluorophenyl)-4-[[6-methoxy-7-[2-[(2R)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]ethoxy]-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




IT 786684-50-2  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reactant; preparation of quinazoline derivs. as aurora kinase inhibitors)

10/ 539,220

RN 786684-50-2 ZCAPLUS  
CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-4-[[7-(3-pyrrolidinylmethoxy)-4-quinazolinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 786684-46-6  
CMF C24 H24 F N7 O2



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2004:566625 ZCAPLUS  
DOCUMENT NUMBER: 141:123758  
TITLE: Preparation of phosphonoxy quinazoline derivatives as therapeutic agents  
INVENTOR(S): Mortlock, Andrew Austen  
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited  
SOURCE: PCT Int. Appl., 97 pp.  
CODEN: PIXXD2



DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058782	A1	20040715	WO 2003-GB5640	20031222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003294142	A1	20040722	AU 2003-294142	20031222
EP 1575966	A1	20050921	EP 2003-789562	20031222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006512387	T	20060413	JP 2004-563355	20031222
US 2006058325	A1	20060316	US 2005-539483	20050617
PRIORITY APPLN. INFO.:			EP 2002-293240	A 20021224
			WO 2003-GB5640	W 20031222
OTHER SOURCE(S):		MARPAT 141:123758		
GI				



AB Preparation of phosphonooxy quinazoline derivs. I (A = 6-membered heteroaryl containing nitrogen atom and optionally containing one or two further nitrogen atoms; X = O, S, S(O), S(O)<sub>2</sub>, organoamino; m = 0-4; Y = O, carbonylamido, etc.; Z = organoamino, phosphonooxy, C3-6 (un)substituted phosphonooxy cycloalkyl, etc.; R<sub>3</sub> = H, halo, cyano, nitro, C1-6 alkoxy, C1-6 alkyl, carbonylamido, sulfonylamido, organoamino, etc.; R<sub>4</sub> = H, C1-4 alkyl, heteroaryl, heteroaryl C1-4 alkyl, aryl, aryl C1-4 alkyl, halo Me Et, cyclopropyl, ethynyl substituted alkyl, etc.), compns. containing them, processes for their preparation and their use in therapy, is described. Thus, reaction of N-{6-[(3-chlorobenzyl)oxy]pyridin-3-yl}-7-(3-chloropropoxy)-6-methoxyquinazolin-4-amine (preparation given) with 3-amino-3-methylbutanol in di-Me acetamide in the presence of KI gave 75% 3-[(3-{[4-({6-[(3-chlorobenzyl)oxy]pyridin-3-yl)amino)-6-methoxyquinazolin-7-yl]oxy}propyl)amino]-3-methylbutan-1-ol which on treatment with di-tert-butyl-N,N-diethylphosphoramidite, oxidation with H<sub>2</sub>O<sub>2</sub>, and hydrolysis

of the formed phosphate ester gave title compound, 3-[[[3-[[4-[[6-[(3-chlorobenzyl)oxy]pyridin-3-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]-3-methylbutyl dihydrogen phosphate.

IT 722485-50-9P 722485-52-1P 722485-56-5P

722485-58-7P 722485-61-2P 722485-63-4P

722487-06-1P 722487-38-9P 722492-71-9P


722492-74-2P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phosphonooxy quinazoline derivs. as therapeutic agents)


RN 722485-50-9 ZCAPLUS

CN Benzamide, 3-chloro-N-[5-[[7-[3-[cyclohexyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 722485-52-1 ZCAPLUS

CN Benzamide, 3-chloro-N-[5-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 722485-56-5 ZCAPLUS  
 CN 4-Piperidinol, 1-[3-[[4-[[2-[[[(3-chloro-4-fluorophenyl)amino]methyl]-5-pyrimidinyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-, dihydrogen phosphate (ester) (9CI) (CA INDEX NAME)



RN 722485-58-7 ZCAPLUS  
 CN 1-Butanol, 3-[[3-[[4-[[2-[(3-chloro-4-fluorophenyl)methoxy]-5-pyrimidinyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]-3-methyl-, dihydrogen phosphate (ester) (9CI) (CA INDEX NAME)


PAGE 1-A



F

RN 722485-61-2 ZCAPLUS


CN Benzamide, 3-chloro-4-fluoro-N-[5-[[6-methoxy-7-[[2-  
 [(phosphonoxy)methyl]cyclopropyl]methoxy]-4-quinazolinyl]amino]-2-  
 pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 722485-63-4 ZCAPLUS

CN Benzamide, 3-chloro-4-fluoro-N-[5-[[6-methoxy-7-[[1-[2-  
 (phosphonoxy)ethyl]-4-piperidinyl]methoxy]-4-quinazolinyl]amino]-2-  
 pyrimidinyl]- (9CI) (CA INDEX NAME)


10/ 539,220



RN 722487-06-1 ZCAPLUS

CN Benzamide, 3-chloro-N-[5-[[7-[3-[ethyl[2-(phosphonoxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]-4-fluoro-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● 2 HCl

RN 722487-38-9 ZCAPLUS  
 CN Benzamide, 3-chloro-4-fluoro-N-[5-[[6-methoxy-7-[[1-[2-(phosphonooxy)ethyl]-4-piperidinyl]methoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]-, monohydrobromide (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● HBr


RN 722492-71-9 ZCAPLUS  
 CN Benzamide, 3-chloro-N-[5-[[7-[3-[(2,2-dimethylpropyl)[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 722492-74-2 ZCAPLUS

CN Benzamide, 3-chloro-N-[5-[[7-[3-[(2,2-dimethylpropyl)[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



IT 331792-39-3P 722486-97-7P 722487-04-9P  
722487-10-7P 722487-20-9P 722487-30-1P  
722487-32-3P 722487-34-5P 722487-36-7P  
722487-43-6P 722492-72-0P 722492-73-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT




(Reactant or reagent)

(preparation of phosphonooxy quinazoline derivs. as therapeutic agents)


RN 331792-39-3 ZCAPLUS

CN Benzamide, 3-chloro-4-fluoro-N-[5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 722486-97-7 ZCAPLUS

CN Benzamide, 3-chloro-N-[5-[[7-[3-[cyclohexyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]-4-fluoro- (9CI) (CA INDEX NAME)




10/ 539,220

RN 722487-04-9 ZCAPLUS

CN Benzamide, 3-chloro-N-[5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]-4-fluoro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

F

RN 722487-10-7 ZCAPLUS


CN 4-Piperidinol, 1-[3-[[4-[[2-[[3-chloro-4-fluorophenyl]amino]methyl]-5-pyrimidinyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 722487-20-9 ZCAPLUS  
 CN 1-Butanol, 3-[[[3-[[[4-[[2-[(3-chloro-4-fluorophenyl)methoxy]-5-pyrimidinyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]-3-methyl-9CI] (CA INDEX NAME)


PAGE 1-A



|  
F

RN 722487-30-1 ZCAPLUS


CN Benzamide, 3-chloro-4-fluoro-N-[5-[[7-[[2-(hydroxymethyl)cyclopropyl]methoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 722487-32-3 ZCAPLUS


CN Cyclopropanecarboxylic acid, 2-[[[4-[[2-[(3-chloro-4-fluorobenzoyl)amino]-5-pyrimidinyl]amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

10/ 539,220



RN 722487-34-5 ZCAPLUS


CN Benzamide, 3-chloro-4-fluoro-N-[5-[[7-[[1-(2-hydroxyethyl)-4-piperidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



RN 722487-36-7 ZCAPLUS

CN Phosphoric acid, 2-[4-[[[4-[[2-[(3-chloro-4-fluorobenzoyl)amino]-5-pyrimidinyl]amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-1-piperidinyl]ethyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

10/ 539,220




RN 722487-43-6 ZCAPLUS

CN    Benzamide, 3-chloro-4-fluoro-N-[5-[[6-methoxy-7-(4-piperidinylmethoxy)-4-quinazolinyl]amino]-2-pyrimidinyl]-, bis(trifluoroacetate) (9CI)    (CA INDEX NAME)

CM 1

CRN 722487-42-5


CMF C26 H25 C1 F N7 O3




CM 2

10/ 539,220



CRN 76-05-1  
CMF C2 H F3 O2



RN 722492-72-0 ZCAPLUS  
CN Benzamide, 3-chloro-N-[5-[[7-[3-[(2,2-dimethylpropyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]-(9CI) (CA INDEX NAME)



RN 722492-73-1 ZCAPLUS  
CN Phosphoric acid, 2-[[3-[[4-[[2-[(3-chlorobenzoyl)amino]-5-pyrimidinyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl](2,2-dimethylpropyl)amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




L4 ANSWER 18 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2004:566624 ZCAPLUS  
 DOCUMENT NUMBER: 141:123757  
 TITLE: Preparation of phosphonooxy quinazoline derivatives  
 and their pharmaceutical use  
 INVENTOR(S): Heron, Nicola Murdoch; Jung, Frederic Henri; Pasquet,  
 Georges Rene; Mortlock, Andrew Austen  
 PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited  
 SOURCE: PCT Int. Appl., 150 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058781	A1	20040715	WO 2003-GB5613	20031222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				



LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,  
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2511613 A1 20040715 CA 2003-2511613 20031222  
 AU 2003290313 A1 20040722 AU 2003-290313 20031222  
 AU 2003290313 B2 20070510  
 EP 1578755 A1 20050928 EP 2003-782672 20031222  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 BR 2003017717 A 20051122 BR 2003-17717 20031222  
 JP 2006512418 T 20060413 JP 2005-509716 20031222  
 CN 1764668 A 20060426 CN 2003-80109902 20031222  
 NO 2005002855 A 20050803 NO 2005-2855 20050613  
 US 2006116357 A1 20060601 US 2005-539220 20050617  
 IN 2005DN02718 A 20061229 IN 2005-DN2718 20050620  
 PRIORITY APPLN. INFO.: EP 2002-293238 A 20021224  
 EP 2003-291315 A 20030602  
 WO 2003-GB5613 W 20031222  
 OTHER SOURCE(S): MARPAT 141:123757  
 GI



I

AB Preparation of phosphonooxy quinazoline derivs., I (A = 5-membered heteroaryl containing a nitrogen atom and one or two further nitrogen atoms; X = O, S, S(O), S(O)<sub>2</sub>, organoamino; m = 0-3; Z = organoamino, phosphonooxy, (un)substituted C3-6 cycloalkyl, etc.; R<sub>3</sub> = H, halo, cyano, nitro, C1-6 alkoxy, C1-6 alkyl, alkoxycarbonyl, organoamido, sulfonylamido, etc.; R<sub>4</sub> = H, C1-4 alkyl, heteroaryl, heteroaryl C1-4 alkyl, aryl, etc.; R<sub>5</sub> = H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, etc.; R<sub>6</sub>, R<sub>7</sub> = H, halo, C1-4 alkyl, C3-6 cycloalkyl, hydroxy, C1-4 alkoxy, etc.), and compns. containing them, processes for their preparation and their use in therapy is described. Thus, reaction of N-(3-fluorophenyl)-2-{3-[(7-{3-[4-(hydroxymethyl)piperidin-1-yl]propoxy}-6-methoxyquinazolin-4-yl)amino]-1H-pyrazol-5-yl}acetamide (preparation given) with di-tert-butyl-diethylphosphoramidite gave 70% di-tert-Bu {1-[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1Hpyrazol-3-yl)amino]-6-methoxyquinazolin-

7-yl}oxy)propyl]piperidin-4-yl}methyl phosphate which on acidic hydrolysis gave 94% title compound, di-tert-Bu {1-[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1Hpyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]piperidin-4-yl}methyl dihydrogen phosphate. In vitro Aurora-A and Aurora-B kinase inhibition activity and cell proliferation and cycle anal. of the prepared compds. were determined


IT 722542-92-9P 722542-93-0P 722542-94-1P  
 722542-95-2P 722542-96-3P 722542-97-4P  
 722542-98-5P 722542-99-6P 722543-00-2P  
 722543-01-3P 722543-02-4P 722543-03-5P  
 722543-04-6P 722543-05-7P 722543-06-8P  
 722543-07-9P 722543-08-0P 722543-09-1P  
 722543-10-4P 722543-11-5P 722543-12-6P  
 722543-13-7P 722543-14-8P 722543-15-9P  
 722543-17-1P 722543-18-2P 722543-19-3P  
 722543-20-6P 722543-21-7P 722543-22-8P  
 722543-23-9P 722543-24-0P 722543-25-1P  
 722543-26-2P 722543-27-3P 722543-28-4P  
 722543-29-5P 722543-30-8P 722543-31-9P  
 722543-32-0P 722543-33-1P 722543-34-2P  
 722543-35-3P 722543-36-4P 722543-37-5P  
 722543-38-6P 722543-39-7P 722543-40-0P  
 722543-41-1P 722543-42-2P 722543-43-3P  
 722543-44-4P 722543-45-5P 722543-46-6P  
 722543-47-7P 722543-48-8P 722543-49-9P  
 722543-50-2P 722543-51-3P 722543-53-5P  
 722543-54-6P 722543-55-7P 722543-56-8P  
 722543-57-9P 722543-58-0P 722543-60-4P  
 722543-61-5P 722543-62-6P 722543-78-4P  
 722544-03-8P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phosphonooxy quinazoline derivs. and their pharmaceutical use)


RN 722542-92-9 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[6-methoxy-7-[3-[4-[(phosphonooxy)methyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)



RN 722542-93-0 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[ethyl[2-(phosphonoxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)


PAGE 1-A






RN 722542-94-1 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[6-methoxy-7-[3-[(2S)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722542-95-2 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[6-methoxy-7-[3-[(2R)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 722542-96-3 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[6-methoxy-7-[3-[(2S)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/ 539,220




RN 722542-97-4 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[6-methoxy-7-[3-[[2-(phosphonoxy)ethyl]propylamino]propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 722542-98-5 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[6-methoxy-7-[3-[[2-(phosphonoxy)ethyl]propylamino]propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)


10/ 539,220

methylpropyl) [2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-  
(9CI) (CA INDEX NAME)



PAGE 1-A





PAGE 2-A



RN 722542-99-6 ZCAPLUS  
CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[6-methoxy-7-[3-[(2-methylpropyl) [2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-  
(9CI) (CA INDEX NAME)





RN 722543-00-2 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[6-methoxy-7-[3-[[2-(phosphonoxy)ethyl]propylamino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 722543-01-3 ZCAPLUS



CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[6-methoxy-7-[3-[(2-methylpropyl)[2-(phosphonoxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)






RN 722543-02-4 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[[7-[3-[(2,2-dimethylpropyl)[2-(phosphonoethoxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)]- (9CI) (CA INDEX NAME)



RN 722543-03-5 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[6-methoxy-7-[3-[3-(phosphonoxy)-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



RN 722543-04-6 ZCAPLUS



CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[6-methoxy-7-[3-[(2R)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 722543-05-7 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[6-methoxy-7-[3-[[2-(phosphonooxy)ethyl]-2-propynylamino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 722543-06-8 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[6-methoxy-7-[3-[(1-methylethyl)[2-(phosphonoxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 722543-07-9 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[6-methoxy-7-[3-[[2-(phosphonoxy)ethyl]-2-propynylamino]propoxy]-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 722543-08-0 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[6-methoxy-7-[3-[(2-methoxyethyl)[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-  
(9CI) (CA INDEX NAME)




RN 722543-09-1 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[[6-methoxy-7-[3-[[2-(phosphonoxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 722543-10-4 ZCAPLUS



CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[(cyclobutylmethyl)[2-(  
 (phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-  
 difluorophenyl)- (9CI) (CA INDEX NAME)





RN 722543-11-5 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[6-methoxy-7-[3-[[2-(  
 (phosphonooxy)ethyl](3,3,3-trifluoropropyl)amino]propoxy]-4-  
 quinazolinyl]amino]- (9CI) (CA INDEX NAME)






RN 722543-12-6 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[6-methoxy-7-[3-[[2-(phosphonooxy)ethyl]-2-propenylamino]propoxy]-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)



RN 722543-13-7 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[cyclobutyl[2-(phosphonoxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)

10/ 539,220




RN 722543-14-8 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[cyclopentyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 722543-15-9 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[cyclopropyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 722543-17-1 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[(cyclopropylmethyl)[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 722543-18-2 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[cyclobutyl[2-(phosphonoxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



10/ 539,220



RN 722543-19-3 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[[1-[2-(phosphonooxy)ethyl]-4-piperidinyl]methoxy]-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)




RN 722543-20-6 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 722543-21-7 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(1-methylethyl)[2-(phosphonoxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-  
 (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 722543-22-8 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[[1,1-dimethyl-3-(phosphonoxy)propyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)






RN 722543-23-9 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2S)-2-[2-(phosphonoxy)ethyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 722543-24-0 ZCAPLUS

10/ 539,220

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2R)-2-  
[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 722543-25-1 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[[2-  
(phosphonooxy)ethyl]propylamino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA  
INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 722543-26-2 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[butyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 722543-27-3 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[cyclopentyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 722543-28-4 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2S)-2-  
[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 722543-29-5 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2S)-2-  
[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/ 539,220



RN 722543-30-8 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[cyclopentyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 722543-31-9 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (CA INDEX NAME)




RN 722543-32-0 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[[1,1-dimethyl-3-(phosphonoxy)propyl]amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 722543-33-1 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[[2-(phosphonoxy)ethyl]propylamino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 722543-34-2 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2R)-2-  
 [(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 722543-35-3 ZCAPLUS




10/ 539,220

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl[3-(phosphonooxy)propyl]amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 722543-36-4 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2-methoxyethyl)[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)





RN 722543-37-5 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[4-[[2-(phosphonoxy)ethyl]propylamino]butoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 722543-38-6 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[4-[ethyl[2-(phosphonoxy)ethyl]amino]butoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 722543-39-7 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[4-[(2R)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]butoxy]-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 722543-40-0 ZCAPLUS


10/ 539,220

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[4-[methyl[2-(phosphonooxy)ethyl]amino]butoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 722543-41-1 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[4-[(2S)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]butoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/ 539,220




RN 722543-42-2 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl[2-(phosphonoxy)ethyl]amino]propoxy]-6-fluoro-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 722543-43-3 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[[1,1-dimethyl-3-(phosphonoxy)propyl]amino]propoxy]-6-fluoro-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220

(phosphonooxy)propyl]amino]propoxy]-4-quinazolinyl]amino]-,  
dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● 2 HCl

RN 722543-44-4 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2S)-2-[2-(phosphonooxy)ethyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-,  
dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



● 2 HCl

RN 722543-45-5 ZCAPLUS  
CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2R)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



Absolute stereochemistry.



● 2 HCl



RN 722543-46-6 ZCAPLUS  
CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[[2-(phosphonoxy)ethyl]propylamino]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)






● 2 HCl

RN 722543-47-7 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[butyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)-, dihydrochloride (9CI)  
 (CA INDEX NAME)



● 2 HCl

RN 722543-48-8 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[cyclopentyl[2-(phosphonoxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 722543-49-9 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2S)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

10/ 539,220


RN 722543-50-2 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



● 2 HCl



RN 722543-51-3 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[[1,1-dimethyl-3-(phosphonooxy)propyl]amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 722543-53-5 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[[2-(phosphonooxy)ethyl]propylamino]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 722543-54-6 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2R)-2-  
 [(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-,  
 dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● 2 HCl

RN 722543-55-7 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl[3-(phosphonooxy)propyl]amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 722543-56-8 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[4-[[2-(phosphonooxy)ethyl]propylamino]butoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● 2 HCl




10/ 539,220

RN 722543-57-9 ZCAPLUS  
CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[4-[ethyl[2-(phosphonooxy)ethyl]amino]butoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● 2 HCl

RN 722543-58-0 ZCAPLUS  
CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[4-[(2R)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]butoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● 2 HCl

RN 722543-60-4 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[4-[methyl[2-(phosphonooxy)ethyl]amino]butoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A






● 2 HCl

RN 722543-61-5 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[4-[(2S)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]butoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● 2 HCl

RN 722543-62-6 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-fluoro-4-quinazolinyl]amino]-N-(3-fluorophenyl)-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



● 2 HCl

RN 722543-78-4 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[6-methoxy-7-[3-[[2-(phosphonooxy)ethyl]propylamino]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 722544-03-8 ZCAPLUS

1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[6-methoxy-7-[3-[(2R)-2-  
[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-,  
dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

IT 557769-47-8P 557769-61-6P 557769-63-8P  
 557769-79-6P 557769-80-9P 557769-84-3P  
 557769-87-6P 557769-92-3P 557770-14-6P  
 557770-22-6P 557770-23-7P 557770-28-2P  
 557770-29-3P 557770-31-7P 557770-38-4P  
 557770-39-5P 557770-40-8P 557770-41-9P  
 557770-42-0P 557770-43-1P 557770-44-2P  
 557770-45-3P 557770-50-0P 557770-51-1P  
 557770-54-4P 557770-87-3P 557770-92-0P  
 557770-93-1P 557770-94-2P 722543-63-7P  
 722543-65-9P 722543-66-0P 722543-67-1P  
 722543-69-3P 722543-72-8P 722543-80-8P  
 722543-83-1P 722543-87-5P 722543-91-1P  
 722543-95-5P 722543-99-9P 722544-01-6P  
 722544-05-0P 722544-06-1P 722544-08-3P  
 722544-10-7P 722544-12-9P 722544-13-0P  
 722544-15-2P 722544-17-4P 722544-18-5P  
 722544-19-6P 722544-20-9P 722544-21-0P  
 722544-22-1P 722544-23-2P 722544-24-3P  
 722544-25-4P 722544-27-6P 722544-28-7P  
 722544-29-8P 722544-30-1P 722544-31-2P  
 722544-32-3P 722544-33-4P 722544-34-5P  
 722544-35-6P 722544-36-7P 722544-37-8P  
 722544-38-9P 722544-39-0P 722544-40-3P  
 722544-41-4P 722544-42-5P 722544-43-6P  
 722544-44-7P 722544-45-8P 722544-47-0P  
 722544-48-1P 722544-49-2P 722544-50-5P  
 722544-51-6P 722544-52-7P 722544-53-8P  
 722544-54-9P 722544-55-0P 722544-56-1P  
 722544-57-2P 722544-58-3P 722544-59-4P  
 722544-60-7P 722544-61-8P 722544-62-9P  
 722544-63-0P 722544-67-4P 722544-68-5P  
 722544-69-6P 722544-70-9P 722544-71-0P  
 722544-72-1P 722544-73-2P 722544-74-3P  
 722544-75-4P 722544-76-5P 722544-80-1P  
 722544-81-2P 722544-84-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of phosphonooxy quinazoline derivs. and their pharmaceutical use)

10/ 539,220

RN 557769-47-8 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 557769-61-6 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-(3-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




RN 557769-63-8 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(CA INDEX NAME)




RN 557769-79-6 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)(2-methylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A






PAGE 2-A




RN 557769-80-9 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[(2,2-dimethylpropyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 557769-84-3 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[cyclopropyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 557769-87-6 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[cyclobutyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 557769-92-3 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)(3,3,3-trifluoropropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 557770-14-6 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 557770-22-6 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



RN 557770-23-7 ZCAPLUS



CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 557770-28-2 ZCAPLUS



CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[(2S)-2-hydroxyethyl)(2-methylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



RN 557770-29-3 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)propylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)





RN 557770-31-7 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)-2-propynylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)





RN 557770-38-4 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)propylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)






RN 557770-39-5 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)(2-methylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 557770-40-8 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[cyclobutyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)

10/ 539,220



RN 557770-41-9 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-(cyclopentyl(2-hydroxyethyl)amino)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 557770-42-0 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)


10/ 539,220

Absolute stereochemistry.




RN 557770-43-1 ZCAPLUS  
CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)-2-propynylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 557770-44-2 ZCAPLUS

10/ 539,220

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[(cyclopropylmethyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 557770-45-3 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[(cyclobutylmethyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)

10/ 539,220




RN 557770-50-0 ZCAPLUS  
CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)(2-methoxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 557770-51-1 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)-2-propenylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 557770-54-4 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)(1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)





RN 557770-87-3 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)






RN 557770-92-0 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)(1-methylethyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)



RN 557770-93-1 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 557770-94-2 ZCAPLUS


10/ 539,220

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)propylamino]propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 722543-63-7 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) [1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-piperidinyl]methyl ester (9CI) (CA INDEX NAME)





ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722543-65-9 ZCAPLUS

CN Phosphoric acid, 2-[[3-[[4-[[5-[2-[(3,5-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]ethylamino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A






ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722543-66-0 ZCAPLUS

CN Phosphoric acid, [(2S)-1-[3-[[4-[[5-[2-[(3,5-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722543-67-1 ZCAPLUS

CN Phosphoric acid, [(2R)-1-[3-[[4-[[5-[2-[(3,5-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722543-69-3 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) [(2S)-1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 722543-72-8 ZCAPLUS

CN Phosphinic acid, bis(1,1-dimethylethyl)-, 2-[[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]propylamino]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 722543-80-8 ZCAPLUS

CN Phosphoric acid, 2-[[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl](2-methylpropyl)amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722543-83-1 ZCAPLUS

CN Phosphoric acid, 2-[[3-[[4-[[5-[2-[(3,5-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl](2-methylpropyl)amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)





ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722543-87-5 ZCAPLUS

CN Phosphoric acid, 2-[[3-[[4-[[5-[2-[(3,5-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]propylamino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)







ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722543-91-1 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl](2-methylpropyl)amino]ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 722543-95-5 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[(2,2-dimethylpropyl)[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722543-99-9 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-3-piperidinyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-01-6 ZCAPLUS

CN Phosphoric acid, [(2R)-1-[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 722544-05-0 ZCAPLUS

CN Phosphoric acid, 2-[[3-[[4-[[5-[2-[(3,5-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-propynylamino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 722544-06-1 ZCAPLUS

CN Phosphoric acid, 2-[[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl](1-methylethyl)amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A





RN 722544-08-3 ZCAPLUS  
 CN Phosphoric acid, 2-[[[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-propynylamino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-10-7 ZCAPLUS

CN Phosphoric acid, 2-[[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl](2-methoxyethyl)amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-12-9 ZCAPLUS


CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A





PAGE 2-A



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-13-0 ZCAPLUS


CN Phosphoric acid, 2-[cyclopropyl[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-15-2 ZCAPLUS

CN Phosphoric acid, 2-[(cyclobutylmethyl)[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl bis(1,1-dimethylethyl) ester (9CI)  
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 722544-17-4 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[[[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl](3,3,3-trifluoropropyl)amino]ethyl ester (9CI)  
(CA INDEX NAME)

PAGE 1-A



PAGE 2-A




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 722544-18-5 ZCAPLUS

CN Phosphoric acid, 2-[[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-propenylamino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/ 539,220

RN 722544-19-6 ZCAPLUS



CN Phosphoric acid, 2-[cyclobutyl[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-20-9 ZCAPLUS



CN Phosphoric acid, 2-[cyclopentyl[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-21-0 ZCAPLUS

CN Phosphoric acid, 2-[(cyclopropylmethyl)[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl bis(1,1-dimethylethyl) ester (9CI)  
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-22-1 ZCAPLUS

CN Phosphoric acid, 2-[cyclobutyl[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-23-2 ZCAPLUS

CN Phosphoric acid, 2-[4-[[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]methyl]-1-piperidinyl]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-24-3 ZCAPLUS

CN 1H-Pyrazole-3-acetic acid, 5-[[7-(phenylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220



RN 722544-25-4 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-(phenylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 722544-27-6 ZCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 722544-28-7 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-(4-piperidinylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 722544-29-8 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[[1-[2-[[1,1-dimethylethyl]dimethylsilyl]oxy]ethyl]-4-piperidinyl]methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)





RN 722544-30-1 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[[1-(2-hydroxyethyl)-4-piperidinyl]methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 722544-31-2 ZCAPLUS



CN Phosphoric acid, 2-[[[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]propyl]ethylamino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-32-3 ZCAPLUS

CN Phosphoric acid, 2-[[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]propyl](1-methylethyl)amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 722544-33-4 ZCAPLUS

CN Phosphoric acid, 3-[[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]propyl]amino]-3-methylbutyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-34-5 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(3-hydroxy-1,1-dimethylpropyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 722544-35-6 ZCAPLUS

CN Phosphoric acid, 2-[(2S)-1-[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-36-7 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2S)-2-(2-hydroxyethyl)-1-pyrrolidiny]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 722544-37-8 ZCAPLUS

CN Phosphoric acid, [(2R)-1-[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]propyl]-2-pyrrolidiny]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 722544-38-9 ZCAPLUS

CN Phosphoric acid, 2-[[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]propyl]propylamino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 722544-39-0 ZCAPLUS

CN Phosphoric acid, 2-[butyl[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]propyl]amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 722544-40-3 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[butyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 722544-41-4 ZCAPLUS

CN Phosphoric acid, 2-[cyclopentyl[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]propyl]amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-42-5 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[cyclopentyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)-(9CI) (CA INDEX NAME)


10/ 539,220



RN 722544-43-6 ZCAPLUS

CN Phosphoric acid, [(2S)-1-[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyllmethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-44-7 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyllpropoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



RN 722544-45-8 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) [(2S)-1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-47-0 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 722544-48-1 ZCAPLUS

CN Phosphoric acid, 2-[cyclopentyl[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]propyl]amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-49-2 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[cyclopentyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)-(9CI) (CA INDEX NAME)

10/ 539,220




RN 722544-50-5 ZCAPLUS  
 CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[ethyl[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]propyl]amino]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 722544-51-6 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 722544-52-7 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 3-[[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]propyl]amino]-3-methylbutyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 722544-53-8 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(3-hydroxy-1,1-dimethylpropyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A





RN 722544-54-9 ZCAPLUS  
 CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]propyl]propylamino]ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-55-0 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)propylamino]propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 722544-56-1 ZCAPLUS

CN    Phosphoric acid, bis(1,1-dimethylethyl) [(2R)-1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl ester (9CI)    (CA INDEX NAME)

Absolute stereochemistry.




10/ 539,220

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-57-2 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 722544-58-3 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 3-[ethyl 3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]propyl]amino]propyl ester (9CI) (CA INDEX NAME)




PAGE 1-A



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE



RN 722544-59-4 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(3-hydroxypropyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 722544-60-7 ZCAPLUS



CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl(3-hydroxypropyl)amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 722544-61-8 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]propyl](2-methoxyethyl)amino]ethyl ester (9CI) (CA INDEX NAME)







ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE



RN 722544-62-9 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)(2-methoxyethyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 722544-63-0 ZCAPLUS

CN Phosphoric acid, 2-[[4-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]butyl]propylamino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 722544-67-4 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[4-[(2-hydroxyethyl)propylamino]butoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 722544-68-5 ZCAPLUS

CN Phosphoric acid, 2-[[4-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]butyl]ethylamino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-69-6 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[4-[ethyl(2-hydroxyethyl)amino]butoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 722544-70-9 ZCAPLUS

CN Phosphoric acid, [(2R)-1-[4-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]butyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/ 539,220

RN 722544-71-0 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[4-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]butoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 722544-72-1 ZCAPLUS

CN Phosphoric acid, 2-[[4-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]butyl]methylamino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



PAGE 1-A

PAGE 2-A




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 722544-73-2 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[4-[(2-hydroxyethyl)methylamino]butoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 722544-74-3 ZCAPLUS

CN Phosphoric acid, [(2S)-1-[4-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]butyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-75-4 ZCAPLUS



CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]butoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722544-76-5 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[ethyl[3-[[6-fluoro-4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]amino]-7-quinazolinyl]oxy]propyl]amino]ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 722544-80-1 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[6-fluoro-7-(phenylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220





RN 722544-81-2 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[6-fluoro-7-(phenylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 722544-84-5 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-fluoro-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2004:566600 ZCAPLUS  
 DOCUMENT NUMBER: 141:123646  
 TITLE: Preparation of quinazolines as inhibitors of Aurora kinase  
 INVENTOR(S): Mortlock, Andrew Austen  
 PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited  
 SOURCE: PCT Int. Appl., 155 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058752	A1	20040715	WO 2003-GB5636	20031222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,				

NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2508921	A1	20040715	CA 2003-2508921	20031222
AU 2003290322	A1	20040722	AU 2003-290322	20031222
EP 1575946	A1	20050921	EP 2003-782681	20031222
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003017680	A	20051129	BR 2003-17680	20031222
CN 1753889	A	20060329	CN 2003-80109899	20031222
JP 2006516138	T	20060622	JP 2004-563353	20031222
NO 2005002991	A	20050719	NO 2005-2991	20050617
US 2006058523	A1	20060316	US 2005-539481	20050617
PRIORITY APPLN. INFO.:			EP 2002-293239	A 20021224
			WO 2003-GB5636	W 20031222

OTHER SOURCE(S):           MARPAT 141:123646  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [A = 5-membered heteroaryl; X = O, SOO-2, amino; m = 0-3; Z = amino, phosphonooxy, cycloalkyl, etc.; R3 = H, halo, CN, NO2, etc.; R4 = H, alkyl, heteroaryl, etc.; R5 = H, alk(en/yn)yl, cycloalkyl, etc.; R6-7 = H, halo, alkyl, etc.] are prepared For instance, N'-[5-(3-chloropropoxy)-2-cyano-4-methoxyphenyl]-N,N-dimethylimidoforamide (preparation given) is reacted with tert-Bu [5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]carbamate (HOAc, reflux, 2 h) to give the corresponding quinazoline. This is used to alkylate (piperidin-4-yl)methanol and the resulting product reacted with tetrazole and di-tert-butyl-diethylphosphoramidite. Treatment of this penultimate intermediate with 4N HCl afforded II. Compds. of the invention have IC50 in the range of 0.3 nM to 1000 nM for Aurora-B kinase.

IT 723278-08-8P 723278-11-3P, [1-[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-4-yl]methyl dihydrogen phosphate 723278-42-0P, (R)-[1-[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723278-50-0P, 2-[4-[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperazin-1-yl]ethyl dihydrogen phosphate 723278-57-7P, [1-[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-3-yl] dihydrogen phosphate 723278-65-7P, 1-[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-3-yl] dihydrogen phosphate 723278-73-7P, 2-[Ethyl[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]ethyl dihydrogen phosphate 723278-82-8P 723278-85-1P, (S)-[1-[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723278-93-1P, (S)-2-[N-Ethyl-N-[[1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-

methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl]amino]ethyl dihydrogen phosphate 723279-10-5P, 1-[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-4-yl dihydrogen phosphate 723279-18-3P, (S)-2-[[[1-[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl]amino]ethyl dihydrogen phosphate 723279-35-4P, 2-[[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]ethyl dihydrogen phosphate 723279-47-8P, 3-[Ethyl[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]propyl dihydrogen phosphate 723279-56-9P, 2-[(2-Fluoroethyl)[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]ethyl dihydrogen phosphate 723279-65-0P, 2-[1-[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-4-yl]ethyl dihydrogen phosphate 723279-73-0P, 2-[[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl](2-methoxyethyl)amino]ethyl dihydrogen phosphate 723279-82-1P, (S)-2-[1-[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]ethyl dihydrogen phosphate 723279-91-2P, 2-[[3-[[4-[[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]-2-methylpropyl dihydrogen phosphate 723279-99-0P, (R)-[1-[3-[[4-[[5-[2-[(3-Chlorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723280-18-0P, 2-[1-[3-[[4-[[5-[2-[(3-Chlorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-4-yl]ethyl dihydrogen phosphate 723280-26-0P, 2-[4-[3-[[4-[[5-[2-[(3,5-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperazin-1-yl]ethyl dihydrogen phosphate 723280-38-4P, 2-[[3-[[4-[[5-[2-[(3,5-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl](methyl)amino]ethyl dihydrogen phosphate 723280-46-4P, (S)-[1-[3-[[4-[[5-[2-[(3,5-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723280-54-4P 723280-65-7P, (R)-[1-[3-[[4-[[5-[2-[(3,4-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723280-82-8P, (S)-[1-[3-[[4-[[5-[2-[(3,4-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723280-93-1P, 1-[3-[[4-[[5-[2-[(3,4-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-4-yl]methyl dihydrogen phosphate 723281-02-5P 723281-04-7P, [1-[3-[[4-[[5-[2-[(2-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-4-yl]methyl dihydrogen phosphate 723281-15-0P 723281-16-1P, (R)-[1-[3-[[4-[[5-[2-[(2-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723281-21-8P 723281-23-0P, (S)-[1-[3-[[4-[[5-[2-[(2-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723281-28-5P 723281-30-9P,

2-[Ethyl[3-[[4-[[5-[2-[(2-fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]ethyl dihydrogen phosphate 723281-34-3P 723281-35-4P,  
2-[1-[3-[[4-[[5-[2-[(2-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-2-yl]ethyl dihydrogen phosphate 723281-38-7P 723281-39-8P,  
(R)-[1-[3-[[4-[[5-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723281-49-0P 723281-51-4P,  
(S)-[1-[3-[[4-[[5-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723281-56-9P 723281-58-1P,  
2-[[3-[[4-[[5-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl](methyl)amino]ethyl dihydrogen phosphate 723281-62-7P 723281-64-9P,  
2-[1-[3-[[4-[[5-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-2-yl]ethyl dihydrogen phosphate 723281-69-4P 723281-71-8P,  
2-[[3-[[4-[[5-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl](ethyl)amino]ethyl dihydrogen phosphate 723281-77-4P, 1-[3-[[4-[[5-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-4-ylmethyl dihydrogen phosphate 723281-82-1P, 2-[4-[3-[[4-[[5-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperazin-1-yl]ethyl dihydrogen phosphate 723281-88-7P, 3-[[3-[[4-[[5-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]-3-methylbutyl dihydrogen phosphate 723281-94-5P, 2-[[3-[[4-[[5-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]-2-methylpropyl dihydrogen phosphate 723282-00-6P, 2-[[3-[[4-[[5-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]ethyl dihydrogen phosphate 723282-06-2P 723282-08-4P, (R)-[1-[3-[[4-[[5-[2-[(2,5-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723282-20-0P 723282-21-1P,  
(S)-[1-[3-[[4-[[5-[2-[(2,5-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723282-26-6P 723282-28-8P,  
2-[[3-[[4-[[5-[2-[(2,5-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl](ethyl)amino]ethyl dihydrogen phosphate 723282-34-6P, (S)-[1-[3-[[4-[[5-[2-[(2,4-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723282-45-9P, 2-[1-[3-[[4-[[5-[2-[(2,4-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]piperidin-2-yl]ethyl dihydrogen phosphate 723282-51-7P, 2-[Cyclopropyl[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]ethyl dihydrogen phosphate 723282-57-3P, 2-[Cyclopropyl[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]ethyl dihydrogen phosphate 723282-63-1P, [1-[2-[[4-[[5-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]ethyl]piperidin-4-yl]methyl dihydrogen phosphate 723282-73-3P 723282-75-5P, (R)-[1-[2-[[4-[[5-[2-[(2,3-

Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]ethyl]pyrrolidin-2-yl]methyl dihydrogen phosphate 723282-79-9P, 2-[4-[2-[4-[5-[2-[(2,3-Difluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]ethyl]piperazin-1-yl]ethyl dihydrogen phosphate 723282-85-7P 723282-87-9P, 2-[1-[2-[4-[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]ethyl]piperidin-2-yl]ethyl dihydrogen phosphate 723282-94-8P, 2-[1-[2-[4-[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]ethyl]piperidin-4-yl]ethyl dihydrogen phosphate 723282-98-2P, 4-[Ethyl[2-[4-[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]ethyl]amino]butyl dihydrogen phosphate 723283-03-2P, 2-[Ethyl[2-[4-[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]ethyl]amino]ethyl dihydrogen phosphate 723283-07-6P 723283-08-7P, [1-[3-[4-[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]quinazolin-7-yl]oxy]propyl]piperidin-4-yl]methyl dihydrogen phosphate 723283-17-8P 723283-19-0P, 2-[4-[4-[5-[2-[(3-Fluorophenyl)amino]-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxy]methyl]piperidin-1-yl]ethyl dihydrogen phosphate


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazolines as inhibitors of Aurora kinase)

RN 723278-08-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[4-[(phosphonoxy)methyl]-1-piperidiny]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A






● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-11-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[4-  
[(phosphonoxy)methyl]-1-piperidiny]propoxy]-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-42-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[(2R)-2-  
[(phosphonoxy)methyl]-1-pyrrolidiny]propoxy]-4-quinazolinyl]amino]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-50-0 ZCAPLUS

10/ 539,220


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[4-[2-(phosphonooxy)ethyl]-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-57-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[4-[2-(phosphonooxy)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-65-7 ZCAPLUS

10/ 539,220


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[3-(phosphonooxy)-1-piperidiny]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-73-7 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/ 539,220

RN 723278-82-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-85-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-93-1 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[(2S)-2-[[ethyl[2-(phosphonoxy)ethyl]amino]methyl]-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-10-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[4-(phosphonooxy)-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 723279-18-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[[6-methoxy-7-[[3-[(2S)-2-[[[2-(phosphonooxy)ethyl]amino]methyl]-1-pyrrolidiny]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-35-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-47-8 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[ethyl[3-(phosphonooxy)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-56-9 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[(2-fluoroethyl)[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-65-0 ZCAPLUS



10/ 539,220


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[4-[2-(phosphonooxy)ethyl]-1-piperidiny]propoxy]-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-73-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[4-[2-(2-methoxyethyl)[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-82-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[2-(phosphonooxy)ethyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-91-2 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[[1,1-dimethyl-2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-99-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[6-methoxy-7-[3-[(2R)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-18-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[6-methoxy-7-[3-[4-[2-(phosphonoxy)ethyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-26-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[3-[4-[2-(phosphonoxy)ethyl]-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-38-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[3-[methyl(2-(phosphonooxy)ethyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 723280-46-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-

10/ 539,220

(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-54-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[3-[[ (2R)-2-(phosphonoxy)propyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-65-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-[3-[[ (2R)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-82-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-93-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-[3-[4-(phosphonoxy)-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-02-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-[3-[4-[(phosphonooxy)methyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-04-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-[3-[4-  
[(phosphonoxy)methyl]-1-piperidiny]propoxy]-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 723281-15-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-[3-[(2R)-2-  
[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-,  
dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/ 539,220




●2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-16-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-[3-[(2R)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-21-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




●2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-23-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-28-5 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2-fluorophenyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-30-9 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[ethyl[2-(phosphonoxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2-fluorophenyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-34-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-[3-[2-[2-(phosphonoxy)ethyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-35-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-[3-[2-[2-(phosphonoxy)ethyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI)

10/ 539,220

(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-38-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[(2R)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-39-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[(2R)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

10/ 539,220

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-49-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-51-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-56-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[methyl(2-(phosphonooxy)ethyl)amino]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● 2 HCl


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-58-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[methyl(2-(phosphonooxy)ethyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220


NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-62-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[2-[2-(phosphonoxy)ethyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE



10/ 539,220

RN 723281-64-9 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[2-[2-(phosphonooxy)ethyl]-1-piperidiny]propoxy]-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-69-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-71-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[ethyl[2-(phosphonoxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-77-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[4-(phosphonoxy)-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-82-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[4-[2-(phosphonoxy)ethyl]-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI)

10/ 539,220


(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-88-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[[1,1-dimethyl-3-(phosphonooxy)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-94-5 ZCAPLUS

10/ 539,220


CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[[1,1-dimethyl-2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-00-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[3-[[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-06-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[6-methoxy-7-[3-[(2R)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-08-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[6-methoxy-7-[3-[(2R)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-20-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




●2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-21-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-26-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[7-[3-[ethyl[2-(phosphonoxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-28-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)



10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-34-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,4-difluorophenyl)-2-[[6-methoxy-7-[3-[(2S)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-45-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,4-difluorophenyl)-2-[[6-methoxy-7-[3-[2-[2-(phosphonoxy)ethyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-51-7 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[cyclopropyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-57-3 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[cyclopropyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-63-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[2-[4-[(phosphonooxy)methyl]-1-piperidinyl]ethoxy]-4-quinazolinyl]amino]- (9CI)

10/ 539,220

(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-73-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[2-[(2R)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]ethoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-75-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[2-[(2R)-2-[(phosphonoxy)methyl]-1-pyrrolidinyl]ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-79-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[6-methoxy-7-[2-[4-[2-(phosphonoxy)ethyl]-1-piperazinyl]ethoxy]-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-85-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[2-[2-[2-(phosphonoxy)ethyl]-1-piperidiny]ethoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-87-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[2-[2-(2-(phosphonooxy)ethyl]-1-piperidinyl]ethoxy]-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-94-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[2-[4-[2-(phosphonooxy)ethyl]-1-piperidinyl]ethoxy]-4-quinazolinyl]amino]- (9CI)

10/ 539,220


(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-98-2 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[2-[ethyl[4-(phosphonoxy)butyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-03-2 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[2-[ethyl[2-(phosphonoxy)ethyl]amino]ethoxy]-6-

10/ 539,220

methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-07-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[4-[(phosphonoxy)methyl]-1-piperidinyl]propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A






● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-08-7 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[4-[(phosphonooxy)methyl]-1-piperidiny]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-17-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[[1-[2-(phosphonooxy)ethyl]-4-piperidiny]methoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-19-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[[1-[2-(phosphonoxy)ethyl]-4-piperidinyl]methoxy]-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 723282-71-1


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of quinazolines as inhibitors of Aurora kinase)

RN 723282-71-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 385781-90-8P, N-(3-Fluorophenyl)-2-[2-[[7-[3-[(1-hydroxy-2-methylpropan-2-yl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 385781-98-6P 385781-99-7P  
 385782-10-5P, N-(3,4-Difluorophenyl)-2-[2-[[7-[3-[4-(hydroxymethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 385782-18-3P 385782-26-3P,  
 N-(3-Chlorophenyl)-2-[2-[[7-[3-[4-(2-hydroxyethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide  
 385782-38-7P 385782-44-5P, N-(3,5-Difluorophenyl)-2-[2-[[7-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 385782-51-4P,  
 N-(3,5-Difluorophenyl)-2-[2-[[7-[3-[(2-hydroxyethyl)(methyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide  
 385782-54-7P, N-(3,5-Difluorophenyl)-2-[2-[[7-[3-[(2R)-2-hydroxypropyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 385782-81-0P, N-(3-Fluorophenyl)-2-[2-[[7-[3-(4-hydroxypiperidin-1-yl)propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 385782-82-1P, N-(3-Fluorophenyl)-2-[2-[[7-[3-(3-hydroxypyrrolidin-1-yl)propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 385782-85-4P, N-(3-Fluorophenyl)-2-[2-[[7-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 385782-87-6P,  
 N-(3-Fluorophenyl)-2-[2-[[7-[3-[4-(2-hydroxyethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide  
 385782-88-7P, N-(3-Fluorophenyl)-2-[2-[[7-[3-(3-hydroxypiperidin-1-yl)propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide  
 385782-89-8P, N-(3-Fluorophenyl)-2-[2-[[7-[3-[4-(hydroxymethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 385782-92-3P 385782-93-4P  
 723278-14-6P 723278-45-3P 723278-52-2P  
 723278-60-2P 723278-68-0P 723278-76-0P

723278-79-3P, N-(3-Fluorophenyl)-2-[2-[[7-[3-[(2-hydroxyethyl)(ethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 723278-88-4P 723278-96-4P  
723279-07-0P 723279-13-8P 723279-21-8P  
723279-29-6P 723279-32-1P 723279-38-7P  
723279-41-2P, N-(3-Fluorophenyl)-2-[2-[[7-[3-[(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 723279-44-5P 723279-50-3P  
723279-53-6P, 2-[2-[[7-[3-[Ethyl(3-hydroxypropyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]-N-(3-fluorophenyl)acetamide 723279-59-2P 723279-62-7P,  
2-[2-[[7-[3-[(2-Fluoroethyl)(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]-N-(3-fluorophenyl)acetamide 723279-68-3P 723279-76-3P  
723279-79-6P, N-(3-Fluorophenyl)-2-[2-[[7-[3-[(2-hydroxyethyl)(2-methoxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 723279-85-4P 723279-88-7P  
723279-94-5P 723280-02-2P 723280-21-5P  
723280-29-3P 723280-41-9P 723280-49-7P  
723280-58-8P 723280-69-1P 723280-87-3P  
723280-97-5P 723281-07-0P 723281-13-8P,  
N-(2-Fluorophenyl)-2-[2-[[7-[3-[4-(hydroxymethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide  
723281-18-3P 723281-19-4P 723281-25-2P  
723281-27-4P 723281-31-0P 723281-33-2P,  
2-[2-[[7-[3-[Ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]-N-(2-fluorophenyl)acetamide  
723281-36-5P 723281-37-6P, N-(2-Fluorophenyl)-2-[2-[[7-[3-[2-(2-hydroxyethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 723281-41-2P  
723281-47-8P 723281-52-5P 723281-54-7P  
723281-59-2P 723281-61-6P, N-(2,3-Difluorophenyl)-2-[2-[[7-[3-[(2-hydroxyethyl)(methyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 723281-65-0P  
723281-67-2P, N-(2,3-Difluorophenyl)-2-[2-[[7-[3-[2-(2-hydroxyethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 723281-73-0P 723281-75-2P,  
N-(2,3-Difluorophenyl)-2-[2-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide  
723281-78-5P 723281-80-9P, N-(2,3-Difluorophenyl)-2-[2-[[7-[3-[4-(hydroxymethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 723281-84-3P  
723281-86-5P, N-(2,3-Difluorophenyl)-2-[2-[[7-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 723281-90-1P 723281-92-3P,  
N-(2,3-Difluorophenyl)-2-[2-[[7-[3-[(1-hydroxy-3-methylbutan-3-yl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 723281-96-7P 723281-98-9P,  
N-(2,3-Difluorophenyl)-2-[2-[[7-[3-[(3-hydroxy-2-methylpropan-2-yl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 723282-02-8P 723282-04-0P,  
N-(2,3-Difluorophenyl)-2-[2-[[7-[3-[(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide  
723282-10-8P 723282-18-6P 723282-22-2P  
723282-24-4P 723282-30-2P 723282-32-4P,  
N-(2,5-Difluorophenyl)-2-[2-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide  
723282-36-8P 723282-43-7P 723282-47-1P  
723282-49-3P, N-(2,4-Difluorophenyl)-2-[2-[[7-[3-[2-(2-hydroxyethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-

thiazol-5-yl]acetamide 723282-53-9P 723282-55-1P,  
 2-[2-[[7-[3-[Cyclopropyl(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]-N-(3-fluorophenyl)acetamide  
 723282-59-5P 723282-61-9P, 2-[2-[[7-[3-[Cyclopropyl(2-hydroxyethyl)amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]-N-(2,3-difluorophenyl)acetamide 723282-65-3P  
 723282-69-7P 723282-77-7P 723282-81-3P  
 723282-83-5P, N-(2,3-Difluorophenyl)-2-[2-[[7-[2-[4-(2-hydroxyethyl)piperazin-1-yl]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 723282-89-1P, N-(3-Fluorophenyl)-2-[2-[[7-[2-[2-(2-hydroxyethyl)piperidin-1-yl]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 723282-96-0P,  
 N-(3-Fluorophenyl)-2-[2-[[7-[2-[4-(2-hydroxyethyl)piperidin-1-yl]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide  
 723283-00-9P, 2-[2-[[7-[2-[Ethyl(4-hydroxybutyl)amino]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]-N-(3-fluorophenyl)acetamide 723283-05-4P, 2-[2-[[7-[2-[Ethyl(2-hydroxyethyl)amino]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]-N-(3-fluorophenyl)acetamide 723283-10-1P  
 723283-15-6P, N-(3-Fluorophenyl)-2-[2-[[7-[3-[4-(hydroxymethyl)piperidin-1-yl]propoxy]quinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 723283-21-4P 723283-27-0P,  
 N-(3-Fluorophenyl)-2-[2-[[6-methoxy-7-((piperidin-4-yl)methoxy)quinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide 723283-29-2P,  
 2-[2-[[7-[[1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]piperidin-4-yl]methoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]-N-(3-fluorophenyl)acetamide 723283-31-6P, N-(3-Fluorophenyl)-2-[2-[[7-[[1-(2-hydroxyethyl)piperidin-4-yl]methoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of quinazolines as inhibitors of Aurora kinase)  
 RN 385781-90-8 ZCAPLUS  
 CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-98-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-99-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-10-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-18-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-26-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 385782-38-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-44-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-51-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-54-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[(2R)-2-hydroxypropyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-81-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-82-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-(3-hydroxy-1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-85-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-87-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-88-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-(3-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-89-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-92-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-93-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-14-6 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) [1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-piperidinyl]methyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-45-3 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) [(2R)-1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-52-2 ZCAPLUS


CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[4-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-60-2 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-68-0 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-3-piperidinyl ester (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-76-0 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[ethyl[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/ 539,220

RN 723278-79-3 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723278-88-4 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) [(2S)-1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 723278-96-4 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[ethyl[[[(2S)-1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl]amino]ethyl ester (9CI) (CA INDEX NAME)


10/ 539,220

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-07-0 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[(2S)-2-[[ethyl(2-hydroxyethyl)amino]methyl]-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




— F

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-13-8 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-piperidiny] ester (9CI) (CA INDEX NAME)





ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-21-8 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[[[(2S)-1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl]amino]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-29-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2S)-2-[[2-(2-hydroxyethyl)amino]methyl]-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B

F


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-32-1 ZCAPLUS

CN Carbamic acid, [[(2S)-1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl](2-hydroxyethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

F


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-38-7 ZCAPLUS


CN 5,7-Dioxa-2-aza-6-phosphanonanoic acid, 6-(1,1-dimethylethoxy)-2-[3-[[4-

[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-8,8-dimethyl-, 1,1-dimethylethyl ester, 6-oxide  
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-41-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 723279-44-5 ZCAPLUS

CN Carbamic acid, [3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl](2-hydroxyethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A








ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-50-3 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 3-[ethyl[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]propyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-53-6 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[ethyl(3-hydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-59-2 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[(2-fluoroethyl) [3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-62-7 ZCAPLUS

10/ 539,220


CN 5-Thiazoleacetamide, 2-[[7-[3-[(2-fluoroethyl) (2-hydroxyethyl) amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-68-3 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[1-[3-[[4-[[5-[2-[(3-fluorophenyl) amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-piperidinyl]ethyl ester (9CI) (CA INDEX NAME)




10/ 539,220

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-76-3 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl](2-methoxyethyl)amino]ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-79-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)(2-methoxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 723279-85-4 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl 2-[(2S)-1-[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-88-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2S)-2-(2-hydroxyethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723279-94-5 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]-2-methylpropyl ester (9CI) (CA INDEX NAME)

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-02-2 ZCAPLUS

CN Phosphoric acid, [(2R)-1-[3-[[4-[[5-[2-[(3-chlorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-21-5 ZCAPLUS


CN Phosphoric acid, 2-[1-[3-[[4-[[5-[2-[(3-chlorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-piperidinyl]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-29-3 ZCAPLUS

CN Phosphoric acid, 2-[4-[3-[[4-[[5-[2-[(3,5-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-1-piperazinyl]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-41-9 ZCAPLUS

CN Phosphoric acid, 2-[3-[[4-[[5-[2-[(3,5-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]methyamino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-49-7 ZCAPLUS

CN Phosphoric acid, [(2S)-1-[3-[[4-[[5-[2-[(3,5-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-58-8 ZCAPLUS

CN Phosphoric acid, (1R)-2-[[3-[[4-[[5-[2-[(3,5-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]-1-methylethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-69-1 ZCAPLUS

CN Phosphoric acid, [(2R)-1-[3-[[4-[[5-[2-[(3,4-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-87-3 ZCAPLUS

CN Phosphoric acid, [(2S)-1-[3-[[4-[[5-[2-[(3,4-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723280-97-5 ZCAPLUS


CN Phosphoric acid, 1-[3-[[4-[[5-[2-[(3,4-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-piperidinyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-07-0 ZCAPLUS


CN Phosphoric acid, bis(1,1-dimethylethyl) [1-[3-[[4-[[5-[2-[(2-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-piperidinyl]methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-13-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-18-3 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) [(2R)-1-[3-[[4-[[5-[2-[(2-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-19-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-25-2 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) [(2S)-1-[3-[[4-[[5-[2-[(2-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/ 539,220

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-27-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-31-0 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[ethyl[3-[[4-[[5-[2-[(2-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-33-2 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2-fluorophenyl)- (9CI) (CA INDEX NAME)

10/ 539,220





ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-36-5 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[1-[3-[[4-[[5-[2-[(2-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-piperidinyl]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A






ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-37-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[7-[3-[2-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 723281-41-2 ZCAPLUS

CN Phosphoric acid, [(2R)-1-[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-47-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-52-5 ZCAPLUS

CN Phosphoric acid, [(2S)-1-[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/ 539,220

RN 723281-54-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-59-2 ZCAPLUS

CN Phosphoric acid, 2-[[[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxylpropyl]methylamino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-61-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)

10/ 539,220





ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-65-0 ZCAPLUS

CN Phosphoric acid, 2-[1-[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-piperidinyl]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A






ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-67-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[2-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-73-0 ZCAPLUS

CN Phosphoric acid, 2-[[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]ethylamino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-75-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-78-5 ZCAPLUS

10/ 539,220


CN Phosphoric acid, 1-[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-piperidinyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-80-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-84-3 ZCAPLUS

10/ 539,220


CN Phosphoric acid, 2-[4-[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-1-piperazinyl]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-86-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-90-1 ZCAPLUS

10/ 539,220

CN Phosphoric acid, 3-[[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]-3-methylbutyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-92-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[(3-hydroxy-1,1-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-96-7 ZCAPLUS

CN Phosphoric acid, 2-[[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]-2-methylpropyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723281-98-9 ZCAPLUS

10/ 539,220

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-02-8 ZCAPLUS

CN Phosphoric acid, 2-[[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-04-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 723282-10-8 ZCAPLUS

CN Phosphoric acid, [(2R)-1-[3-[[4-[[5-[2-[(2,5-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-

10/ 539,220

pyrrolidinyl)methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-18-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-22-2 ZCAPLUS

CN Phosphoric acid, [(2S)-1-[3-[[4-[[5-[2-[(2,5-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-24-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-30-2 ZCAPLUS

CN Phosphoric acid, 2-[[3-[[4-[[5-[2-[(2,5-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]ethylamino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-32-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-36-8 ZCAPLUS

10/ 539,220

CN Phosphoric acid, [(2S)-1-[3-[[4-[[5-[2-[(2,4-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-pyrrolidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-43-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,4-difluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 723282-47-1 ZCAPLUS

CN Phosphoric acid, 2-[1-[3-[[4-[[5-[2-[(2,4-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-piperidinyl]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-49-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,4-difluorophenyl)-2-[[7-[3-[2-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)







ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-53-9 ZCAPLUS

CN Phosphoric acid, 2-[cyclopropyl[3-[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A






ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-55-1 ZCAPLUS



CN 5-Thiazoleacetamide, 2-[[7-[3-[cyclopropyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-59-5 ZCAPLUS

CN Phosphoric acid, 2-[cyclopropyl[3-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-61-9 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[cyclopropyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-65-3 ZCAPLUS

CN Phosphoric acid, [1-[2-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]-4-piperidinyl]methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-69-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[2-[4-(hydroxymethyl)-1-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-77-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[2-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyloxy]-6-methoxy-4-quinazolinyl]amino]-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-81-3 ZCAPLUS

CN Phosphoric acid, 2-[4-[2-[[4-[[5-[2-[(2,3-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-83-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,3-difluorophenyl)-2-[[7-[2-[4-(2-hydroxyethyl)-1-piperazinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-89-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[2-[2-(2-hydroxyethyl)-1-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723282-96-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[2-[4-(2-hydroxyethyl)-1-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-00-9 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[2-[ethyl(4-hydroxybutyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-05-4 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[2-[ethyl(2-hydroxyethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 723283-10-1 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) [1-[3-[[4-[[5-[2-[(3-



10/ 539,220


fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-7-quinazolinyl]oxy]propyl]-4-piperidiny]methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-15-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidiny]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-21-4 ZCAPLUS

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-[4-[[[4-[[5-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-

10/ 539,220


quinazolinyl]oxy)methyl]-1-piperidinyl]ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-27-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-(4-piperidinylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-29-2 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[[1-[2-[[1,1-dimethylethyl]dimethylsilyl]oxy]ethyl]-4-piperidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 723283-31-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[[1-(2-hydroxyethyl)-4-piperidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 20 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:532525 ZCAPLUS

DOCUMENT NUMBER: 139:101142

TITLE: Preparation of substituted quinazoline derivatives as inhibitors of aurora kinases  
 INVENTOR(S): Jung, Frederic Henri; Pasquet, Georges Rene  
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SOURCE: PCT Int. Appl., 175 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055491	A1	20030710	WO 2002-GB5845	20021220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2471577	A1	20030710	CA 2002-2471577	20021220
AU 2002353196	A1	20030715	AU 2002-353196	20021220
EP 1463506	A1	20041006	EP 2002-788214	20021220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015312	A	20041207	BR 2002-15312	20021220
HU 200402454	A2	20050329	HU 2004-2454	20021220
CN 1620296	A	20050525	CN 2002-828305	20021220
JP 2005525307	T	20050825	JP 2003-556068	20021220
NZ 533440	A	20060831	NZ 2002-533440	20021220
IN 2004DN01632	A	20070112	IN 2004-DN1632	20040610
ZA 2004004923	A	20050922	ZA 2004-4923	20040622
NO 2004003158	A	20040916	NO 2004-3158	20040723
US 2005070561	A1	20050331	US 2004-499684	20041117
PRIORITY APPLN. INFO.:			EP 2001-403357	A 20011224
			WO 2002-GB5845	W 20021220
OTHER SOURCE(S):			MARPAT 139:101142	
GI				


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [X = O, SOO-2, amino, etc.; R1-4 = H, halo, CN, NO2, CF3, etc.; R5 = pyrazolyl] are prepared For instance, 4-chloro-6-methoxy-7-(3-(morpholinyl)propoxy)quinazoline is heated in the presence of Me (5-amino-1H-pyrazol-3-yl)acetate (pentan-2-ol, HCl, 120°, 2 h) to give Me [5-[(6-methoxy-7-(3-(morpholinyl)propoxy)quinazolin-4-yl)amino]-1H-pyrazol-3-yl]acetate. This intermediate is saponified and condensed with aniline to give II. I are inhibitors of aurora kinase [no data].  
 IT 557770-04-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of substituted quinazoline derivs. as inhibitors of aurora

kinases)  
 RN 557770-04-4 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[[ (2R)-1-[2-(1,1-dimethylethoxy)ethyl]-2-pyrrolidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 557769-34-3P, 2-[5-[[6-Methoxy-7-[3-[morpholinyl]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-phenylacetamide 557769-38-7P, N-[3-Fluorophenyl]-2-[5-[[6-methoxy-7-[3-[morpholinyl]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-46-7P, 2-[5-[[7-[3-[Ethyl[2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[3-fluorophenyl]acetamide 557769-52-5P, N-[3-Fluorophenyl]-2-[5-[[6-methoxy-7-[3-(piperidinyl)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-49-0P, N-[3-Fluorophenyl]-2-[5-[[6-methoxy-7-[3-(pyrrolidinyl)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-50-3P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-51-4P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[2-hydroxy-1,1-dimethylethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-52-5P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[2-hydroxyethyl][methyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-53-6P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[1-[hydroxymethyl]-2-methylpropyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-54-7P, N-[3-Fluorophenyl]-2-[5-[[6-methoxy-7-[3-[4-methylpiperazin-1-yl]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-55-8P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[2-hydroxy-1-methylethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-56-9P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[4-hydroxybutyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-57-0P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[4-hydroxypiperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-58-1P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[2-[2-hydroxyethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-59-2P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[4-[2-hydroxyethyl]piperazin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-60-5P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[4-[2-hydroxyethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-61-6P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[3-hydroxypiperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-62-7P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[2-hydroxybutyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-

pyrazol-3-yl]acetamide 557769-63-8P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[4-[hydroxymethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-64-9P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[3-hydroxy-2,2-dimethylpropyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-65-0P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[1-[hydroxymethyl]cyclopentyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-67-2P 557769-68-3P 557769-69-4P 557769-70-7P 557769-71-8P, 2-[5-[[7-[3-[2-Fluoroethyl][2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[3-fluorophenyl]acetamide 557769-72-9P, N-[3-Fluorophenyl]-2-[5-[[7-[2-[1-[2-hydroxyethyl]piperidin-4-yl]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-77-4P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[2-hydroxyethyl][propyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-78-5P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[2-hydroxyethyl][isopropyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-79-6P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[2-hydroxyethyl][isobutyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-80-9P, 2-[5-[[7-[3-[2,2-Dimethylpropyl][2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[3-fluorophenyl]acetamide 557769-82-1P, 2-[5-[[7-[3-[Allyl][2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[3-fluorophenyl]acetamide 557769-83-2P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[2-hydroxyethyl][propan-2-yn-1-yl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-84-3P, 2-[5-[[7-[3-[Cyclopropyl][2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[3-fluorophenyl]acetamide 557769-85-4P, 2-[5-[[7-[3-[Cyclopropylmethyl][2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[3-fluorophenyl]acetamide 557769-87-6P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[Cyclobutyl][2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-88-7P, 2-[5-[[7-[3-[Cyclopentyl][2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[3-fluorophenyl]acetamide 557769-89-8P, 2-[5-[[7-[3-[2,2-Dimethoxyethyl][2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[3-fluorophenyl]acetamide 557769-90-1P, 2-[5-[[7-[3-[2,2-Difluoroethyl][2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[3-fluorophenyl]acetamide 557769-92-3P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[2-hydroxyethyl][3,3,3-trifluoropropyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-93-4P, 2-[5-[[7-[3-[Cyclobutylmethyl][2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[3-fluorophenyl]acetamide 557769-96-7P, N-[3-Fluorophenyl]-2-[5-[[7-[3-[2-hydroxyethyl][2-methoxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557769-97-8P, 2-[5-[[7-[3-[1,3-Dioxolan-2-ylmethyl][2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[3-fluorophenyl]acetamide 557770-02-2P 557770-03-3P, N-[3-Fluorophenyl]-2-[5-[[7-[4-[2-hydroxyethyl][isobutyl]amino]butoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-09-9P 557770-10-2P, N-[3,5-Difluorophenyl]-2-[5-[[6-methoxy-7-[3-(pyrrolidinyl)propoxy]quinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-11-3P, N-[3,5-Difluorophenyl]-2-[5-[[7-[3-[2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide

557770-12-4P, N-[3,5-Difluorophenyl]-2-[5-[[7-[3-[[2-hydroxy-1,1-dimethylethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-13-5P, N-[3,5-Difluorophenyl]-2-[5-[[6-methoxy-7-[3-[4-methylpiperazin-1-yl]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-14-6P, N-[3,5-Difluorophenyl]-2-[5-[[7-[3-[ethyl[2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-15-7P, N-[3,5-Difluorophenyl]-2-[5-[[7-[3-[2-[2-hydroxyethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-16-8P, N-[3,5-Difluorophenyl]-2-[5-[[7-[3-[4-[2-hydroxyethyl]piperazin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-17-9P, N-[3,5-Difluorophenyl]-2-[5-[[7-[3-[4-[2-hydroxyethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-18-0P, N-[3,5-Difluorophenyl]-2-[5-[[7-[3-[3-hydroxypiperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-19-1P, N-[3,5-Difluorophenyl]-2-[5-[[7-[3-[[2-hydroxybutyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-20-4P, N-[3,5-Difluorophenyl]-2-[5-[[7-[3-[4-[hydroxymethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-21-5P, N-[3,5-Difluorophenyl]-2-[5-[[7-[3-[[3-hydroxy-2,2-dimethylpropyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-22-6P 557770-23-7P 557770-24-8P 557770-25-9P 557770-26-0P 557770-27-1P 557770-28-2P, N-[3,5-Difluorophenyl]-2-[5-[[7-[3-[[2-hydroxyethyl][isobutyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-29-3P, N-[3,5-Difluorophenyl]-2-[5-[[7-[3-[[2-hydroxyethyl][propyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-30-6P, 2-[5-[[7-[3-[Allyl[2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[3,5-difluorophenyl]acetamide 557770-31-7P, N-[3,5-Difluorophenyl]-2-[5-[[7-[3-[[2-hydroxyethyl][propan-2-yn-1-yl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-32-8P, N-[3,5-Difluorophenyl]-2-[5-[[7-[3-[[2-hydroxyethyl][isopropyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-33-9P, N-[3,5-Difluorophenyl]-2-[5-[[7-[3-[[2,2-dimethylpropyl][2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-34-0P, 2-[5-[[7-[3-[Cyclobutyl[2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[3,5-difluorophenyl]acetamide 557770-35-1P, 2-[5-[[7-[3-[[Cyclopropylmethyl][2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[3,5-difluorophenyl]acetamide 557770-36-2P 557770-37-3P 557770-38-4P, N-[2,3-Difluorophenyl]-2-[5-[[7-[3-[[2-hydroxyethyl][propyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-39-5P, N-[2,3-Difluorophenyl]-2-[5-[[7-[3-[[2-hydroxyethyl][isobutyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-40-8P, N-[2,3-Difluorophenyl]-2-[5-[[7-[3-[cyclobutyl[2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-41-9P, 2-[5-[[7-[3-[Cyclopentyl[2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[2,3-difluorophenyl]acetamide 557770-42-0P 557770-43-1P, N-[2,3-Difluorophenyl]-2-[5-[[7-[3-[[2-hydroxyethyl][propan-2-yn-1-yl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-44-2P, 2-[5-[[7-[3-[[Cyclopropylmethyl][2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[2,3-

difluorophenyl]acetamide 557770-45-3P, 2-[5-[[7-[3-  
[[Cyclobutylmethyl][2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-  
yl]amino]-1H-pyrazol-3-yl]-N-[2,3-difluorophenyl]acetamide  
557770-46-4P, N-[2,3-Difluorophenyl]-2-[5-[[7-[3-[[2,2-  
dimethoxyethyl][2-hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-  
yl]amino]-1H-pyrazol-3-yl]acetamide 557770-47-5P,  
N-[2,3-Difluorophenyl]-2-[5-[[7-[3-[4-[2-hydroxyethyl]piperidin-1-  
yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide  
557770-48-6P, N-[2,3-Difluorophenyl]-2-[5-[[7-[3-[4-  
hydroxypiperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-  
3-yl]acetamide 557770-49-7P, N-[2,3-Difluorophenyl]-2-[5-[[7-[3-  
[4-[2-hydroxyethyl]piperazin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-  
1H-pyrazol-3-yl]acetamide 557770-50-0P, N-[2,3-Difluorophenyl]-2-  
[5-[[7-[3-[[2-hydroxyethyl][2-methoxyethyl]amino]propoxy]-6-  
methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide  
557770-51-1P, 2-[5-[[7-[3-[Allyl][2-hydroxyethyl]amino]propoxy]-6-  
methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[2,3-  
difluorophenyl]acetamide 557770-52-2P, N-[2,3-Difluorophenyl]-2-  
[5-[[7-[3-[[1,3-dioxolan-2-ylmethyl][2-hydroxyethyl]amino]propoxy]-6-  
methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide  
557770-53-3P, N-[2,3-Difluorophenyl]-2-[5-[[7-[3-[ethyl[2-  
hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-  
yl]acetamide 557770-54-4P, N-[2,3-Difluorophenyl]-2-[5-[[7-[3-  
[[2-hydroxyethyl][isopropyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-  
1H-pyrazol-3-yl]acetamide 557770-55-5P, N-[2,3-Difluorophenyl]-2-  
[5-[[7-[3-[[2-hydroxy-1,1-dimethylethyl]amino]propoxy]-6-methoxyquinazolin-  
4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-56-6P  
557770-58-8P 557770-59-9P 557770-60-2P,  
N-[3-Chlorophenyl]-2-[5-[[7-[3-[3-hydroxypiperidin-1-yl]propoxy]-6-  
methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide  
557770-61-3P, N-[3-Chlorophenyl]-2-[5-[[7-[3-[ethyl[2-  
hydroxyethyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-  
yl]acetamide 557770-62-4P, 2-[5-[[7-[3-[4-  
[Hydroxymethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-  
pyrazol-3-yl]-N-[3-methoxyphenyl]acetamide 557770-64-6P,  
2-[5-[[7-[3-[4-[Hydroxymethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-  
4-yl]amino]-1H-pyrazol-3-yl]-N-phenylacetamide 557770-65-7P,  
N-[4-Fluorophenyl]-2-[5-[[7-[3-[4-[hydroxymethyl]piperidin-1-yl]propoxy]-6-  
methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide  
557770-66-8P, N-[3,5-Dichlorophenyl]-2-[5-[[7-[3-[4-  
[hydroxymethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-  
pyrazol-3-yl]acetamide 557770-67-9P, N-[5-Chloro-2-  
methoxyphenyl]-2-[5-[[7-[3-[4-[hydroxymethyl]piperidin-1-yl]propoxy]-6-  
methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide  
557770-68-0P, 2-[5-[[7-[3-[4-[Hydroxymethyl]piperidin-1-  
yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[3-  
[trifluoromethyl]phenyl]acetamide 557770-69-1P,  
2-[5-[[7-[3-[4-[Hydroxymethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-  
4-yl]amino]-1H-pyrazol-3-yl]-N-[3-hydroxyphenyl]acetamide  
557770-70-4P, 2-[5-[[7-[3-[4-[Hydroxymethyl]piperidin-1-  
yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[3-  
nitrophenyl]acetamide 557770-71-5P, 2-[5-[[7-[3-[4-  
[Hydroxymethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-  
pyrazol-3-yl]-N-1H-indazol-5-ylacetamide 557770-72-6P,  
N-[4-Bromo-2-fluorophenyl]-2-[5-[[7-[3-[4-[hydroxymethyl]piperidin-1-  
yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide  
557770-73-7P, N-[3-Chlorophenyl]-2-[5-[[7-[3-[4-  
[hydroxymethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-  
pyrazol-3-yl]acetamide 557770-74-8P,  
N-[2-Fluorophenyl]-2-[5-[[7-[3-[4-[hydroxymethyl]piperidin-1-yl]propoxy]-6-




methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide  
 557770-75-9P, N-[3,5-Dimethoxyphenyl]-2-[5-[[7-[3-[4-  
 [hydroxymethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-  
 pyrazol-3-yl]acetamide 557770-76-0P, N-[5-Methylpyridin-2-yl]-2-  
 [5-[[7-[3-[4-[hydroxymethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-  
 yl]amino]-1H-pyrazol-3-yl]acetamide 557770-77-1P,  
 N-[2,3-Difluorophenyl]-2-[5-[[7-[3-[4-[hydroxymethyl]piperidin-1-  
 yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide  
 557770-78-2P, N-[3-Chloro-2-fluorophenyl]-2-[5-[[7-[3-[4-  
 [hydroxymethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-  
 pyrazol-3-yl]acetamide 557770-79-3P, N-[2,5-Difluorophenyl]-2-[5-  
 [[7-[3-[4-[hydroxymethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-  
 yl]amino]-1H-pyrazol-3-yl]acetamide 557770-80-6P,  
 N-[2-Fluoro-5-[trifluoromethyl]phenyl]-2-[5-[[7-[3-[4-  
 [hydroxymethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-  
 pyrazol-3-yl]acetamide 557770-81-7P, N-[3,4-Difluorophenyl]-2-[5-  
 [[7-[3-[4-[hydroxymethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-  
 yl]amino]-1H-pyrazol-3-yl]acetamide 557770-82-8P,  
 N-[2,4-Difluorophenyl]-2-[5-[[7-[3-[4-[hydroxymethyl]piperidin-1-  
 yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide  
 557770-83-9P, N-[3-Chloro-4-fluorophenyl]-2-[5-[[7-[3-[4-  
 [hydroxymethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-  
 pyrazol-3-yl]acetamide 557770-84-0P, N-[2-  
 [Difluoromethoxy]phenyl]-2-[5-[[7-[3-[4-[hydroxymethyl]piperidin-1-  
 yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide  
 557770-85-1P, N-[3-Cyanophenyl]-2-[5-[[7-[3-[4-  
 [hydroxymethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-  
 pyrazol-3-yl]acetamide 557770-86-2P, N-[3-Bromophenyl]-2-[5-[[7-  
 [3-[4-[hydroxymethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-  
 yl]amino]-1H-pyrazol-3-yl]acetamide 557770-87-3P,  
 N-[2,3-Difluorophenyl]-2-[5-[[7-[3-[ethyl[2-hydroxyethyl]amino]propoxy]qui-  
 nazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-92-0P,  
 N-[2,3-Difluorophenyl]-2-[5-[[7-[3-[[2-hydroxyethyl][isopropyl]amino]propoxy]Quinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetamide 557770-93-1P  
 557770-94-2P, N-[2,3-Difluorophenyl]-2-[5-[[7-[3-[[2-  
 hydroxyethyl][propyl]amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-3-  
 yl]acetamide 557770-95-3P, N-[2,3-Difluorophenyl]-2-[5-[[7-[3-  
 [[2-hydroxyethyl][propan-2-yn-1-yl]amino]propoxy]quinazolin-4-yl]amino]-1H-  
 pyrazol-3-yl]acetamide 557770-96-4P, N-[2,3-Difluorophenyl]-2-[5-  
 [[7-[3-[[2-hydroxyethyl][isobutyl]amino]propoxy]quinazolin-4-yl]amino]-1H-  
 pyrazol-3-yl]acetamide 557770-97-5P, N-[2,3-Difluorophenyl]-2-[5-  
 [[7-[3-[[2,2-dimethylpropyl][2-hydroxyethyl]amino]propoxy]quinazolin-4-  
 yl]amino]-1H-pyrazol-3-yl]acetamide 557770-98-6P,  
 N-[3-Fluorophenyl]-2-[5-[[5-[[1-[2-hydroxyethyl]piperidin-4-yl]oxy]-7-[3-  
 [4-methylpiperazin-1-yl]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-3-  
 yl]acetamide 557771-37-6P, N-[3-Fluorophenyl]-5-[[7-[3-[[2-  
 hydroxyethyl][isobutyl]amino]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-  
 pyrazole-3-carboxamide 557771-44-5P, N-[2,3-Difluorophenyl]-5-  
 [[7-[3-[[2-hydroxyethyl][isobutyl]amino]propoxy]-6-methoxyquinazolin-4-  
 yl]amino]-1H-pyrazole-3-carboxamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of substituted quinazoline derivs. as inhibitors of aurora  
 kinases)

RN 557769-34-3 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-  
 quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)

10/ 539,220





RN 557769-38-7 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 557769-46-7 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (CA INDEX NAME)



RN 557769-47-8 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 557769-48-9 ZCAPLUS


10/ 539,220

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 557769-49-0 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 557769-50-3 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 557769-51-4 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 557769-52-5 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)



PAGE 1-A




PAGE 2-A



RN 557769-53-6 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[[1-(hydroxymethyl)-2-methylpropyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 557769-54-7 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 557769-55-8 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[[3-[(2-hydroxy-1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A








RN 557769-56-9 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(4-hydroxybutyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)





RN 557769-57-0 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 557769-58-1 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[2-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A





RN 557769-59-2 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 557769-60-5 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220





RN 557769-61-6 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-(3-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 557769-62-7 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2-hydroxybutyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)





RN 557769-63-8 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 557769-64-9 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(3-hydroxy-2,2-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 557769-65-0 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[[1-(hydroxymethyl)cyclopentyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



RN 557769-67-2 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[[ (2S)-2-hydroxypropyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/ 539,220

RN 557769-68-3 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2R)-2-hydroxypropyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 557769-69-4 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(3S)-3-hydroxy-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 557769-70-7 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(3R)-3-hydroxy-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/ 539,220




RN 557769-71-8 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[(2-fluoroethyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 557769-72-9 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[2-[1-(2-hydroxyethyl)-4-


10/ 539,220

piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 557769-77-4 ZCAPLUS  
CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)propylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 557769-78-5 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)(1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



PAGE 1-A





PAGE 2-A





RN 557769-79-6 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)(2-methylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)





RN 557769-80-9 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[(2,2-dimethylpropyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 557769-82-1 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)-2-propenylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 557769-83-2 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)-2-propynylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 557769-84-3 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[cyclopropyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 557769-85-4 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[7-[[3-[(cyclopropylmethyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)






RN 557769-87-6 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[cyclobutyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

10/ 539,220





RN 557769-88-7 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-(cyclopentyl(2-hydroxyethyl)amino)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)





RN 557769-89-8 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[(2,2-dimethoxyethyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)





RN 557769-90-1 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[(2,2-difluoroethyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 557769-92-3 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)(3,3,3-trifluoropropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 557769-93-4 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[[3-[(cyclobutylmethyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 557769-96-7 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[[3-[(2-hydroxyethyl)(2-methoxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 557769-97-8 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[(1,3-dioxolan-2-ylmethyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 557770-02-2 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[4-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]butoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/ 539,220




RN 557770-03-3 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[4-[(2-hydroxyethyl) (2-methylpropyl) amino]butoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 557770-09-9 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[(2R)-1-(2-



10/ 539,220


hydroxyethyl)-2-pyrrolidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 557770-10-2 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 557770-11-3 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 557770-12-4 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A







RN 557770-13-5 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 557770-14-6 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 557770-15-7 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[2-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-  
 (9CI) (CA INDEX NAME)

10/ 539,220



RN 557770-16-8 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 557770-17-9 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220





RN 557770-18-0 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-(3-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 557770-19-1 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[(2-hydroxybutyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 557770-20-4 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-  
 (CA INDEX NAME)




RN 557770-21-5 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[[3-[(3-hydroxy-2,2-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A








RN 557770-22-6 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 557770-23-7 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 557770-24-8 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[[[(2S)-2-hydroxypropyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



RN 557770-25-9 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[(2R)-2-hydroxypropyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 557770-26-0 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[(3S)-3-hydroxy-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 557770-27-1 ZCAPLUS

10/ 539,220

CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[(3R)-3-hydroxy-1-pyrrolidiny]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 557770-28-2 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)(2-methylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 557770-29-3 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)propylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)



PAGE 1-A





PAGE 2-A





RN 557770-30-6 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)-2-propenylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)





RN 557770-31-7 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)-2-propynylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 557770-32-8 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)(1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-  
 (9CI) (CA INDEX NAME)




RN 557770-33-9 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3,5-difluorophenyl)-5-[[7-[3-[(2,2-dimethylpropyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 557770-34-0 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[cyclobutyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)




10/ 539,220



RN 557770-35-1 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[(cyclopropylmethyl) (2-hydroxyethyl) amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 557770-36-2 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 557770-37-3 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2,2-dimethylpropyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




PAGE 2-A




RN 557770-38-4 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)propylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 557770-39-5 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)(2-methylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 557770-40-8 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[cyclobutyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)

10/ 539,220



RN 557770-41-9 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-(cyclopentyl(2-hydroxyethyl)amino)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 557770-42-0 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)


10/ 539,220

Absolute stereochemistry.




RN 557770-43-1 ZCAPLUS  
CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)-2-propynylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 557770-44-2 ZCAPLUS

10/ 539,220

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[(cyclopropylmethyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 557770-45-3 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[(cyclobutylmethyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,3-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 557770-46-4 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2,2-dimethoxyethyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazoliny]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A








RN 557770-47-5 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 557770-48-6 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)

10/ 539,220





RN 557770-49-7 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)





RN 557770-50-0 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)(2-methoxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 557770-51-1 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)-2-propenylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)





RN 557770-52-2 ZCAPLUS



CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(1,3-dioxolan-2-ylmethyl)(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-  
(9CI) (CA INDEX NAME)





RN 557770-53-3 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 557770-54-4 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)(1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-  
 (9CI) (CA INDEX NAME)



RN 557770-55-5 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 557770-56-6 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[[[(2R)-1-(2-hydroxyethyl)-2-pyrrolidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 557770-58-8 ZCAPLUS



10/ 539,220

CN 1H-Pyrazole-3-acetamide, N-(3-chlorophenyl)-5-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 557770-59-9 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-chlorophenyl)-5-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 557770-60-2 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(3-chlorophenyl)-5-[[7-[3-(3-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


10/ 539,220




RN 557770-61-3 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-chlorophenyl)-5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 557770-62-4 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-methoxyphenyl)-  
 (CA INDEX NAME)



RN 557770-64-6 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-phenyl- (CA INDEX NAME)




RN 557770-65-7 ZCAPLUS

10/ 539,220

CN 1H-Pyrazole-3-acetamide, N-(4-fluorophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 557770-66-8 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(3,5-dichlorophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 557770-67-9 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(5-chloro-2-methoxyphenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



RN 557770-68-0 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-[3-(trifluoromethyl)phenyl]-(CA INDEX NAME)

10/ 539,220



RN 557770-69-1 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-hydroxyphenyl)-  
(CA INDEX NAME)



RN 557770-70-4 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-nitrophenyl)-  
(CA INDEX NAME)

10/ 539,220




RN 557770-71-5 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-1H-indazol-5-yl- (9CI) (CA INDEX NAME)



RN 557770-72-6 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(4-bromo-2-fluorophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 557770-73-7 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-chlorophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)




10/ 539,220




RN 557770-74-8 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(2-fluorophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidiny]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 557770-75-9 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3,5-dimethoxyphenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidiny]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 557770-76-0 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, 5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(5-methoxy-2-pyridinyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



Me

RN 557770-77-1 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-  
(CA INDEX NAME)




RN 557770-78-2 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-chloro-2-fluorophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-  
(9CI) (CA INDEX NAME)


10/ 539,220



RN 557770-79-3 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,5-difluorophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidiny]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




RN 557770-80-6 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-[2-fluoro-5-(trifluoromethyl)phenyl]-5-[[7-[3-[4-(hydroxymethyl)-1-piperidiny]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



RN 557770-81-7 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3,4-difluorophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-  
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

F

RN 557770-82-8 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,4-difluorophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

F


RN 557770-83-9 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-chloro-4-fluorophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




RN 557770-84-0 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-[2-(difluoromethoxy)phenyl]-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-  
(9CI) (CA INDEX NAME)

10/ 539,220




RN 557770-85-1 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-cyanophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 557770-86-2 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-bromophenyl)-5-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)






RN 557770-87-3 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 557770-92-0 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)(1-methylethyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 557770-93-1 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.

10/ 539,220




RN 557770-94-2 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)propylamino]propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)



PAGE 1-A





PAGE 2-A





RN 557770-95-3 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)-2-propynylamino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 557770-96-4 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl)(2-methylpropyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)




RN 557770-97-5 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2,2-dimethylpropyl)(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]- (9CI)  
 (CA INDEX NAME)




RN 557770-98-6 ZCAPLUS  
 CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[5-[[1-(2-hydroxyethyl)-4-piperidinyl]oxy]-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220




RN 557771-37-6 ZCAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-fluorophenyl)-5-[[7-[3-[(2-hydroxyethyl) (2-methylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 557771-44-5 ZCAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2,3-difluorophenyl)-5-[[7-[3-[(2-hydroxyethyl) (2-methylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



IT 557769-66-1


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of substituted quinazoline derivs. as inhibitors of aurora kinases)

RN 557769-66-1 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, N-(3-fluorophenyl)-5-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-  
(CA INDEX NAME)

Absolute stereochemistry.



IT 557769-35-4P, [5-[[6-Methoxy-7-[3-[morpholinyl]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetic acid 557769-37-6P, Methyl [5-[[6-methoxy-7-[3-[morpholinyl]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetate 557769-73-0P, 2-[5-[[7-[2-[1-[2-tert-Butoxyethyl]piperidin-4-yl]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[3-fluorophenyl]acetamide 557769-76-3P, [5-[[7-[2-[1-[2-tert-Butoxyethyl]piperidin-4-yl]ethoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetic acid 557770-05-5P 557770-57-7P 557770-63-5P, [5-[[7-[3-[4-[Hydroxymethyl]piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetic acid 557770-99-7P,




2-[5-[[5-[[1-[2-tert-Butoxyethyl]piperidin-4-yl]oxy]-7-[3-[4-methylpiperazin-1-yl]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-3-yl]-N-[3-fluorophenyl]acetamide 557771-05-8P, [5-[[5-[[1-[2-tert-Butoxyethyl]piperidin-4-yl]oxy]-7-[3-[4-methylpiperazin-1-yl]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-3-yl]acetic acid

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted quinazoline derivs. as inhibitors of aurora kinases)


RN 557769-35-4 ZCAPLUS

CN 1H-Pyrazole-3-acetic acid, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 557769-37-6 ZCAPLUS


CN 1H-Pyrazole-3-acetic acid, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 557769-73-0 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[7-[2-[1-[2-(1,1-dimethylethoxy)ethyl]-4-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

10/ 539,220




RN 557769-76-3 ZCAPLUS  
CN 1H-Pyrazole-3-acetic acid, 5-[[7-[2-[1-[2-(1,1-dimethylethoxy)ethyl]-4-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 557770-05-5 ZCAPLUS  
CN 1H-Pyrazole-3-acetic acid, 5-[[7-[[[(2R)-1-[2-(1,1-dimethylethoxy)ethyl]-2-pyrrolidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



RN 557770-57-7 ZCAPLUS


CN 1H-Pyrazole-3-acetamide, N-(2,3-difluorophenyl)-5-[[7-[[[(2R)-1-[2-(1,1-dimethylethoxy)ethyl]-2-pyrrolidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 557770-63-5 ZCAPLUS

CN 1H-Pyrazole-3-acetic acid, 5-[[7-[[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 557770-99-7 ZCAPLUS

CN 1H-Pyrazole-3-acetamide, 5-[[5-[[1-[2-(1,1-dimethylethoxy)ethyl]-4-piperidinyl]oxy]-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 557771-05-8 ZCAPLUS  
CN 1H-Pyrazole-3-acetic acid, 5-[[5-[[1-(2-(1,1-dimethylethoxy)ethyl)-4-piperidinyl]oxy]-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2003:301212 ZCAPLUS  
DOCUMENT NUMBER: 138:316772  
TITLE: Crystal structure of human Aurora A kinase catalytic  
domain complexed with ATP analog and inhibitor and  
applications to structure-based drug design  
INVENTOR(S): Anderson, Malcolm; Keen, Nicholas John; Pannifer,  
Andrew David Bruce; Pauptit, Richard Alexander;  
Rowsell, Sian  
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited  
SOURCE: PCT Int. Appl., 137 pp.

CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003031606	A2	20030417	WO 2002-GB4589	20021008
WO 2003031606	A3	20031218		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002334125	A1	20030422	AU 2002-334125	20021008
EP 1485472	A2	20041215	EP 2002-800665	20021008
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
JP 2005504548	T	20050217	JP 2003-534576	20021008
US 2006078975	A1	20060413	US 2004-491854	20041029
US 7214518	B2	20070508		

## PRIORITY APPLN. INFO.:

GB 2001-24299 A 20011010  
 WO 2002-GB4589 W 20021008

AB The invention relates to crystallized human Aurora A kinase and the use of its three-dimensional structure to investigate Aurora kinase homologs and to design Aurora kinase modulators. The invention provides two crystalline forms of a polypeptide corresponding to the catalytic domain of human Aurora A kinase. One crystalline form is obtained when [T287D]Aurora A(122-396) was crystallized in the presence of the ATP analog AMP-PNP. The second

crystalline form

was obtained when GSHM-[T287D]Aurora A(122-400) was crystallized in the presence of a synthetic inhibitor. The active site ATP binding pocket is defined by its amino acid residues and their atomic coordinates. This structure may be used to select or design chemical modulators of Aurora kinase, particularly Aurora inhibitors. These modulators may be used to treat diseases of cell proliferation, e.g. cancer.

IT 331788-25-1DP, complexes with Aurora A kinase catalytic domain


RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation); USES (Uses)

(crystal structure of human Aurora A kinase catalytic domain complexed with ATP analog and inhibitor and applications to structure-based drug design)

RN 331788-25-1 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-2-hydroxy-3-(1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 22 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:10468 ZCAPLUS

DOCUMENT NUMBER: 136:85826

TITLE: Preparation of substituted quinazoline derivatives and their use as inhibitors of AURORA-2 kinase

INVENTOR(S): Mortlock, Andrew; Jung, Frederic

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 249 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000649	A1	20020103	WO 2001-SE1450	20010621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2412592	A1	20020103	CA 2001-2412592	20010621
EP 1299381	A1	20030409	EP 2001-944061	20010621
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011754	A	20030429	BR 2001-11754	20010621
HU 200301236	A2	20031028	HU 2003-1236	20010621
JP 2004501914	T	20040122	JP 2002-505773	20010621
CN 1496364	A	20040512	CN 2001-814620	20010621
EE 200200715	A	20040816	EE 2002-715	20010621
NZ 522696	A	20040827	NZ 2001-522696	20010621
RU 2283311	C2	20060910	RU 2003-102389	20010621
IN 2002MN01598	A	20041211	IN 2002-MN1598	20021112
ZA 2002009412	A	20040219	ZA 2002-9412	20021119
BG 107376	A	20030930	BG 2002-107376	20021211
NO 2002006010	A	20021213	NO 2002-6010	20021213
US 2003187002	A1	20031002	US 2002-311916	20021216

10/ 539,220

US 6919338	B2	20050719		
US 2006046987	A1	20060302	US 2005-70057	20050302
PRIORITY APPLN. INFO.:			EP 2000-401842	A 20000628
			WO 2001-SE1450	W 20010621
			US 2002-311916	A1 20021216
OTHER SOURCE(S):	MARPAT 136:85826			
GI				



AB The title compds. [I; X = O, S, S:O, SO<sub>2</sub>, NR; R = H, C1-6alkyl; R<sub>1</sub> = OCH<sub>3</sub>, 3-(4-morpholinyl)propoxy, N-methylpiperidine-4-ylmethoxy, 3-(N-methylpiperazine-4-yl)propoxy, 3-(pyrrolidine-1-yl)propoxy, (CH<sub>3</sub>)<sub>2</sub>N(CH<sub>2</sub>)<sub>3</sub>O, etc.; Q = (un)substituted 5-membered heteroarom.], pharmaceutically acceptable salts, in vivo hydrolysable esters, and amides are prepared as AURORA-2 kinase inhibitors in warm blooded animals. The title compds. together with pharmaceutical compns. containing them are also described and claimed. Thus, the title compound II was prepared and tested in vitro for the ability to arrest MCF7 cells in specific phases of the cell cycle.

IT 385780-18-7P 385780-21-2P 385780-22-3P  
385780-23-4P 385780-24-5P 385780-25-6P  
385780-30-3P 385780-31-4P 385780-36-9P  
385780-37-0P 385780-40-5P 385780-41-6P  
385780-48-3P 385780-49-4P 385784-17-8P  
385784-60-1P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of quinazoline derivs. and use as inhibitors of AURORA-2 kinase)

RN 385780-18-7 ZCAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-21-2 ZCAPLUS


CN 4-Thiazolecarboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-22-3 ZCAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 385780-23-4 ZCAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-



10/ 539,220


quinazolinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-24-5 ZCAPLUS


CN 5-Thiazolecarboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-25-6 ZCAPLUS

CN 4-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/ 539,220


RN 385780-30-3 ZCAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 385780-31-4 ZCAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 385780-36-9 ZCAPLUS


CN 1H-Pyrrole-2-carboxylic acid, 4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



10/ 539,220


RN 385780-37-0 ZCAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 385780-40-5 ZCAPLUS

CN 1H-Imidazole-2-carboxylic acid, 4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-1-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 385780-41-6 ZCAPLUS


CN 1H-Imidazole-2-carboxylic acid, 4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



10/ 539,220

RN 385780-48-3 ZCAPLUS


CN 1H-1,2,4-Triazole-3-carboxylic acid, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-49-4 ZCAPLUS


CN 1H-1,2,4-Triazole-3-carboxylic acid, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-17-8 ZCAPLUS


CN Ethanone, 1-[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl-5-thiazolyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-60-1 ZCAPLUS

CN 5-Thiazolecarboxaldehyde, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 385779-70-4P 385779-71-5P 385779-72-6P  
 385779-73-7P 385779-74-8P 385779-75-9P  
 385779-76-0P 385779-77-1P 385779-78-2P  
 385779-79-3P 385779-80-6P 385779-81-7P  
 385779-82-8P 385779-83-9P 385779-84-0P  
 385779-85-1P 385779-86-2P 385779-87-3P  
 385779-88-4P 385779-89-5P 385779-90-8P  
 385779-91-9P 385779-93-1P 385779-94-2P  
 385779-95-3P 385779-96-4P 385779-97-5P  
 385779-98-6P 385780-19-8P 385780-20-1P  
 385780-26-7P 385780-32-5P 385780-33-6P  
 385780-34-7P 385780-35-8P 385780-38-1P  
 385780-39-2P 385780-42-7P 385780-43-8P  
 385780-44-9P 385780-45-0P 385780-46-1P  
 385780-47-2P 385780-50-7P 385780-51-8P  
 385780-52-9P 385780-53-0P 385780-54-1P  
 385780-55-2P 385780-56-3P 385780-57-4P  
 385780-58-5P 385780-59-6P 385780-60-9P  
 385780-61-0P 385780-62-1P 385780-63-2P  
 385780-64-3P 385780-65-4P 385780-66-5P  
 385780-67-6P 385780-68-7P 385780-69-8P  
 385780-70-1P 385780-71-2P 385780-72-3P  
 385780-73-4P 385780-74-5P 385780-75-6P  
 385780-76-7P 385780-77-8P 385780-78-9P  
 385780-79-0P 385780-80-3P 385780-81-4P

385780-82-5P 385780-83-6P 385780-84-7P  
 385780-85-8P 385780-86-9P 385780-87-0P  
 385780-88-1P 385780-89-2P 385780-90-5P  
 385780-91-6P 385780-92-7P 385780-93-8P  
 385780-94-9P 385780-95-0P 385780-96-1P  
 385780-97-2P 385780-98-3P 385780-99-4P  
 385781-00-0P 385781-01-1P 385781-02-2P  
 385781-04-4P 385781-05-5P 385781-07-7P  
 385781-08-8P 385781-09-9P 385781-10-2P  
 385781-11-3P 385781-12-4P 385781-13-5P  
 385781-14-6P 385781-15-7P 385781-16-8P  
 385781-17-9P 385781-18-0P 385781-19-1P  
 385781-20-4P 385781-21-5P 385781-22-6P  
 385781-23-7P 385781-24-8P 385781-25-9P  
 385781-26-0P 385781-27-1P 385781-28-2P  
 385781-29-3P 385781-30-6P 385781-31-7P  
 385781-32-8P 385781-33-9P 385781-34-0P  
 385781-35-1P 385781-36-2P 385781-37-3P  
 385781-38-4P 385781-39-5P 385781-40-8P  
 385781-41-9P 385781-42-0P 385781-43-1P  
 385781-44-2P 385781-45-3P 385781-46-4P  
 385781-47-5P 385781-48-6P 385781-49-7P  
 385781-50-0P 385781-51-1P 385781-52-2P  
 385781-53-3P 385781-54-4P 385781-55-5P  
 385781-56-6P 385781-57-7P 385781-58-8P  
 385781-59-9P 385781-60-2P 385781-61-3P  
 385781-62-4P 385781-63-5P 385781-64-6P  
 385781-65-7P 385781-66-8P 385781-68-0P  
 385781-70-4P 385781-71-5P 385781-72-6P  
 385781-73-7P 385781-74-8P 385781-75-9P  
 385781-76-0P 385781-77-1P 385781-78-2P  
 385781-79-3P 385781-80-6P 385781-81-7P  
 385781-82-8P 385781-83-9P 385781-84-0P  
 385781-85-1P 385781-86-2P 385781-87-3P  
 385781-88-4P 385781-90-8P 385781-91-9P  
 385781-92-0P 385781-93-1P 385781-94-2P  
 385781-95-3P 385781-96-4P 385781-97-5P  
 385781-98-6P 385781-99-7P 385782-00-3P  
 385782-01-4P 385782-02-5P 385782-03-6P  
 385782-04-7P 385782-05-8P 385782-06-9P  
 385782-07-0P 385782-08-1P 385782-09-2P  
 385782-10-5P 385782-11-6P 385782-12-7P  
 385782-13-8P 385782-14-9P 385782-15-0P  
 385782-16-1P 385782-17-2P 385782-18-3P  
 385782-19-4P 385782-20-7P 385782-21-8P  
 385782-22-9P 385782-23-0P 385782-24-1P  
 385782-25-2P 385782-26-3P 385782-27-4P  
 385782-28-5P 385782-29-6P 385782-30-9P  
 385782-31-0P 385782-32-1P 385782-33-2P  
 385782-34-3P 385782-35-4P 385782-36-5P  
 385782-37-6P 385782-38-7P 385782-39-8P  
 385782-40-1P 385782-41-2P 385782-42-3P  
 385782-43-4P 385782-44-5P 385782-45-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)


(preparation of quinazoline derivs. and use as inhibitors of AURORA-2  
 kinase)

RN 385779-70-4 ZCAPLUS

CN 4-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-

10/ 539,220


quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-71-5 ZCAPLUS

CN 4-Thiazoleacetamide, N-(4-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-72-6 ZCAPLUS

CN 4-Thiazoleacetamide, N-[4-(dimethylamino)phenyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-73-7 ZCAPLUS

CN 4-Thiazoleacetamide, N-(4-chlorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-74-8 ZCAPLUS

CN 4-Thiazoleacetamide, N-(6-chloro-3-pyridinyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-75-9 ZCAPLUS

CN Morpholine, 4-[[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-thiazolyl]acetyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-76-0 ZCAPLUS

CN Pyrrolidine, 1-[[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-thiazolyl]acetyl]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-77-1 ZCAPLUS

CN 4-Thiazoleacetamide, N-cyclohexyl-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-78-2 ZCAPLUS

CN 4-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-79-3 ZCAPLUS

CN 4-Thiazolecarboxamide, N-(4-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-80-6 ZCAPLUS

CN 4-Thiazolecarboxamide, N-(4-chlorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-81-7 ZCAPLUS

CN 4-Thiazolecarboxamide, N-cyclohexyl-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-guinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-82-8 ZCAPLUS

CN	4-Thiazolecarboxamide, N-(2-cyanoethyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-methyl-	(9CI)	(CA INDEX NAME)
----	--	-------	-----------------


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-83-9 ZCAPLUS

CN 4-Piperidinol, 1-[[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-84-0 ZCAPLUS

CN 4-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-4-pyridinyl- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-85-1 ZCAPLUS

CN 4-Thiazolecarboxamide, N-(2-chlorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-86-2 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-87-3 ZCAPLUS

CN 5-Thiazolecarboxamide, N-(4-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-88-4 ZCAPLUS

CN 5-Thiazolecarboxamide, N-(4-chlorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-89-5 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-2-propenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-90-8 ZCAPLUS

CN 5-Thiazolecarboxamide, N-(2-cyanoethyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-91-9 ZCAPLUS

CN 4-Piperidinol, 1-[[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-93-1 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-4-pyridinyl]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-94-2 ZCAPLUS

CN 4-Thiazoleacetamide, 2-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-methyl-N-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-95-3 ZCAPLUS

CN 4-Thiazoleacetamide, N-(4-fluorophenyl)-2-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-methyl- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-96-4 ZCAPLUS

CN 4-Thiazoleacetamide, N-(4-chlorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-methyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-97-5 ZCAPLUS

CN 4-Piperidinol, 1-[[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-methyl-4-thiazolyl]acetyl]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385779-98-6 ZCAPLUS

CN 4-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-19-8 ZCAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-20-1 ZCAPLUS


CN 4-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-26-7 ZCAPLUS

CN 4-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/ 539,220


RN 385780-32-5 ZCAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-1-methyl-N-phenyl- (9CI) (CA INDEX NAME)



RN 385780-33-6 ZCAPLUS


CN 1H-Pyrrole-2-carboxamide, N-(4-fluorophenyl)-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 385780-34-7 ZCAPLUS


CN 1H-Pyrrole-2-carboxamide, N-cyclohexyl-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-1-methyl- (9CI) (CA INDEX NAME)

10/ 539,220



RN 385780-35-8 ZCAPLUS


CN 1H-Pyrrole-2-carboxamide, N-[4-(dimethylamino)phenyl]-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 385780-38-1 ZCAPLUS


CN 1H-Pyrrole-2-carboxamide, 4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)

10/ 539,220



RN 385780-39-2 ZCAPLUS

CN 1H-Pyrrole-2-carboxamide, N-cyclohexyl-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 385780-42-7 ZCAPLUS

CN 1H-Imidazole-2-carboxamide, 4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-1-methyl-N-phenyl- (9CI) (CA INDEX NAME)




10/ 539,220



RN 385780-43-8 ZCAPLUS


CN 1H-Imidazole-2-carboxamide, N-(4-fluorophenyl)-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 385780-44-9 ZCAPLUS


CN 1H-Imidazole-2-carboxamide, N-[4-(dimethylamino)phenyl]-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-1-methyl- (9CI) (CA INDEX NAME)

10/ 539,220



RN 385780-45-0 ZCAPLUS


CN 1H-Imidazole-2-carboxamide, N-(4-chlorophenyl)-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 385780-46-1 ZCAPLUS

CN Pyrrolidine, 1-[[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-1-methyl-1H-imidazol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

10/ 539,220




RN 385780-47-2 ZCAPLUS  
 CN 1H-Imidazole-2-carboxamide, N-cyclohexyl-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 385780-50-7 ZCAPLUS  
 CN 1H-1,2,4-Triazole-3-carboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-51-8 ZCAPLUS

CN 1H-1,2,4-Triazole-3-carboxamide, N-(4-fluorophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-52-9 ZCAPLUS

CN 1H-1,2,4-Triazole-3-carboxamide, 5-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-2-propenyl]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-53-0 ZCAPLUS


CN 4-Quinazolinamine, N-1H-imidazol-2-yl-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-54-1 ZCAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-55-2 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-56-3 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-57-4 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-2-pyridinyl- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-58-5 ZCAPLUS

CN 5-Thiazolecarboxamide, N-[2-(hydroxymethyl)phenyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-59-6 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-60-9 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-61-0 ZCAPLUS

CN 5-Thiazolecarboxamide, N-(cyanomethyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-62-1 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(2-methyl-5-nitrophenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-63-2 ZCAPLUS

CN 5-Thiazolecarboxamide, N-cyclopropyl-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-64-3 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-65-4 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[2-(phenylamino)ethyl]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-66-5 ZCAPLUS

CN 5-Thiazolecarboxamide, N-(2-furanylmethyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-67-6 ZCAPLUS

CN 5-Thiazolecarboxamide, N-(3-chlorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-68-7 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-69-8 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-70-1 ZCAPLUS

CN 5-Thiazolecarboxamide, N-(2,2-dimethylpropyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-71-2 ZCAPLUS

CN 5-Thiazolecarboxamide, N-[(2,6-difluorophenyl)methyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-72-3 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(2-methyl-2-propenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-73-4 ZCAPLUS

CN 5-Thiazolecarboxamide, N-(4-fluoro-2-methylphenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-74-5 ZCAPLUS

CN 5-Thiazolecarboxamide, N-(2-fluoro-5-methylphenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-75-6 ZCAPLUS

CN 5-Thiazolecarboxamide, N-[(4-fluorophenyl)methyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-76-7 ZCAPLUS

CN 5-Thiazolecarboxamide, N-[(3,4-difluorophenyl)methyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-77-8 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-78-9 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-79-0 ZCAPLUS

CN 5-Thiazolecarboxamide, N-1H-indol-5-yl-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-80-3 ZCAPLUS

CN 5-Thiazolecarboxamide, N-(3-cyanophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-81-4 ZCAPLUS

CN 5-Thiazolecarboxamide, N-[(2,4-difluorophenyl)methyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-82-5 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-83-6 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-methyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-84-7 ZCAPLUS

CN 5-Thiazolecarboxamide, N-[(2-aminophenyl)methyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-85-8 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-86-9 ZCAPLUS

CN 5-Thiazolecarboxamide, N-[(1-hydroxycyclohexyl)methyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-87-0 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(pyrazinylmethyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-88-1 ZCAPLUS

CN 5-Thiazolecarboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-89-2 ZCAPLUS

CN 5-Thiazolecarboxamide, N-[(4-chlorophenyl)methyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-90-5 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-91-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-92-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(4-chlorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-93-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-94-9 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-95-0 ZCAPLUS


CN 5-Thiazoleacetamide, N-(2-chlorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-96-1 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[ [6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-97-2 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[ [6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-98-3 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385780-99-4 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-2-pyridinyl- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-00-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-[2-(hydroxymethyl)phenyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-01-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-[1-(hydroxymethyl)-2-methylpropyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-02-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-hydroxyethyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-04-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-methylphenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-05-5 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-07-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(cyanomethyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-08-8 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(2-methyl-5-nitrophenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-09-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(5-chloro-2-pyridinyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-10-2 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-11-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-12-4 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-13-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-14-6 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-15-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-hydroxy-2-phenylethyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-16-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-[3-(1-hydroxyethyl)phenyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-17-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,2-dimethylpropyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-18-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluoro-4-methoxyphenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-19-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(4-fluoro-2-methylphenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-20-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-21-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(4-chloro-2-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-22-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluoro-4-methylphenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-23-7 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-24-8 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-25-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-1H-indol-5-yl-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-26-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,4-difluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-27-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-cyanophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-28-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(5-fluoro-2-methylphenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-29-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(5-chloro-2-methylphenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-30-6 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-31-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-32-8 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-N-2-pyridinyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-33-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-34-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-chlorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-35-1 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-36-2 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-37-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(4-chlorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-38-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(4-fluorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-39-5 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-40-8 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 385781-41-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(5-chloro-2-pyridinyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)






10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-44-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluoro-4-methoxyphenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidiny)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-45-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(4-fluoro-2-methylphenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidiny)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-46-4 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-47-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-48-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(4-chloro-2-fluorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyloxy)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-49-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluoro-5-methylphenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyloxy)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-50-0 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-51-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,4-difluorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-52-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluoro-4-methylphenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-53-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-cyanophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-54-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(5-fluoro-2-methylphenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-55-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-56-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-57-7 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-58-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-59-9 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-N-2-pyridinyl]- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-60-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-61-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-chlorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-62-4 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-63-5 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-64-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(4-chlorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-65-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(4-fluorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-66-8 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-68-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(5-chloro-2-pyridinyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-70-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-71-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-72-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-cyanophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-73-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluoro-4-methylphenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-74-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluoro-4-methoxyphenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-75-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(4-fluoro-2-methylphenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220


NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-76-0 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-77-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,5-difluorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-78-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(4-chloro-2-fluorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-79-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-fluoro-5-methylphenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220


NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-80-6 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-81-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2,4-difluorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-82-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(5-fluoro-2-methylphenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-83-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-84-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-85-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-86-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-87-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-(dimethylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)





ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-88-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A






ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-90-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-91-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-92-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[[2-(dimethylamino)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-93-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)







ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-94-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)

PAGE 1-A







ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-95-3 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[(2-amino-2-methylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3,4-difluorophenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-96-4 ZCAPLUS

10/ 539,220

CN 5-Thiazoleacetamide, 2-[[7-[3-(cyclohexylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3,4-difluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-97-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[[2-(dimethylamino)ethyl]methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-98-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385781-99-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidiny]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-00-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-(3-hydroxy-1-pyrrolidiny]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-01-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-[3-[[2-(1-pyrrolidinyl)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-02-5 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[[7-[3-(4-acetyl-1-piperazinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3,4-difluorophenyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-03-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-[3-[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-04-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[2-(2-hydroxyethyl)-1-

10/ 539,220


piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-05-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE



10/ 539,220

RN 385782-06-9 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[7-[3-(cyclopentylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3,4-difluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-07-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-08-1 ZCAPLUS

CN L-Alanine, N-[3-[[4-[[5-[2-[(3,4-difluorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-09-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-(3-hydroxy-1-piperidinyloxy]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-10-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyloxy]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)





ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-11-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[3-[(2-hydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A






ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-12-7 ZCAPLUS

CN L-Alanine, N-[3-[[4-[[5-[2-[(3-chlorophenyl)amino]-2-oxoethyl]-2-thiazolyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-13-8 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-14-9 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[(2-amino-2-methylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-15-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-(cyclohexylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-16-1 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[[2-(dimethylamino)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-17-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[[2-(dimethylamino)ethyl]methanolamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-18-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 385782-19-4 ZCAPLUS



10/ 539,220

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-20-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-21-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-(3-hydroxy-1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-22-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[6-methoxy-7-[3-[[2-(1-pyrrolidinyl)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-23-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-24-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-25-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-(cyclopentylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-26-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-27-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-(3-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-28-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[(2S)-2-hydroxypropyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-29-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[(2R)-2-hydroxypropyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-30-9 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[6-methoxy-7-[3-(1-hydroxy-1-methylpropyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-31-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[2-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-32-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




Cl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-33-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-[4-[2-(dimethylamino)ethyl]-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-34-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-(dimethylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-35-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[3-  
[(cyclopropylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-36-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[6-methoxy-7-[3-(1-  
piperidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-37-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[[3-[4-[2-(dimethylamino)ethyl]-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-38-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-39-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-40-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-(3-hydroxy-1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-41-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[3-[[2-(1-pyrrolidinyl)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-42-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-43-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[2-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-44-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-45-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 385782-46-7P 385782-47-8P 385782-48-9P  
385782-49-0P 385782-50-3P 385782-51-4P  
385782-52-5P 385782-53-6P 385782-54-7P  
385782-55-8P 385782-56-9P 385782-57-0P  
385782-58-1P 385782-59-2P 385782-60-5P

385782-61-6P 385782-62-7P 385782-63-8P  
 385782-64-9P 385782-65-0P 385782-66-1P  
 385782-67-2P 385782-68-3P 385782-69-4P  
 385782-70-7P 385782-71-8P 385782-72-9P  
 385782-73-0P 385782-74-1P 385782-75-2P  
 385782-76-3P 385782-77-4P 385782-78-5P  
 385782-79-6P 385782-80-9P 385782-81-0P  
 385782-82-1P 385782-83-2P 385782-84-3P  
 385782-85-4P 385782-86-5P 385782-87-6P  
 385782-88-7P 385782-89-8P 385782-90-1P  
 385782-92-3P 385782-93-4P 385782-94-5P  
 385782-95-6P 385782-96-7P 385782-97-8P  
 385782-98-9P 385782-99-0P 385783-00-6P  
 385783-01-7P 385783-02-8P 385783-03-9P  
 385783-04-0P 385783-05-1P 385783-06-2P  
 385783-07-3P 385783-08-4P 385783-09-5P  
 385783-10-8P 385783-11-9P 385783-12-0P  
 385783-13-1P 385783-14-2P 385783-15-3P  
 385783-16-4P 385783-17-5P 385783-18-6P  
 385783-19-7P 385783-20-0P 385783-21-1P  
 385783-22-2P 385783-23-3P 385783-24-4P  
 385783-25-5P 385783-27-7P 385783-28-8P  
 385783-29-9P 385783-30-2P 385783-31-3P  
 385783-32-4P 385783-33-5P 385783-34-6P  
 385783-35-7P 385783-36-8P 385783-37-9P  
 385783-42-6P 385783-44-8P 385783-46-0P  
 385783-48-2P 385783-50-6P 385783-52-8P  
 385783-99-3P 385784-01-0P 385784-03-2P  
 385784-15-6P 385784-20-3P 385784-22-5P  
 385784-26-9P 385784-28-1P 385784-31-6P  
 385784-33-8P 385784-35-0P 385784-37-2P  
 385784-40-7P 385784-41-8P 385784-43-0P  
 385784-45-2P 385784-47-4P 385784-49-6P  
 385784-51-0P 385784-53-2P 385784-55-4P  
 385784-57-6P 385784-59-8P 385784-62-3P  
 385784-63-4P 385784-64-5P 385784-65-6P  
 385784-66-7P 385784-67-8P 385785-60-4P  
 385843-31-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of quinazoline derivs. and use as inhibitors of AURORA-2  
 kinase)

RN 385782-46-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-(3-hydroxy-1-  
 piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX  
 NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-47-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[[2-(dimethylamino)ethyl]methyamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-48-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[3-(1-(dimethylamino)ethyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-49-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-50-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-51-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-52-5 ZCAPLUS

10/ 539,220

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[[2-(dimethylamino)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-53-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[[ (2S)-2-hydroxypropyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-54-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[[ (2R)-2-hydroxypropyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-55-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[3-(1-hydroxypropyl)-4-quinazolinyl]amino]-9CI] (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-56-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[6-methoxy-7-[3-[4-(2-propenyl)-1-piperazinyl]propoxy]-4-quinazolinyl]amino]-9CI] (CA INDEX NAME)

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-57-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidiny]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-58-1 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-(cyclopentylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)

10/ 539,220





ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-59-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)

PAGE 1-A







ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-60-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-[[2-(dimethylamino)ethyl]methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-61-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[3-[4-(2-propenyl)-1-piperazinyl]propoxy]-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)

10/ 539,220


NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-62-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-63-8 ZCAPLUS



10/ 539,220


CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-(3-hydroxy-1-pyrrolidinyloxy)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-64-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[3-[[2-(1-pyrrolidinyloxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-65-0 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[7-[3-(4-acetyl-1-piperazinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-chloro-4-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-66-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-[2-(2-hydroxyethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-67-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 385782-68-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-(cyclopentylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



10/ 539,220


NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-71-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]-  
(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-72-9 ZCAPLUS


10/ 539,220

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[3-[(2-hydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-73-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[3-(1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-74-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[3-[4-(2-morpholinyl)ethyl]-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-75-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-76-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-77-4 ZCAPLUS



10/ 539,220


CN 5-Thiazoleacetamide, 2-[[7-[3-[(2-amino-2-methylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-78-5 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-[[2-(dimethylamino)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-79-6 ZCAPLUS

10/ 539,220


CN 5-Thiazoleacetamide, 2-[[7-[3-[[2-(dimethylamino)ethyl]methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-80-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[4-(2-propenyl)-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/ 539,220

RN 385782-81-0 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-82-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-(3-hydroxy-1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/ 539,220

RN 385782-83-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[[2-(1-pyrrolidinyl)ethyl]amino]propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-84-3 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-(4-acetyl-1-piperazinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-85-4 ZCAPLUS

10/ 539,220


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-86-5 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[3-(cyclopentylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-87-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[4-(2-hydroxyethyl)-1-

10/ 539,220


piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-88-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-(3-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-89-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[4-(hydroxymethyl)-1-

10/ 539,220


piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-90-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2-hydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/ 539,220

RN 385782-92-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-93-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-94-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-(1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-95-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[6-methoxy-7-[3-[4-(4-morpholinyl)ethyl]-1-piperazinyl]propoxy]-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-96-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-hydroxy-1,1-dimethylethyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-97-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-ethyl-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-98-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385782-99-0 ZCAPLUS

CN Glycine, N-(3-chloro-4-fluorophenyl)-N-[[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-thiazolyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-00-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(cyanomethyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)

10/ 539,220


NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-01-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(2-cyanoethyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-02-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-N-[2-(1,1-dimethylethoxy)ethyl]-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-03-9 ZCAPLUS


CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl-N-2-propenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-04-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-1,3-benzodioxol-5-yl-N-ethyl-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)





ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-05-1 ZCAPLUS

CN Benzoic acid, 4-[butyl[[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-thiazolyl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A






ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-06-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-ethyl-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-07-3 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl-N-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-08-4 ZCAPLUS

10/ 539,220


CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-09-5 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl-N-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 385783-10-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[6-methoxy-7-[3-(4-



10/ 539,220

morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-11-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-12-0 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-13-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-14-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-piperazinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-15-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[(2S)-3-(cyclopentylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-16-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-17-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-methyl-2-methylpropyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-18-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-19-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(4-hydroxy-1-piperidinyloxy)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-20-0 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[(2S)-3-(cyclopentylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3,4-difluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-21-1 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-22-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-23-3 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[(2S)-3-(cyclopentylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-24-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[(2S)-2-hydroxy-3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-25-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-methyl-2-methylpropyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 385783-27-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-28-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-29-9 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-30-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-31-3 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[(2S)-3-(4-acetyl-1-piperazinyl)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-32-4 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,5-difluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-piperazinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-33-5 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-34-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-35-7 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-2-[[7-[(2S)-2-hydroxy-3-(1-piperazinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-36-8 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[(2S)-3-(4-acetyl-1-piperazinyl)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-37-9 ZCAPLUS

CN 5-Thiazoleacetamide, 2-[[7-[(2S)-3-(cyclopentylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-42-6 ZCAPLUS

CN 5-Thiazoleacetamide,  $\alpha$ -hydroxy-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-44-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)- $\alpha$ -hydroxy-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-46-0 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)-α-hydroxy-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-48-2 ZCAPLUS


CN 5-Thiazoleacetamide, N-(3-fluorophenyl)-α-hydroxy-2-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-50-6 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3-chlorophenyl)- $\alpha$ -hydroxy-2-[[6-methoxy-7-[3-(1-piperidiny)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-52-8 ZCAPLUS

CN 5-Thiazoleacetamide, N-(3,4-difluorophenyl)- $\alpha$ -(hydroxyimino)-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385783-99-3 ZCAPLUS

CN 1H-Imidazole-4-carboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-01-0 ZCAPLUS

CN 1H-Imidazole-4-carboxamide, N-(4-fluorophenyl)-2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-03-2 ZCAPLUS

CN 1H-Imidazole-4-carboxamide, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-2-propenyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-15-6 ZCAPLUS

CN 4-Quinazolinamine, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-N-(4-phenyl-2-thiazolyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-20-3 ZCAPLUS


CN 5-Thiazolecarboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-22-5 ZCAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-26-9 ZCAPLUS

10/ 539,220


CN Acetamide, N-[4-[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-thiazolyl]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-28-1 ZCAPLUS

CN 4-Quinazolinamine, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-N-[5-phenyl-4-(trifluoromethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-31-6 ZCAPLUS

CN 4-Quinazolinamine, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-N-[4-(trifluoromethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-33-8 ZCAPLUS


CN 4-Quinazolinamine, N-[4-(1,1-dimethylethyl)-2-thiazolyl]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-35-0 ZCAPLUS

CN 4-Quinazolinamine, N-(4,5-dimethyl-2-thiazolyl)-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-37-2 ZCAPLUS

CN 4-Quinazolinamine, 6-methoxy-N-(4-methyl-2-thiazolyl)-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-40-7 ZCAPLUS


CN Ethanone, 1-[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl-5-thiazolyl]-, oxime (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-41-8 ZCAPLUS

CN Carbamic acid, [2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-thiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-43-0 ZCAPLUS

10/ 539,220


CN Ethanone, 1-[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl-5-thiazolyl]-, O-methyloxime (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-45-2 ZCAPLUS

CN Ethanone, 1-[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl-5-thiazolyl]-, O-phenyloxime (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-47-4 ZCAPLUS

CN 4-Quinazolinamine, 6-methoxy-N-[5-(4-methoxyphenyl)-2-thiazolyl]-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-49-6 ZCAPLUS


CN 4-Quinazolinamine, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-N-(5-phenyl-2-thiazolyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-51-0 ZCAPLUS

CN 4-Quinazolinamine, N-(5-ethyl-2-thiazolyl)-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-53-2 ZCAPLUS



10/ 539,220


CN 4-Quinazolinamine, 6-methoxy-N-[5-(1-methylethyl)-2-thiazolyl]-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-55-4 ZCAPLUS


CN 4-Quinazolinamine, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-N-[5-(phenylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-57-6 ZCAPLUS

CN 4-Quinazolinamine, 6-methoxy-N-(5-methyl-2-thiazolyl)-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-59-8 ZCAPLUS

CN 4-Quinazolinamine, N-(5-butyl-2-thiazolyl)-6-methoxy-7-[3-(4-

10/ 539,220


morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-62-3 ZCAPLUS


CN 5-Thiazolecarboxaldehyde, 2-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, oxime (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-63-4 ZCAPLUS

CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-64-5 ZCAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-6-methoxy-7-[3-


(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-65-6 ZCAPLUS


CN 4-Quinazolinamine, N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-66-7 ZCAPLUS

CN 4-Quinazolinamine, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-N-(5-phenyl-1,3,4-thiadiazol-2-yl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-67-8 ZCAPLUS

10/ 539,220


CN 1H-1,2,4-Triazole-3,5-diamine, N-[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]-N'-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385785-60-4 ZCAPLUS

CN 4-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 385843-31-2 ZCAPLUS

CN 5-Thiazoleacetamide, N-[2(or 3)-methoxyphenyl]-2-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



D1-O-Me



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 385785-53-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of quinazoline derivs. and use as inhibitors of AURORA-2 kinase)

RN 385785-53-5 ZCAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 385784-81-6P 385784-82-7P 385784-83-8P

385784-91-8P 385784-92-9P 385784-98-5P

385785-12-6P 385785-13-7P 385785-35-3P

385785-36-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of quinazoline derivs. and use as inhibitors of AURORA-2 kinase)

RN 385784-81-6 ZCAPLUS

CN 5-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-82-7 ZCAPLUS


CN 5-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-83-8 ZCAPLUS

CN 5-Thiazoleacetic acid, 2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-91-8 ZCAPLUS

CN 5-Thiazoleacetic acid, 2-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-92-9 ZCAPLUS


CN 5-Thiazoleacetic acid, 2-[[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385784-98-5 ZCAPLUS

CN 5-Thiazoleacetic acid, 2-[[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385785-12-6 ZCAPLUS

10/ 539,220


CN 5-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385785-13-7 ZCAPLUS


CN 5-Thiazoleacetic acid, 2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385785-35-3 ZCAPLUS

CN 4-Quinazolinamine, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-N-2-thiazolyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 385785-36-4 ZCAPLUS

CN 5-Thiazoleacetic acid,  $\alpha$ -hydroxy-2-[[6-methoxy-7-[3-(4-



morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:228867 ZCAPLUS

DOCUMENT NUMBER: 134:266318

TITLE: Preparation of quinazolines as aurora 2 kinase inhibitors

INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 208 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021597	A1	20010329	WO 2000-GB3593	20000919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2384296	A1	20010329	CA 2000-2384296	20000919
BR 2000014137	A	20020521	BR 2000-14137	20000919
TR 200200717	T2	20020621	TR 2002-717	20000919
EP 1218355	A1	20020703	EP 2000-960850	20000919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003509500	T	20030311	JP 2001-524976	20000919
EE 200200118	A	20030415	EE 2002-118	20000919
HU 200300205	A2	20030528	HU 2003-205	20000919
AU 762697	B2	20030703	AU 2000-73019	20000919
IN 2002MN00295	A	20050318	IN 2002-MN295	20020308
BG 106526	A	20021031	BG 2002-106526	20020318

ZA 2002002232	A	20030619	ZA 2002-2232	20020319
NO 2002001400	A	20020506	NO 2002-1400	20020320
PRIORITY APPLN. INFO.:			GB 1999-22171	A 19990921
			WO 2000-GB3593	W 20000919

OTHER SOURCE(S):           MARPAT 134:266318  
GI



AB Title compds. (I) [wherein X = O, S, SO, SO<sub>2</sub>, NH, or NR<sub>6</sub>; R<sub>6</sub> = H or alkyl; R<sub>5</sub> = (un)substituted 6-membered aromatic ring containing at least one N; R<sub>1</sub>-R<sub>4</sub>

= independently halo, CN, NO<sub>2</sub>, alkylsulfanyl, N(OH)R<sub>7</sub>, or R<sub>9</sub>X<sub>1</sub>; R<sub>7</sub> = H or alkyl; X<sub>1</sub> = a direct bond, O, CH<sub>2</sub>, OC(O), CO, S, SO, SO<sub>2</sub>, or (un)substituted NHCO, CONH, SO<sub>2</sub>NH, NHSO<sub>2</sub>, or NH; R<sub>9</sub> = H or (un)substituted hydrocarbonyl, heterocyclyl, or alkoxy; and at least one of R<sub>2</sub> or R<sub>3</sub> is other than H; or a salt, ester, amide, or prodrug thereof] were prepared as aurora 2 kinase inhibitors for the treatment of proliferative diseases, such as cancer. For example, 2-(N-benzoylamino)-5-aminopyrimidine and 4-chloro-6,7-dimethoxyquinazoline were coupled in i-PrOH to yield II (58%). The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concentration of 0.00785 μM. In addition, II gave 50% inhibition of MCF-7 cell proliferation at 1.7 μM and reduced BrdU incorporation into cellular DNA by 50% at 1.92-2.848 μM.

IT 331806-83-8P 331806-88-3P 331807-93-3P  
331807-99-9P 331808-15-2P 331808-36-7P  
331808-94-7P 331809-00-8P 331809-02-0P  
331809-03-1P 331809-58-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediates; preparation of substituted quinazoline derivs. as inhibitors of aurora 2 kinase for the treatment of breast and colorectal cancers)

RN 331806-83-8 ZCAPLUS

CN 4-Quinazolinamine, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-N-(5-nitro-2-pyrimidinyl)- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 331806-88-3 ZCAPLUS

CN 2,5-Pyrimidinediamine, N2-[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 331807-93-3 ZCAPLUS

CN Benzamide, N-[5-[[6-methoxy-7-[(2S)-2-methyloxiranyl]methoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331807-99-9 ZCAPLUS


10/ 539,220

CN 2,5-Pyrimidinediamine, N5-[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]-  
(9CI) (CA INDEX NAME)



RN 331808-15-2 ZCAPLUS


CN Benzamide, 3-chloro-N-[5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331808-36-7 ZCAPLUS


CN Benzamide, 4-fluoro-N-[5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331808-94-7 ZCAPLUS


CN 2-Pyrimidinecarboxylic acid, 5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 331809-00-8 ZCAPLUS

CN 4-Quinazolinamine, N-[2-(diethoxymethyl)-5-pyrimidinyl]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)


10/ 539,220



RN 331809-02-0 ZCAPLUS  
CN 2-Pyrimidinecarboxaldehyde, 5-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 331809-01-9  
CMF C21 H24 N6 O4




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 331809-03-1 ZCAPLUS  
CN 2,5-Pyrimidinediamine, N5-[(3-chloro-4-fluorophenyl)methyl]-N2-[6-methoxy-7-[(2R)-oxiranylmethoxy]-4-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 331809-58-6 ZCAPLUS

CN 2-Pyrimidinecarboxylic acid, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



IT 331809-42-8 331809-50-8


RL: RCT (Reactant); RACT (Reactant or reagent)

(starting materials; preparation of substituted quinazoline derivs. as inhibitors of aurora 2 kinase for the treatment of breast and colorectal cancers)

RN 331809-42-8 ZCAPLUS


CN Benzamide, N-[5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/ 539,220



● HCl

RN 331809-50-8 ZCAPLUS  
CN 2,5-Pyrimidinediamine, N5-[(3-chloro-4-fluorophenyl)methyl]-N2-[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 331787-38-3P 331787-99-6P 331788-25-1P  
331791-19-6P 331791-37-8P 331791-48-1P  
331792-44-0P 331794-66-2P 331799-96-3P  
331800-01-2P 331800-27-2P 331800-66-9P  
331801-90-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)




10/ 539,220

(target compds.; preparation of substituted quinazoline derivs. as inhibitors of aurora 2 kinase for the treatment of breast and colorectal cancers)

RN 331787-38-3 ZCAPLUS

CN Benzamide, N-[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-pyrimidinyl]-4-nitro- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 331787-99-6 ZCAPLUS

CN Benzamide, N-[5-[[6-methoxy-7-[(2S)-oxiranylmethoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331788-25-1 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-2-hydroxy-3-(1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



RN 331791-19-6 ZCAPLUS

CN Phosphoric acid, (1S)-1-[[[4-[[2-(benzoylamino)-5-pyrimidinyl]amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-(1-piperidinyl)ethyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331791-37-8 ZCAPLUS

CN Benzamide, 4-chloro-N-[5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


10/ 539,220



RN 331791-48-1 ZCAPLUS

CN Benzamide, 4-chloro-N-[5-[[6-methoxy-7-[(2R)-oxiranylmethoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331792-44-0 ZCAPLUS


CN 2,5-Pyrimidinediamine, N5-[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331794-66-2 ZCAPLUS

CN 2-Pyrimidinecarboxylic acid, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 331799-96-3 ZCAPLUS

CN 5-Pyrimidinecarboxamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 331800-01-2 ZCAPLUS

CN 5-Pyrimidinecarboxamide, N-(2,4-difluorophenyl)-2-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 331800-27-2 ZCAPLUS

CN 5-Pyrimidinecarboxamide, N-(3-chloro-4-fluorophenyl)-2-[[6-methoxy-7-[(2S)-oxiranylmethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 331800-66-9 ZCAPLUS

CN Carbamic acid, [[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 331801-90-2 ZCAPLUS

CN Benzamide, 3-chloro-4-fluoro-N-[5-[[7-[(1-methyl-4-piperidiny]methoxy]-6-nitro-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



IT	331787-26-9P	331787-33-8P	331787-43-0P
	331787-58-7P	331787-62-3P	331787-81-6P
	331787-93-0P	331788-05-7P	331788-11-5P
	331788-16-0P	331788-32-0P	331788-38-6P
	331788-45-5P	331788-52-4P	331788-59-1P
	331788-66-0P	331788-73-9P	331788-78-4P
	331788-83-1P	331788-88-6P	331788-94-4P
	331788-99-9P	331789-05-0P	331789-13-0P
	331789-19-6P	331789-26-5P	331789-32-3P
	331789-37-8P	331789-42-5P	331789-48-1P
	331789-52-7P	331789-57-2P	331789-62-9P
	331789-67-4P	331789-72-1P	331789-78-7P
	331789-84-5P	331789-89-0P	331789-95-8P
	331790-00-2P	331790-06-8P	331790-12-6P
	331790-17-1P	331790-34-2P	331790-38-6P
	331790-46-6P	331790-52-4P	331790-58-0P
	331790-64-8P	331790-69-3P	331791-03-8P
	331791-09-4P	331791-16-3P	331791-27-6P
	331791-32-3P	331791-53-8P	331791-59-4P
	331791-65-2P	331791-72-1P	331791-84-5P
	331791-89-0P	331791-94-7P	331792-01-9P
	331792-07-5P	331792-13-3P	331792-18-8P
	331792-23-5P	331792-29-1P	331792-34-8P
	331792-39-3P	331792-49-5P	331792-54-2P
	331792-59-7P	331792-64-4P	331792-69-9P
	331792-74-6P	331792-80-4P	331793-17-0P
	331793-25-0P	331793-32-9P	331793-38-5P
	331793-43-2P	331793-48-7P	331793-54-5P
	331793-59-0P	331793-65-8P	331793-71-6P
	331793-77-2P	331793-83-0P	331793-88-5P
	331793-92-1P	331793-96-5P	331794-00-4P
	331794-05-9P	331794-09-3P	331794-13-9P
	331794-17-3P	331794-21-9P	331794-25-3P
	331794-30-0P	331794-35-5P	331794-40-2P
	331794-44-6P	331794-50-4P	331794-55-9P
	331794-60-6P	331794-71-9P	331794-76-4P

331794-83-3P 331794-89-9P 331794-94-6P  
 331795-00-7P 331795-05-2P 331795-07-4P  
 331795-12-1P 331795-17-6P 331795-20-1P  
 331795-23-4P 331795-28-9P 331795-33-6P  
 331795-38-1P 331795-42-7P 331795-47-2P  
 331795-52-9P 331795-57-4P 331795-62-1P  
 331795-67-6P 331795-73-4P 331795-78-9P  
 331795-83-6P 331795-88-1P 331795-92-7P  
 331795-96-1P 331796-01-1P 331796-07-7P  
 331796-11-3P 331796-15-7P 331796-20-4P  
 331796-25-9P 331796-30-6P 331796-35-1P  
 331796-40-8P 331796-45-3P 331796-50-0P  
 331796-54-4P 331796-58-8P 331796-63-5P  
 331796-68-0P 331796-73-7P 331796-77-1P  
 331796-81-7P 331796-86-2P 331796-91-9P  
 331796-97-5P 331797-03-6P 331797-09-2P  
 331797-15-0P 331797-21-8P 331797-27-4P  
 331797-33-2P 331797-40-1P 331797-46-7P  
 331797-52-5P 331797-59-2P 331797-65-0P  
 331797-71-8P 331797-77-4P 331797-82-1P  
 331797-88-7P 331797-93-4P 331797-99-0P  
 331798-06-2P 331798-11-9P 331798-16-4P  
 331798-21-1P 331798-27-7P 331798-33-5P  
 331798-39-1P 331798-44-8P 331798-49-3P  
 331798-55-1P 331798-58-4P 331798-65-3P  
 331798-70-0P 331798-76-6P 331798-81-3P  
 331798-87-9P 331798-93-7P 331799-08-7P  
 331799-18-9P 331799-25-8P 331799-32-7P  
 331799-39-4P 331799-49-6P 331799-55-4P  
 331799-61-2P 331799-67-8P 331799-73-6P  
 331799-79-2P 331799-85-0P 331799-91-8P  
 331800-32-9P 331800-37-4P 331800-42-1P  
 331800-47-6P 331800-52-3P 331800-55-6P  
 331800-61-4P 331800-71-6P 331800-76-1P  
 331800-78-3P 331800-82-9P 331800-87-4P  
 331800-93-2P 331800-99-8P 331801-05-9P  
 331801-11-7P 331801-16-2P 331801-22-0P  
 331801-27-5P 331801-30-0P 331801-36-6P  
 331801-42-4P 331801-47-9P 331801-52-6P  
 331801-57-1P 331801-65-1P 331801-70-8P  
 331801-85-5P 331802-06-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (target compds.; preparation of substituted quinazoline derivs. as inhibitors of aurora 2 kinase for the treatment of breast and colorectal cancers)

RN 331787-26-9 ZCAPLUS

CN Benzamide, N-[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 331787-33-8 ZCAPLUS

CN Benzamide, 4-(dimethylamino)-N-[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 331787-43-0 ZCAPLUS

CN Benzenesulfonamide, N-[2-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-5-pyrimidinyl]-4-nitro- (9CI) (CA INDEX NAME)


10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 331787-58-7 ZCAPLUS


CN Benzamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331787-62-3 ZCAPLUS


CN Benzamide, N-[5-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331787-81-6 ZCAPLUS


CN Benzamide, N-[5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331787-93-0 ZCAPLUS

CN Benzamide, N-[5-[[6-methoxy-7-[(2R)-oxiranylmethoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/ 539,220

RN 331788-05-7 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-2-hydroxy-3-(3-hydroxy-1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331788-11-5 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-3-(1-azetidiny)l)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331788-16-0 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



RN 331788-32-0 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-3-(cyclobutylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331788-38-6 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-3-(cyclopentylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/ 539,220

RN 331788-45-5 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-2-hydroxy-3-[[5-methyl-2-furanyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331788-52-4 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-2-hydroxy-3-[(2-thienylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331788-59-1 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-2-hydroxy-3-[(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



RN 331788-66-0 ZCAPLUS


CN Benzamide, N-[5-[[7-[(2S)-3-[[2-(ethylthio)ethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331788-73-9 ZCAPLUS


CN Benzamide, N-[5-[[7-[2-[[2-(dimethylamino)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



10/ 539,220


RN 331788-78-4 ZCAPLUS

CN Benzamide, N-[5-[[7-[2-[(4-hydroxybutyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331788-83-1 ZCAPLUS

CN Benzamide, N-[5-[[7-[2-[(2-hydroxy-1,1-dimethylethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 331788-88-6 ZCAPLUS

CN Benzamide, N-[5-[[7-[2-[(cyclopropylmethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




10/ 539,220



RN 331788-94-4 ZCAPLUS


CN Benzamide, N-[5-[[6-methoxy-7-[2-[(tetrahydro-2-furanyl)methyl]amino]ethoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



RN 331788-99-9 ZCAPLUS


CN Benzamide, N-[5-[[6-methoxy-7-[2-(1-piperidinyl)ethoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331789-05-0 ZCAPLUS


CN Benzamide, N-[5-[[7-[3-[(4-hydroxybutyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331789-13-0 ZCAPLUS


CN Benzamide, N-[5-[[7-[3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331789-19-6 ZCAPLUS


CN Benzamide, N-[5-[[7-[3-[(cyclopropylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331789-26-5 ZCAPLUS


CN Benzamide, N-[5-[[6-methoxy-7-[3-[[[tetrahydro-2-furanyl)methyl]amino]propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331789-32-3 ZCAPLUS


CN Benzamide, N-[5-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331789-37-8 ZCAPLUS


CN Benzamide, N-[5-[[7-[3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331789-42-5 ZCAPLUS

CN Benzamide, N-[5-[[6-methoxy-7-[[4-(phenylmethyl)-2-morpholinyl]methoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 331789-48-1 ZCAPLUS

CN 4-Piperidinecarboxamide, 1-[(2S)-3-[[4-[[2-(benzoylamino)-5-pyrimidinyl]amino]-6-methoxy-7-quinazolinyl]oxy]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



RN 331789-52-7 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-3-[[1,1-bis(hydroxymethyl)propyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331789-57-2 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-2-hydroxy-3-[(3-hydroxy-1,1-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



RN 331789-62-9 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-2-hydroxy-3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331789-67-4 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-3-(cyclohexylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



RN 331789-72-1 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-2-hydroxy-3-[(2-hydroxy-1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331789-78-7 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-2-hydroxy-3-[(3-hydroxy-2,2-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/ 539,220



RN 331789-84-5 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-3-[[1-(ethyl-2-pyrrolidinyl)methyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331789-89-0 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-3-[(cyclohexylmethyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/ 539,220



RN 331789-95-8 ZCAPLUS


CN Benzamide, N-[5-[[7-[2-(4,5-dihydro-2-methyl-1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331790-00-2 ZCAPLUS


CN Benzamide, N-[5-[[7-[2-(2-ethyl-4,5-dihydro-1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331790-06-8 ZCAPLUS


CN Benzamide, N-[5-[[7-[2-(5,6-dihydro-1(4H)-pyrimidinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331790-12-6 ZCAPLUS


CN Benzamide, N-[5-[[7-[2-(4,5-dihydro-1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331790-17-1 ZCAPLUS


CN Carbamic acid, [2-[[4-[[2-(benzoylamino)-5-pyrimidinyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 331790-34-2 ZCAPLUS

CN Benzamide, N-[5-[[6-methoxy-7-[[4-(phenylmethyl)-3-morpholinyl]methoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


10/ 539,220



RN 331790-38-6 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-2-hydroxy-3-(4-morpholinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331790-46-6 ZCAPLUS

CN Benzamide, N-[5-[[7-[3-(4,5-dihydro-1H-imidazol-1-yl)propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


10/ 539,220



RN 331790-52-4 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-2-hydroxy-2-methyl-3-(1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331790-58-0 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-3-(cyclopentylamino)-2-hydroxy-2-methylpropoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/ 539,220

RN 331790-64-8 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-3-(cyclohexylamino)-2-hydroxy-2-methylpropoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331790-69-3 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-2-hydroxy-2-methyl-3-(4-morpholinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331791-03-8 ZCAPLUS

CN Benzamide, N-[5-[[7-[(2S)-2-hydroxy-2-methyl-3-(1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



RN 331791-09-4 ZCAPLUS


CN Benzamide, N-[5-[[7-[(2S)-3-[[2-(ethylthio)ethyl]amino]-2-hydroxy-2-methylpropoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331791-16-3 ZCAPLUS

CN Benzamide, N-[5-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)






10/ 539,220

RN 331791-27-6 ZCAPLUS

CN Benzamide, N-[5-[[6-methoxy-7-[(2S)-2-(phosphonoxy)-3-(1-piperidinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]-, dihydrobromide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HBr

RN 331791-32-3 ZCAPLUS

CN Benzamide, 4-chloro-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 331791-53-8 ZCAPLUS

CN Benzamide, 4-chloro-N-[5-[[7-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



RN 331791-59-4 ZCAPLUS

CN Benzamide, 4-chloro-N-[5-[[7-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331791-65-2 ZCAPLUS

CN Benzamide, 4-chloro-N-[5-[[7-[(2R)-3-(cyclopentylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



RN 331791-72-1 ZCAPLUS

CN Benzamide, 4-chloro-N-[5-[[7-[(2R)-3-(cyclohexylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331791-84-5 ZCAPLUS


CN Benzamide, 4-chloro-N-[5-[[6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331791-89-0 ZCAPLUS


CN Benzamide, 4-chloro-N-[5-[[6-methoxy-7-[2-(1-piperidinyloxy)]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331791-94-7 ZCAPLUS


CN Benzamide, 4-chloro-N-[5-[[7-[2-(cyclopentylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331792-01-9 ZCAPLUS


CN Benzamide, 4-chloro-N-[5-[[7-[2-(cyclohexylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331792-07-5 ZCAPLUS


CN Benzamide, 4-chloro-N-[5-[[7-[2-[(cyclopropylmethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331792-13-3 ZCAPLUS

CN Benzamide, 4-chloro-N-[5-[[6-methoxy-7-[2-[(tetrahydro-2-furanyl)methyl]amino]ethoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




RN 331792-18-8 ZCAPLUS

CN Benzamide, 3-chloro-N-[5-[[6-methoxy-7-[(2S)-oxiranylmethoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 539,220



RN 331792-23-5 ZCAPLUS

CN Benzamide, 4-fluoro-N-[5-[[6-methoxy-7-[(2S)-oxiranylmethoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331792-29-1 ZCAPLUS


CN Benzamide, 3-chloro-N-[5-[[7-[(2S)-2-hydroxy-3-(1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 539,220




RN 331792-34-8 ZCAPLUS  
 CN Benzamide, 3-chloro-4-fluoro-N-[5-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331792-39-3 ZCAPLUS  
 CN Benzamide, 3-chloro-4-fluoro-N-[5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




10/ 539,220



RN 331792-49-5 ZCAPLUS


CN 4-Pyridinecarboxamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331792-54-2 ZCAPLUS


CN Benzamide, 2,4-difluoro-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331792-59-7 ZCAPLUS


CN Benzamide, 3-bromo-4-fluoro-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331792-64-4 ZCAPLUS


CN Benzamide, 3-bromo-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331792-69-9 ZCAPLUS


CN Benzamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 331792-74-6 ZCAPLUS


CN Benzamide, 3-chloro-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331792-80-4 ZCAPLUS


CN Benzamide, 3,4-dichloro-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331793-17-0 ZCAPLUS


CN Benzamide, 3-chloro-4-fluoro-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331793-25-0 ZCAPLUS


CN Benzamide, 3,5-dichloro-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331793-32-9 ZCAPLUS


CN Benzamide, 3-cyano-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331793-38-5 ZCAPLUS


CN Benzamide, 3-fluoro-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331793-43-2 ZCAPLUS


CN Benzamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]-3,5-dimethyl-4-nitro- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331793-48-7 ZCAPLUS


CN Benzamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 331793-54-5 ZCAPLUS


CN Benzamide, 4-chloro-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]-3-nitro- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331793-59-0 ZCAPLUS

CN 1,3-Benzodioxole-5-carboxamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 331793-65-8 ZCAPLUS

CN Benzamide, 3-methoxy-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




10/ 539,220



RN 331793-71-6 ZCAPLUS


CN Benzamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]-3-phenoxy- (9CI) (CA INDEX NAME)



RN 331793-77-2 ZCAPLUS


CN Benzamide, 4-bromo-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331793-83-0 ZCAPLUS


CN Benzamide, 4-ethyl-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331793-88-5 ZCAPLUS


CN Benzamide, 4-fluoro-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331793-92-1 ZCAPLUS


CN Benzamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]-4-nitro- (9CI) (CA INDEX NAME)



RN 331793-96-5 ZCAPLUS


CN Benzamide, 4-methoxy-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331794-00-4 ZCAPLUS


CN Benzamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]-4-(methylthio)- (9CI) (CA INDEX NAME)



RN 331794-05-9 ZCAPLUS


CN 2-Furancarboxamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331794-09-3 ZCAPLUS


CN 1H-Pyrrole-2-carboxamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 331794-13-9 ZCAPLUS


CN 2-Thiophenecarboxamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331794-17-3 ZCAPLUS


CN Benzenepropanamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331794-21-9 ZCAPLUS


CN Benzenepropanamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331794-25-3 ZCAPLUS


CN Cyclohexanebutanamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331794-30-0 ZCAPLUS


CN Pentanamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331794-35-5 ZCAPLUS

CN Cyclopentanecarboxamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 331794-40-2 ZCAPLUS

CN Cyclohexanecarboxamide, N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




10/ 539,220



RN 331794-44-6 ZCAPLUS


CN Benzamide, 2-chloro-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331794-50-4 ZCAPLUS

CN Benzamide, 4-[(dipropylamino)sulfonyl]-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331794-55-9 ZCAPLUS

CN Benzamide, 4-fluoro-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 331794-60-6 ZCAPLUS


CN Benzamide, 2-chloro-4,5-difluoro-N-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331794-71-9 ZCAPLUS


CN 2-Pyrimidinecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331794-76-4 ZCAPLUS

CN 2-Pyrimidinecarboxamide, N-cyclohexyl-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 331794-83-3 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-(4-chlorophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331794-82-2

CMF C27 H28 Cl N7 O4

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331794-89-9 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(4-methylphenyl)-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331794-88-8

CMF C28 H31 N7 O4

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS




● H<sup>+</sup>

RN 331794-94-6 ZCAPLUS


CN 2-Pyrimidinecarboxamide, 5-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-2-quinolinyl- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331795-00-7 ZCAPLUS


CN 2-Pyrimidinecarboxamide, N-(2,3-difluorophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 331795-05-2 ZCAPLUS


CN 2-Pyrimidinecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(1-methyl-1H-pyrazol-5-yl)- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331795-07-4 ZCAPLUS

CN 2-Pyrimidinecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methyl-4-nitro-5-isoxazolyl)- (9CI) (CA INDEX NAME)




RN 331795-12-1 ZCAPLUS

CN 2-Pyrimidinecarboxamide, N-(2-chlorophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 539,220



RN 331795-17-6 ZCAPLUS


CN 2-Pyrimidinecarboxamide, N-(2-chloro-5-nitrophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 331795-20-1 ZCAPLUS


CN 2-Pyrimidinecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(2-nitrophenyl)- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331795-23-4 ZCAPLUS


CN 2-Pyrimidinecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 331795-28-9 ZCAPLUS


CN 2-Pyrimidinecarboxamide, N-(3-cyanophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331795-33-6 ZCAPLUS


CN 2-Pyrimidinecarboxamide, N-(3-fluorophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 331795-38-1 ZCAPLUS


CN 2-Pyrimidinecarboxamide, N-(3,4-dichlorophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331795-42-7 ZCAPLUS


CN 2-Pyrimidinecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 331795-47-2 ZCAPLUS


CN 2-Pyrimidinecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331795-52-9 ZCAPLUS


CN 2-Pyrimidinecarboxamide, 5-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 331795-57-4 ZCAPLUS


CN 2-Pyrimidinecarboxamide, 5-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331795-62-1 ZCAPLUS


CN 2-Furancarboxylic acid, 5-[[[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]carbonyl]amino]-, methyl ester (9CI)  
(CA INDEX NAME)



RN 331795-67-6 ZCAPLUS


CN 2-Pyrimidinecarboxamide, 5-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331795-73-4 ZCAPLUS


CN 2-Pyrimidinecarboxamide, N-heptyl-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 331795-78-9 ZCAPLUS

CN 2-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

F


RN 331795-83-6 ZCAPLUS  
 CN 2-Thiophenecarboxylic acid, 3-[[[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]carbonyl]amino]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)






RN 331795-88-1 ZCAPLUS  
 CN 2-Pyrimidinecarboxamide, N-[2-(1-cyclohexen-1-yl)ethyl]-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A





RN 331795-92-7 ZCAPLUS


CN 2-Pyrimidinecarboxamide, N-(3,5-dimethylpyrazinyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 331795-96-1 ZCAPLUS


CN 2-Pyrimidinecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331796-01-1 ZCAPLUS


CN 2-Pyrimidinecarboxamide, N-(2-fluoro-5-nitrophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 331796-07-7 ZCAPLUS


CN 2-Pyrimidinecarboxamide, N-cyclopropyl-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331796-11-3 ZCAPLUS


CN 2-Pyrimidinecarboxamide, N-(cyclopropylmethyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 331796-15-7 ZCAPLUS


CN 2-Pyrimidinecarboxamide, N-cyclobutyl-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331796-20-4 ZCAPLUS


CN 2-Pyrimidinecarboxamide, N-cyclopentyl-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 331796-25-9 ZCAPLUS


CN 2-Pyrimidinecarboxamide, N-(2,3-dihydro-1H-inden-2-yl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331796-30-6 ZCAPLUS


CN 2-Pyrimidinecarboxamide, N-(cyclohexylmethyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 331796-35-1 ZCAPLUS

CN 2-Pyrimidinecarboxamide, N-(6-chloro-3-pyridinyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 539,220



RN 331796-40-8 ZCAPLUS

CN 2-Pyrimidinecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A





RN 331796-45-3 ZCAPLUS

CN 2-Pyrimidinecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 331796-50-0 ZCAPLUS


CN 2-Pyrimidinecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[2-(5-methyl-1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A



RN 331796-54-4 ZCAPLUS


CN 2-Pyrimidinecarboxamide, 5-[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-2-pyridinyl- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331796-58-8 ZCAPLUS


CN 2-Pyrimidinecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 331796-63-5 ZCAPLUS


CN 2-Pyrimidinecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-4-pyridinyl- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331796-68-0 ZCAPLUS


CN 2-Pyrimidinecarboxamide, N-1-isoquinolinyl-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 331796-73-7 ZCAPLUS


CN 2-Pyrimidinecarboxamide, N-(2,4-dinitrophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331796-77-1 ZCAPLUS


CN 2-Pyrimidinecarboxamide, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[4-nitro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 331796-81-7 ZCAPLUS


CN 2-Pyrimidinecarboxamide, N-(2-cyanophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331796-86-2 ZCAPLUS


CN 2-Pyrimidinecarboxamide, N-(2-fluorophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 331796-91-9 ZCAPLUS

CN 2-Pyrimidinecarboxamide, N-(2,4-difluorophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220




RN 331796-97-5 ZCAPLUS  
CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-[(3-chloro-4-fluorophenyl)methyl]-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331796-96-4  
CMF C28 H29 Cl F N7 O4

PAGE 1-A






CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



RN 331797-03-6 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(tetrahydro-2,2-dimethyl-2H-pyran-4-yl)-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331797-02-5

CMF C28 H37 N7 O5

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331797-09-2 ZCAPLUS

CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[3-(methylthio)propyl]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 331797-08-1

CMF C25 H33 N7 O4 S



10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



●  $\text{H}^+$

RN 331797-15-0 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[3-(3-methyl-1H-pyrazol-4-yl)propyl]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331797-14-9

CMF C28 H35 N9 O4

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331797-21-8 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(5-methyl-1,3,4-thiadiazol-2-yl)-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331797-20-7

CMF C24 H27 N9 O4 S

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331797-27-4 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-(4-fluorophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331797-26-3

CMF C27 H28 F N7 O4

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331797-33-2 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[4-(methylthio)phenyl]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331797-32-1

CMF C28 H31 N7 O4 S

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331797-40-1 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(phenylmethyl)-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331797-39-8

CMF C28 H31 N7 O4

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331797-46-7 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[(2-methylphenyl)methyl]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331797-45-6

CMF C29 H33 N7 O4

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331797-52-5 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-[(3,4-dichlorophenyl)methyl]-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331797-51-4

CMF C28 H29 Cl2 N7 O4

PAGE 1-A



PAGE 2-A




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



RN 331797-59-2 ZCAPLUS

CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-(3-ethoxypropyl)-5-[[6-




10/ 539,220

methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331797-58-1

CMF C26 H35 N7 O5




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331797-65-0 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-[3-(1H-imidazol-1-yl)propyl]-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331797-64-9

CMF C27 H33 N9 O4

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331797-71-8 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-[(2,4-difluorophenyl)methyl]-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331797-70-7

CMF C28 H29 F2 N7 O4

PAGE 1-A



PAGE 2-A




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



RN 331797-77-4 ZCAPLUS

CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-


10/ 539,220

morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[3-(1-pyrrolidinyl)propyl]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331797-76-3

CMF C28 H38 N8 O4




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



RN 331797-82-1 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-thienylmethyl)-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

10/ 539,220

CM 1

CRN 331797-81-0

CMF C26 H29 N7 O4 S




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331797-88-7 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(tetrahydro-1,1-dioxido-3-thienyl)-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331797-87-6

10/ 539,220

CMF C25 H31 N7 O6 S




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS




● H<sup>+</sup>

RN 331797-93-4 ZCAPLUS

CN 2-Pyrimidinecarboxamide, N-(1,4-dioxan-2-ylmethyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331797-99-0 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-[[4-(dimethylamino)phenyl]methyl]-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331797-98-9

CMF C30 H36 N8 O4

PAGE 1-A






CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS




RN 331798-06-2 ZCAPLUS

CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(3-phenylpropyl)-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331798-05-1

CMF C30 H35 N7 O4






10/ 539,220

CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331798-11-9 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[2-(4-pyridinyl)ethyl]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 331798-10-8

CMF C28 H32 N8 O4

PAGE 1-A






CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



RN 331798-16-4 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-[(3-chlorophenyl)methyl]-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331798-15-3

CMF C28 H30 Cl N7 O4

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331798-21-1 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-(3-bromo-4-methylphenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331798-20-0

CMF C28 H30 Br N7 O4

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331798-27-7 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-(5-ethyl-1,3,4-thiadiazol-2-yl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331798-26-6

CMF C25 H29 N9 O4 S

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331798-33-5 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-pyrazinyl-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331798-32-4

CMF C25 H27 N9 O4

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



●  $H^+$

RN 331798-39-1 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-(3-chlorophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331798-38-0

CMF C27 H28 Cl N7 O4

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331798-44-8 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-(3,5-dichlorophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331798-43-7

CMF C27 H27 Cl2 N7 O4

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331798-49-3 ZCAPLUS

CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-[(2-chlorophenyl)methyl]-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 331798-48-2

CMF C28 H30 Cl N7 O4



10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331798-55-1 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[(3-methylphenyl)methyl]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331798-54-0

CMF C29 H33 N7 O4

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331798-58-4 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(2-phenylethyl)-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331798-57-3

CMF C29 H33 N7 O4

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331798-65-3 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-[(2,5-difluorophenyl)methyl]-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331798-64-2

CMF C28 H29 F2 N7 O4

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331798-70-0 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-[(3,4-difluorophenyl)methyl]-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331798-69-7

CMF C28 H29 F2 N7 O4

PAGE 1-A



PAGE 2-A




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



RN 331798-76-6 ZCAPLUS

CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-


10/ 539,220

morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[(3-methoxyphenyl)methyl]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331798-75-5

CMF C29 H33 N7 O5




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



RN 331798-81-3 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-1H-benzotriazol-5-yl-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

10/ 539,220

CM 1

CRN 331798-80-2

CMF C27 H28 N10 O4




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331798-87-9 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-(2-furanylmethyl)-5-  
[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-  
pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331798-86-8

CMF C26 H29 N7 O5

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331798-93-7 ZCAPLUS

CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-(3-chloro-4-fluorophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 331798-92-6

CMF C27 H27 Cl F N7 O4



10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331799-08-7 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-(3,5-dimethylphenyl)-5-  
[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-  
pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331799-07-6

CMF C29 H33 N7 O4

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331799-18-9 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(4-methoxyphenyl)-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331799-17-8

CMF C28 H31 N7 O5

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331799-25-8 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-[(2-fluorophenyl)methyl]-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331799-24-7

CMF C28 H30 F N7 O4

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331799-32-7 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[(2-methoxyphenyl)methyl]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331799-31-6

CMF C29 H33 N7 O5

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331799-39-4 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-[(3-fluorophenyl)methyl]-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331799-38-3

CMF C28 H30 F N7 O4

10/ 539,220




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331799-49-6 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-[(4-chlorophenyl)methyl]-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331799-48-5

CMF C28 H30 Cl N7 O4

PAGE 1-A



PAGE 2-A


C1

CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS

● H<sup>+</sup>

RN 331799-55-4 ZCAPLUS

CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-

10/ 539,220


morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[(4-methylphenyl)methyl]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331799-54-3

CMF C29 H33 N7 O4

PAGE 1-A



PAGE 2-A

Me

CM 2


CRN 16940-81-1

CMF F6 P . H

CCI CCS



10/ 539,220




RN 331799-61-2 ZCAPLUS

CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-(4-bromophenyl)-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331799-60-1

CMF C27 H28 Br N7 O4




CM 2

CRN 16940-81-1


CMF F6 P . H

CCI CCS

10/ 539,220




RN 331799-67-8 ZCAPLUS  
CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-(1-methylethyl)-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)  
CM 1  
CRN 331799-66-7  
CMF C24 H31 N7 O4



CM 2  
CRN 16940-81-1  
CMF F6 P . H  
CCI CCS

10/ 539,220



RN 331799-73-6 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[(1S)-1-methylpropyl]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331799-72-5

CMF C25 H33 N7 O4

Absolute stereochemistry.




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS

10/ 539,220



RN 331799-79-2 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-N-[(1R)-1-methylpropyl]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331799-78-1

CMF C25 H33 N7 O4

Absolute stereochemistry.




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS


10/ 539,220



RN 331799-85-0 ZCAPLUS  
CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-[4-(dimethylamino)phenyl]-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 331799-84-9  
CMF C29 H34 N8 O4




CM 2

CRN 16940-81-1  
CMF F6 P . H  
CCI CCS

10/ 539,220




RN 331799-91-8 ZCAPLUS  
CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-(2-cyclopropylethyl)-5-  
[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-  
pyrimidinecarboxamide (2:1) (9CI) (CA INDEX NAME)  
CM 1  
CRN 331799-90-7  
CMF C26 H33 N7 O4



CM 2  
CRN 16940-81-1  
CMF F6 P . H  
CCI CCS


10/ 539,220



RN 331800-32-9 ZCAPLUS

CN 5-Pyrimidinecarboxamide, N-(2,4-difluorophenyl)-2-[[6-methoxy-7-[(2S)-oxiranylmethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 331800-37-4 ZCAPLUS

CN 5-Pyrimidinecarboxamide, N-(2-cyclopropylethyl)-2-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 331800-42-1 ZCAPLUS

CN 5-Pyrimidinecarboxamide, N-(3-chloro-4-fluorophenyl)-2-[[7-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 331800-47-6 ZCAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[7-[3-[(cyclopropylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-N-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)




10/ 539,220



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 331800-52-3 ZCAPLUS


CN 2-Pyrimidinecarbonitrile, 5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 331800-55-6 ZCAPLUS


CN 4-Quinazolinamine, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-N-[2-(4-pyridinyl)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331800-61-4 ZCAPLUS


CN Benzamide, 4-[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331800-71-6 ZCAPLUS


CN 4-Quinazolinamine, N-[2-(aminomethyl)-5-pyrimidinyl]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331800-76-1 ZCAPLUS


CN 4-Quinazolinamine, N-[2-[[4-chlorophenyl]amino]methyl]-5-pyrimidinyl]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 331800-78-3 ZCAPLUS


CN 4-Quinazolinamine, 6-methoxy-N-[2-[[[2-(methylthio)phenyl]amino]methyl]-5-pyrimidinyl]-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331800-82-9 ZCAPLUS


CN 4-Quinazolinamine, N-[2-[[[(2,3-difluorophenyl)amino]methyl]-5-pyrimidinyl]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 331800-87-4 ZCAPLUS

CN 4-Quinazolinamine, N-[2-[[[(3-chloro-4-fluorophenyl)amino]methyl]-5-pyrimidinyl]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)


10/ 539,220



RN 331800-93-2 ZCAPLUS  
 CN Phosphate(1-), hexafluoro-, hydrogen, compd. with N-[[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]methyl]-3-methylbutanamide (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 331800-92-1  
 CMF C26 H35 N7 O4



CM 2

CRN 16940-81-1  
 CMF F6 P . H  
 CCI CCS

10/ 539,220




RN 331800-99-8 ZCAPLUS  
CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 4-chloro-N-[[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]methyl]benzamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 331800-98-7  
CMF C28 H30 Cl N7 O4

PAGE 1-A



PAGE 2-A

Cl


10/ 539,220

CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



● H<sup>+</sup>

RN 331801-05-9 ZCAPLUS


CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 4-chloro-N-[[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]methyl]benzeneacetamide (2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 331801-04-8

CMF C29 H32 Cl N7 O4

PAGE 1-A






CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS



RN 331801-11-7 ZCAPLUS

CN Phosphate(1-), hexafluoro-, hydrogen, compd. with 4-chloro-N-[[5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]methyl]benzenepropanamide (2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 331801-10-6


CMF C30 H34 Cl N7 O4



PAGE 1-A




PAGE 2-A




CM 2  
 CRN 16940-81-1  
 CMF F6 P . H  
 CCI CCS

10/ 539,220



RN 331801-16-2 ZCAPLUS


CN 4-Quinazolinamine, 6-methoxy-N-[2-[[ (3-methylbutyl)amino]methyl]-5-pyrimidinyl]-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 331801-22-0 ZCAPLUS

CN 4-Quinazolinamine, N-[2-[[[2-(1-cyclohexen-1-yl)ethyl]amino]methyl]-5-pyrimidinyl]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331801-27-5 ZCAPLUS  
 CN 4-Quinazolinamine, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-N-[2-[(5-nitro-2-pyridinyl)amino]methyl]-5-pyrimidinyl- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331801-30-0 ZCAPLUS


CN 4-Quinazolinamine, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-N-[2-[(3-nitro-2-pyridinyl)amino]methyl]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331801-36-6 ZCAPLUS


CN 4-Quinazolinamine, N-[2-[(3,4-difluorophenyl)amino]methyl]-5-pyrimidinyl]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)

10/ 539,220




RN 331801-42-4 ZCAPLUS

CN 4-Quinazolinamine, N-[2-[[2,4-difluorophenyl]amino]methyl]-5-pyrimidinyl]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 331801-47-9 ZCAPLUS

CN 4-Quinazolinamine, N-[2-[[4-fluorophenyl]amino]methyl]-5-pyrimidinyl]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 331801-52-6 ZCAPLUS


CN 4-Quinazolinamine, N-[2-[(2-chloro-4-fluorophenyl)amino]methyl]-5-pyrimidinyl]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 331801-57-1 ZCAPLUS

CN 4-Quinazolinamine, N-[5-[[ (3-chloro-4-fluorophenyl) amino]methyl]-2-pyrimidinyl]-6-methoxy-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)

10/ 539,220




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 331801-65-1 ZCAPLUS

CN 1-Piperidineethanol,  $\alpha$ -[[[4-[[5-[[3-chloro-4-fluorophenyl)amino]methyl]-2-pyrimidinyl]amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 331801-70-8 ZCAPLUS


CN 4-Quinazolinamine, N-[2-[(3-chloro-4-fluorophenyl)methoxy]-5-pyrimidinyl]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 331801-85-5 ZCAPLUS


CN Benzamide, 3-chloro-4-fluoro-N-[5-[[6-nitro-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 331802-06-3 ZCAPLUS

CN Benzamide, 3-chloro-4-fluoro-N-[5-[[6-(hydroxyamino)-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 24 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:260277 ZCAPLUS

DOCUMENT NUMBER: 132:293771

TITLE: Preparation of quinazolines as VEGF receptor tyrosine kinase inhibitors

INVENTOR(S): Hennequin, Laurent Francois Andre; Pasquet, Georges

PATENT ASSIGNEE(S): Zeneca Limited, UK; Zeneca-Pharma S.A.

SOURCE: PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021955	A1	20000420	WO 1999-GB3295	19991005
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2344290	A1	20000420	CA 1999-2344290	19991005
AU 9961128	A1	20000501	AU 1999-61128	19991005
AU 756556	B2	20030116		
BR 9914326	A	20010626	BR 1999-14326	19991005
EP 1119567	A1	20010801	EP 1999-947758	19991005
EP 1119567	B1	20050504		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

JP 2002527436	T	20020827	JP 2000-575861	19991005
NZ 510434	A	20031031	NZ 1999-510434	19991005
AT 294796	T	20050515	AT 1999-947758	19991005
ES 2241324	T3	20051016	ES 1999-947758	19991005
ZA 2001002655	A	20020930	ZA 2001-2655	20010330
NO 2001001739	A	20010607	NO 2001-1739	20010406
NO 322644	B1	20061113		
HK 1039126	A1	20050930	HK 2002-100744	20020130
PRIORITY APPLN. INFO.:			EP 1998-402496	A 19981008
			WO 1999-GB3295	W 19991005
OTHER SOURCE(S):			MARPAT 132:293771	
GI				



AB The title compds. [I; ring C = 5-6 membered heterocyclic moiety; Z = O, NH, S, CH<sub>2</sub>; R<sub>1</sub> = H, alkyl, alkoxyethyl, etc.; n = 0-5; m = 0-3; R<sub>2</sub> = H, OH, halo, etc.] and their salts which inhibit the effects of VEGF, and therefore useful in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, were prepared and formulated. E.g., a multi-step synthesis of quinazoline II was given. Compds. I are effective at 1-50 mg/kg/day.

IT 264207-48-9P 264207-50-3P 264207-52-5P  
 264207-58-1P 264207-62-7P 264207-66-1P  
 264207-70-7P 264207-72-9P 264207-74-1P  
 264207-76-3P 264207-78-5P 264207-80-9P  
 264207-82-1P 264207-84-3P 264207-86-5P  
 264207-88-7P 264207-90-1P 264207-94-5P  
 264207-96-7P 264207-98-9P 264208-00-6P  
 264208-02-8P 264208-04-0P 264208-06-2P  
 264208-08-4P 264208-10-8P 264208-12-0P  
 264208-14-2P 264208-16-4P 264208-18-6P  
 264208-21-1P 264208-23-3P 264208-26-6P  
 264208-33-5P 264208-35-7P 264208-41-5P  
 264208-43-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazolines as VEGF receptor tyrosine kinase inhibitors)

RN 264207-48-9 ZCAPLUS


CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(phenylmethyl)-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)

10/ 539,220




RN 264207-50-3 ZCAPLUS

CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]- (9CI) (CA INDEX NAME)



RN 264207-52-5 ZCAPLUS

CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 264207-58-1 ZCAPLUS

CN Quinazoline, 4-[[5-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-

10/ 539,220


morpholinyl)propoxy]-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



●19/10 HCl

RN 264207-62-7 ZCAPLUS

CN Quinazoline, 7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]-, hydrochloride (2:5) (9CI) (CA INDEX NAME)




●5/2 HCl

RN 264207-66-1 ZCAPLUS


CN Quinazoline, 4-[[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 264207-70-7 ZCAPLUS


CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(3-pyridinyl)-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)



RN 264207-72-9 ZCAPLUS


CN Quinazoline, 4-[[5-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)

10/ 539,220




RN 264207-74-1 ZCAPLUS

CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(4-pyridinyl)-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)



RN 264207-76-3 ZCAPLUS


CN Quinazoline, 6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]- (9CI) (CA INDEX NAME)



10/ 539,220

RN 264207-78-5 ZCAPLUS

CN 4-Quinazolinamine, 6-methoxy-N-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-7-[(1-methyl-4-piperidinyloxy)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 264207-80-9 ZCAPLUS

CN 4-Quinazolinamine, N-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-6-methoxy-7-[(1-methyl-4-piperidinyloxy)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 264207-82-1 ZCAPLUS

10/ 539,220

CN 4-Quinazolinamine, N-[5-(3,4-dichlorophenyl)-1H-pyrazol-3-yl]-6-methoxy-7-[(1-methyl-4-piperidiny)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 264207-84-3 ZCAPLUS

CN 4-Quinazolinamine, 6-methoxy-N-[5-(4-methylphenyl)-1H-pyrazol-3-yl]-7-[(1-methyl-4-piperidiny)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 264207-86-5 ZCAPLUS

CN 4-Quinazolinamine, 6-methoxy-7-[(1-methyl-4-piperidiny)methoxy]-N-[5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]-, hydrochloride (9CI) (CA INDEX NAME)



10/ 539,220

NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 264207-88-7 ZCAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 264207-90-1 ZCAPLUS

CN 4-Quinazolinamine, 6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-N-(5-phenyl-1H-pyrazol-3-yl)-, hydrochloride (5:12) (9CI) (CA INDEX NAME)

10/ 539,220




●12/5 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 264207-94-5 ZCAPLUS

CN Quinazoline, 4-[[5-(3-furanyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 264207-96-7 ZCAPLUS


CN Quinazoline, 4-[[5-(2-fluorophenyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 264207-98-9 ZCAPLUS


CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(3-nitrophenyl)-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)




RN 264208-00-6 ZCAPLUS

CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(4-nitrophenyl)-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)


10/ 539,220



RN 264208-02-8 ZCAPLUS  
 CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[(5-propyl-1H-pyrazol-3-yl)oxy]- (9CI) (CA INDEX NAME)




RN 264208-04-0 ZCAPLUS  
 CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(3-pentenyl)-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)



RN 264208-06-2 ZCAPLUS


10/ 539,220

CN Quinazoline, 6-methoxy-4-[[5-(methoxymethyl)-1H-pyrazol-3-yl]oxy]-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 264208-08-4 ZCAPLUS

CN Quinazoline, 4-[(5-ethyl-1H-pyrazol-3-yl)oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 264208-10-8 ZCAPLUS

CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[[5-(2-phenylethyl)-1H-pyrazol-3-yl]oxy]- (9CI) (CA INDEX NAME)




RN 264208-12-0 ZCAPLUS

CN Quinazoline, 6-methoxy-4-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-7-[(1-


10/ 539,220

methyl-4-piperidinyloxy]- (9CI) (CA INDEX NAME)



RN 264208-14-2 ZCAPLUS


CN Quinazoline, 6-methoxy-4-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 264208-16-4 ZCAPLUS


CN Quinazoline, 6-methoxy-4-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-7-[[1-[2-(methylsulfonyl)ethyl]-4-piperidinyloxy]methoxy]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 264208-18-6 ZCAPLUS


CN Quinazoline, 6-methoxy-4-[[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 264208-21-1 ZCAPLUS


CN Quinazoline, 6-methoxy-4-[[5-(2-methylpropyl)-1H-pyrazol-3-yl]oxy]-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)

10/ 539,220




RN 264208-23-3 ZCAPLUS

CN Quinazoline, 4-[[5-butyl-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 264208-26-6 ZCAPLUS

CN Quinazoline, 4-[[5-(2-cyclopentylethyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 264208-33-5 ZCAPLUS




10/ 539,220

CN Quinazoline, 4-[[5-(3-furanyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 264208-35-7 ZCAPLUS


CN Quinazoline, 7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-[(5-phenyl-1H-pyrazol-3-yl)oxy]- (9CI) (CA INDEX NAME)




RN 264208-41-5 ZCAPLUS

CN Quinazoline, 4-[[5-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)

10/ 539,220



RN 264208-43-7 ZCAPLUS  
CN 4-Quinazolinamine, 6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 12:25:54 ON 22 JUN 2007)

FILE 'REGISTRY' ENTERED AT 12:26:27 ON 22 JUN 2007

L1 STRUCTURE UPLOADED  
L2 50 S L1  
L3 1704 S L1 FUL

FILE 'ZCAPLUS' ENTERED AT 12:27:06 ON 22 JUN 2007

L4 24 S L3

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
126.66	298.97

FULL ESTIMATED COST

10/ 539,220

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-18.72	-18.72

STN INTERNATIONAL LOGOFF AT 12:28:37 ON 22 JUN 2007